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Abstract  
 
Behavioural sensitisation describes the progressive and enduring augmentation of a drug-induced 
response that develops with repeated exposure. Sensitisation is a putative mechanism in the 
pathophysiology of drug addiction and neuropsychiatric disorders such as schizophrenia. In rodents, 
drug-induced behavioural sensitisation has been described for several different drug classes. The 
neural mechanisms underpinning behavioural sensitisation to most drugs of abuse share similarities, 
such as NMDA receptor (NMDAR) activation, although not all use the same mechanism of action. 
The NMDAR antagonist MK-801 can inhibit sensitisation to other drugs of abuse. However, MK-
801 also produces behavioural sensitisation to its own hyperlocomotor inducing effects, suggesting 
that MK-801 sensitisation has a distinctive mechanism of action.  
The overall aim of my thesis was to investigate the neural mechanisms of behavioural sensitisation 
to MK-801 in rats. First, I established the effect of drug dose, environmental context, length of 
withdrawal period and rat strain on the ability of repeated intermittent MK-801 administration to 
induce behavioural sensitisation. MK-801-induced sensitisation was shown to be dependent on the 
dose of MK-801, length of withdrawal period and the rat strain. Sensitisation however was not 
modulated by the environmental context in which MK-801 administration occurred.  
In the established sensitisation paradigm, a functional and molecular analysis of the nucleus 
accumbens of rats sensitised to MK-801 was undertaken. Ex vivo slice electrophysiology revealed a 
decrease in the excitatory synaptic strength in the nucleus accumbens of rats sensitised to MK-801. 
An LC-MS/MS proteomics approach demonstrated that proteins altered by MK-801 sensitisation 
were predominately related to functions including calcium signalling and mitochondrial 
dysfunction.  
I also probed the role of corticosterone signalling using a pharmacological and physiological 
approach. Pharmacological antagonism of the glucocorticoid receptor with RU486 was found to 
facilitate behavioural sensitisation to MK-801, potentially through its augmenting effect on MK-
801 induced corticosterone levels. Following on from this experiment, I showed that 
pharmacological antagonism of the stress-related kappa opioid receptor with nor-Binaltorphimine 
did not have the same effect as RU486. Lastly, I also used LY354740, a pharmacological agonist of 
the metabotropic glutamate receptors, as a preliminary investigation into the role of glutamatergic 
transmission. Stimulation of these receptors however was without effect on MK-801 sensitisation. 
 
 
ii 
Using a range of approaches I have elucidated some of the neural mechanisms and adaptations 
associated with behavioural sensitisation to MK-801. These results predominately show that 
sensitisation to MK-801 differs from the mechanism of sensitisation to other drugs of abuse. This 
model could prove useful for studying the role of NMDARs in the pathophysiology of drug 
addiction and schizophrenia.  
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Behavioural sensitisation describes the progressive and enduring augmentation of a drug-induced 
response that develops with repeated exposure (Segal and Mandell, 1974, Vanderschuren and 
Kalivas, 2000). When administered to rodents, drugs of abuse can induce hyperlocomotion and 
stereotypic behaviour. When this drug administration is repeated and intermittent, sensitisation to 
these hyperlocomotor effects can occur (Robinson and Becker, 1986). Many different classes of 
addictive drugs including cocaine, amphetamine, morphine, ethanol, nicotine and methylphenidate 
are reported to induce behavioural sensitisation in rodents (Robinson and Berridge, 1993, 
Vanderschuren and Kalivas, 2000). Behavioural sensitisation is a putative mechanism involved in 
the pathophysiology of neuropsychiatric disorders such as schizophrenia (Lieberman et al., 1997, 
Ujike, 2002), bipolar disorder (Post et al., 2001), obsessive-compulsive disorders (Szechtman et al., 
2001), depressive disorders (Patten, 2008) and drug addiction (Robinson and Berridge, 1993, 
Robinson and Berridge, 2000). Understanding the neural mechanisms underpinning behavioural 
sensitisation may help us to understand the aetiology of these disorders (Robinson and Berridge, 
2008, Ujike, 2002). High co-morbidity of drug addiction with schizophrenia is postulated to occur 
via shared glutamatergic mechanisms (Coyle, 2006). To study such mechanisms in rodents, 
researchers have utilised dopaminergic agents such as amphetamine, and N-methyl-D-aspartate 
receptor (NMDAR) agents such as phencyclidine (PCP) and dizocilpine maleate (MK-801) 
(Featherstone et al., 2007, Jentsch and Roth, 1999). Behavioural sensitisation to a particular drug of 
abuse is commonly used in rodents to study the pathophysiology of drug addiction (Steketee and 
Kalivas, 2011).  
Drug-induced sensitisation is divided into two key phases, induction and expression, which are 
mediated by distinct anatomical and neurochemical substrates (Pierce and Kalivas, 1997). The 
induction of sensitisation refers to the neurological changes that develop with repeated drug 
exposure, whereas the expression of sensitisation is characterized as the enhanced response to a 
drug challenge following a period of drug abstinence, referred to as the ‘withdrawal phase’ (Kalivas 
et al., 1993). The neurochemical adaptations associated with the induction and expression of 
sensitisation have been extensively studied in animal models of cocaine- and amphetamine-induced 
sensitisation. In contrast, little is known regarding the mechanisms underpinning behavioural 
sensitisation to glutamatergic NMDAR antagonists. Sensitisation has been reported following 
repeated administration of the non-competitive agents ketamine (Trujillo et al., 2008, Uchihashi et 
al., 1993), PCP (Johnson et al., 1998, Phillips et al., 2001, Xu and Domino, 1994b) and MK-801 
(Tzschentke and Schmidt, 1995, Wolf and Khansa, 1991, Wolf et al., 1993, Yang et al., 2002). Of 
these non-competitive agents MK-801 has the highest selectivity and potency at the NMDAR 
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(Linders et al., 1993). This is one of the primary reasons it has been most widely used to study 
NMDAR antagonist-induced sensitisation.  
Due to its NMDAR antagonist properties, MK-801 was originally used in sensitisation research to 
test the role of NMDAR activation, and it was even considered a potential therapeutic option for 
drug addiction (Karler et al., 1989, Karler et al., 1990). However, it was quickly discovered that 
although co-administration of MK-801 during repeated amphetamine administration blocked 
sensitisation to amphetamine challenge, it produced a sensitised response to a later MK-801 
challenge (Wolf and Khansa, 1991). Subsequent studies also demonstrated the ability of MK-801 to 
block the development of behavioural sensitisation to cocaine (Wolf and Jeziorski, 1993), opiates 
including morphine (Jeziorski et al., 1994, Wolf and Jeziorski, 1993), methadone and 
buprenorphine (Mendez and Trujillo, 2008), apomorphine (Druhan et al., 1993), ethanol (Camarini 
et al., 2000), nicotine (Kelsey et al., 2002) and methylphenidate (Gaytan et al., 2000). This suggests 
that signalling via the NMDAR is a convergent factor for the development of sensitisation to 
several different classes of addictive drugs. This would suggest that the mechanisms involved in 
sensitisation to MK-801, an NMDAR antagonist, are likely to be divergent from those mediating 
sensitisation to other drugs of abuse, which act through this receptor. 
 
1.1 GLUTAMATE 
L- Glutamate is an amino acid and the major excitatory neurotransmitter in the mammalian central 
nervous system (CNS) (Fonnum, 1984). Glutamate is also a precursor for the synthesis of the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) (White, 1981). Dysregulation of 
excitatory transmission can lead to excessive glutamate concentrations in the extracellular space 
leading to cell death (i.e. excitotoxicity) (Choi et al., 1987). Therefore several mechanisms exist to 
keep glutamate levels tightly regulated.  
Active transport mechanisms and enzymatic degradation are utilised in the CNS to regulate 
glutamate. The glutamate transporters are divided into two major superfamilies; the vesicular 
glutamate transporters (VGLUT) (Liguz-Lecznar and Skangiel-Kramska, 2007) and the excitatory 
amino acid transporters (EAAT) (Seal and Amara, 1999). Three VGLUT subtypes have been 
discovered; VGLUT1, VGLUT2 and VGLUT3. The VGLUTs are responsible for packaging 
glutamate into presynaptic vesicles in the glutamatergic neurons (Figure 1.1) (El Mestikawy et al., 
2011). Once packaged, glutamate is released from the pre-synaptic terminal in a calcium (Ca2+) -
dependent manner (Debeller.Js and Bradford, 1972). In the extracellular space both basal and 
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stimulated glutamate levels are controlled by the EAATs (Seal and Amara, 1999). There are five 
EAAT subtypes, with EAAT1 and EAAT2 predominately localized on astrocytes and the remaining 
EAATs 3, 4 and 5 primarily located on neurons (Divito and Underhill, 2014). The EAATs act to 
remove glutamate from the extracellular space into the cytosol (Divito and Underhill, 2014). Once 
in the cytosol enzymes such as glutamate pyruvate transaminase, glutamine synthetase, and 
glutamate dehydrogenase degrade glutamate (Matthews et al., 2000).  
 
1.1.1 Glutamate receptors  
As described, glutamate serves as the major excitatory neurotransmitter. The glutamate receptors 
are divided into two major categories; ionotropic and metabotropic (Conn and Pin, 1997, 
Dingledine et al., 1999). Ionotropic receptors are divided into three families, named after their 
sensitivity to three synthetic glutamate derivatives NMDA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), and kainate (Dingledine et al., 1999). The ionotropic receptors 
are large macromolecular complexes that form a channel pore allowing the exchange of Na+, K+ 
and Ca2+ ions (Dingledine et al., 1999). The metabotropic receptors are G-protein coupled and 
therefore mediate longer-term effects of glutamate (Conn and Pin, 1997). They are classified into 
three main groups based on their coupling mechanisms, sequence homology and pharmacology 
(Nakanishi, 1994).  
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Figure 1.1 Depiction of the glutamate synapse 
Glutamate is packaged into vesicles by the VGLUTs. Extracellular glutamate levels in the synapse are controlled by 
EAAT uptake and through the pre-synaptically located mGlu2/3  receptors which act as autoreceptors to reduce 
presynaptic glutamate release. Glutamate signals on the post-synaptic AMPARs and NMDARs. GluA2-lacking 
AMPARs are calcium-permeable allowing the influx of these ions upon glutamatergic stimulation. Post-synaptic 
mGlu1/5  receptors act to modulate glutamate signalling by interacting with the ionotropic AMPARs and NMDARs 
1.1.1.1 NMDARs  
The NMDARs exhibit a number of characteristics that distinguish them from the other ionotropic 
receptors. In particular, NMDARs display slow activation and deactivation kinetics that occur in a 
ligand-dependent and voltage-dependent manner (Mcbain and Mayer, 1994). Activation of the 
NMDAR requires binding of the ligand glutamate, as well as co-activation of the glycine-binding 
site by glycine or serine (Figure 1.2b) (Mcbain and Mayer, 1994). Under basal conditions the 
NMDAR is blocked by magnesium (Mg2+) within the ion channel (Figure 1.2a) (Mcbain and 
Mayer, 1994). Activation of the AMPARs leads to depolarization of the cell, and this change in 
voltage allows removal of the Mg2+ block and the channel to open (Figure 1.2b) (Mcbain and 
Mayer, 1994). NMDARs may be composed from a repertoire of different subunits. There are eight 
splice variation isoforms of the GluNR1 subunit (Flores-Soto et al., 2012). The GluNR1 subunit 
contains the glycine-binding site (Flores-Soto et al., 2012). There are four different types of 
 
 
6 
GluNR2 subunits (A, B, C and D), and these subunits contain the glutamate-binding site (Flores-
Soto et al., 2012). There are two types of the GluNR3 subunit (A and B). Functional NMDARs 
must therefore be composed of at least one GluNR1 and GluNR2 subunit (Flores-Soto et al., 2012). 
The NMDARs also have a high permeability to Ca2+ ions (Dingledine et al., 1999). This 
permeability contributes to their key role in mediating synaptic plasticity (Zorumski and Izumi, 
2012).  
 
 
Figure 1.2 Activation kinetics of the NMDAR 
NMDARs are closed by Mg2+ block in the ion pore channel (A). Binding of glutamate to the GluNR2 subunit and the 
co-agonist binding of glycine or serine on the GluNR1 subunit activates the NMDAR. The Mg2+ block is removed by 
depolarization of the cell (B). MK-801 binds to the PCP binding site, preferentially when the channel is in the open-
state. This then leads to blocking of the NMDAR channel and inhibits flux of Na+, K+ and Ca2+ ions (C).  
1.1.1.2 AMPARs  
In contrast to the slow kinetics of NMDARs (Mcbain and Mayer, 1994), AMPARs show fast 
activation within hundreds of microseconds, and decay within milliseconds (Colquhoun et al., 1992, 
Hestrin, 1992). AMPAR activation allows the influx of Na+, which mediates the fast depolarization 
required for the activation of NMDARs (Karakas et al., 2015). The AMPARs form functional ion 
channels as homo- or heterotetramers using four possible subunits (GluA1 to 4) (Karakas et al., 
2015). The AMPARs are generally classified based on the inclusion or exclusion of the GluA2 
subunit (Jonas and Burnashev, 1995). This is because the GluA2 subunit determines the Ca2+ 
permeability of the AMPAR (Jonas and Burnashev, 1995). AMPARs containing the GluA2 subunit 
are the most prevalent in the CNS. These AMPARs are also Ca2+ impermeable, and are insensitive 
to blockade by endogenous polyamines such as spermine, spermidine and putrescine (Bowie, 2012). 
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In contrast, AMPARs lacking GluA2 are Ca2+ permeable, can be blocked by endogenous 
polyamines, and display large single-channel currents (Figure 1.1) (Bowie, 2012). As a result, in 
addition to NMDARs, AMPARs also play a critical role in synaptic plasticity (Sprengel, 2006). 
Alterations in the AMPAR subunits responsible for Ca2+ permeability are thought to be particularly 
important for modulating synaptic plasticity (Adesnik and Nicoll, 2007, Plant et al., 2006).  
 
1.1.1.3 Metabotropic glutamate receptors  
The primary function of metabotropic glutamate (mGlu) receptors is to modulate 
neurotransmission, neuronal excitability and synaptic plasticity (Kew and Kemp, 2005). There are 
eight isoforms of the metabotropic glutamate receptor (mGlu1-8) that act diversely within the 
glutamatergic system (Nakanishi, 1994). The mGlu1 and mGlu5 isoforms are classified as Group I 
receptors and are positively coupled to Gq proteins (Nakanishi, 1994). This coupling leads to 
activation of phospholipase C and the formation of inositol 1,4,5-trisphosphate (IP3) and diacyl 
glycerol (DAG) (Conn and Pin, 1997). The majority of Group I mGlu receptors are predominately 
postsynaptic and are localized extrasynaptically where they regulate ionotropic receptor activity and 
intracellular processes (Figure 1.1) (Shigemoto et al., 1997). Group II (mGlu2/3) and Group III 
(mGlu4, mGlu6-8) receptors are negatively coupled to adenylyl cyclase via Gi/Go (Nakanishi, 1994). 
Activation of these receptors leads to an inhibition of forskolin-stimulation cyclic AMP (cAMP) 
formation (Cartmell and Schoepp, 2000). Presynaptic glutamate release is tightly regulated by the 
Group II and Group III mGlu receptors (Conn and Pin, 1997, Meldrum, 2000). To exert control 
over presynaptic release, Group II mGlu receptors are located peri-synaptically, with the mGlu2s 
predominately located on the pre- rather than post-synapse (Figure 1.1) (Petralia et al., 1996, 
Shigemoto et al., 1997). Thus in addition to the active transporters, glutamate release is also 
controlled via the presynaptic mGlu receptors.  
Glutamate signalling is vital for metabolic functions and neurotransmission in the mammalian CNS, 
with a precarious potential for excitotoxicity (Olney, 1990). It is well accepted that disruptions to 
the glutamatergic system contributes to the pathophysiology of several different neuropsychiatric 
disorders (Niciu et al., 2012). This includes neurodevelopmental disorders, epilepsy, CNS trauma as 
well as neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease (Olney, 1990). 
Furthermore, aberrant glutamatergic signalling is strongly associated with the pathophysiology of 
schizophrenia (Olney, 1990).  
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1.2 SCHIZOPHRENIA  
Schizophrenia is a complex neuropsychiatric disorder affecting approximately 1% of the population 
(Bhugra, 2005, Saha et al., 2005). The symptoms are highly heterogeneous and broadly categorized 
into positive and negative symptoms, and cognitive deficits (Tandon et al., 2013). Positive 
symptoms manifest as psychosis, including hallucinations and delusions (Crow, 1980). Negative 
symptoms are seen as blunted affect, poverty of speech and loss of drive (Crow, 1980). Cognitive 
impairments are observed when patients are subjected to psychometric tests that assess working 
memory, attention and vigilance (Green et al., 2004). Schizophrenia is known to have an estimated 
heritability of 65-80% (Lichtenstein et al., 2006, Sullivan et al., 2003). This disorder is a polygenic 
disorder with no single gene significantly contributing to its aetiology. Recent genome-wide 
association studies (GWAS) have identified over 100 common variants associated with 
schizophrenia (Ripke et al., 2014). The aetiology of schizophrenia is dependent not only on genetic 
background, but is also influenced by numerous environmental risk factors (van Os et al., 2010). A 
comprehensive review of all the genetic and environmental risk factors is beyond the theme of this 
thesis (for recent reviews the reader is referred to: (Davis et al., 2016, Kotlar et al., 2015, Lee et al., 
2012)).  
The pathogenesis of schizophrenia involves dysfunction of several neurotransmitter systems. Two 
of the two predominant neurotransmitter theories propose dysfunction of interacting dopamine and 
glutamate systems (Howes et al., 2015, Howes and Kapur, 2009, Snyder and Gao, 2013). The 
dopamine hypothesis of schizophrenia suggests a state of hyperdopaminergia in striatal brain 
regions and hypodopaminergia in prefrontal regions (Howes and Kapur, 2009). This hypothesis was 
first proposed after it was observed that the clinical effectiveness of antipsychotic medications was 
directly proportional to their binding affinity for the dopamine D2 receptor (Creese et al., 1996, 
Seeman and Lee, 1975, Seeman et al., 1976). Evidence for dopamine dysfunction in schizophrenia 
has become apparent from a number of pathological, genetic and neuroimaging studies (Howes and 
Kapur, 2009). In addition to the anti-dopamine effects of antipsychotics, there is additional 
supportive evidence of dopamine dysfunction in schizophrenia based on early work using the 
indirect dopamine agonist, amphetamine (Lieberman et al., 1987a). Amphetamine, which increases 
synaptic dopamine levels (Calipari and Ferris, 2013), was found to induce psychotic symptoms in 
schizophrenic patients (Lieberman et al., 1987a). This finding was strengthened through studies 
measuring the displacement of dopamine receptor radioligands by endogenous dopamine, using 
single photon emission computerized tomography (SPECT) (Abi-Dargham et al., 1998, Laruelle et 
al., 1996). Amphetamine-induced dopamine release in the striatum correlated directly with the 
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exacerbation of positive symptoms (Abi-Dargham et al., 1998, Laruelle et al., 1996). In healthy 
subjects, amphetamine has also been found to induce psychotic symptoms (Angrist et al., 1974, 
Angrist and Gershon, 1970, Janowsky and Risch, 1979). However, amphetamine does not induce 
negative symptoms, nor does it induce the cognitive deficits found in schizophrenia (Krystal et al., 
2005). Therefore there are limitations to the use of dopamine agonists to investigate the broader 
symptoms found in schizophrenia. A critical finding for understanding the connections between the 
neurotransmitter hypotheses of schizophrenia pathophysiology came when it was found that 
NMDAR hypofunction could induce the hyperdopaminergic state (Carlsson and Carlsson, 1990). 
This was demonstrated by the ability of ketamine to increase striatal dopamine in healthy volunteers 
(Aalto et al., 2005, Vollenweider et al., 2000). This suggests that glutamate and dopamine may 
converge on a final common pathway (Kantrowitz and Javitt, 2010).  
 
1.2.1 Schizophrenia and glutamate  
The glutamate hypothesis of schizophrenia was first proposed when it was observed that NMDAR 
antagonists could induce schizophrenia-like symptoms in healthy volunteers (Javitt, 1987). As with 
amphetamine, ketamine recapitulated the positive symptoms of schizophrenia (Aalto et al., 2005, 
Breier et al., 1997a, Krystal et al., 1994). Unlike amphetamine however, ketamine also resulted in 
negative symptoms and cognitive deficits reflective of schizophrenia (Aalto et al., 2005, Breier et 
al., 1997a, Krystal et al., 1994). This generated strong support for the glutamate hypothesis of 
schizophrenia. Furthermore, ketamine was found to exacerbate existing symptomology in 
schizophrenic patients (Lahti et al., 1995, Malhotra et al., 1997). Thus glutamatergic dysfunction, 
via the NMDARs, is thought to contribute to the pathophysiology of schizophrenia (Kantrowitz and 
Javitt, 2010).  
Since the glutamate hypothesis was first proposed in the late 1980’s, several lines of evidence 
supporting glutamate/NMDAR hypofunction in schizophrenia have emerged. As would be expected 
for a polygenic disorder such as schizophrenia, there are many possible causes of NMDAR 
dysfunction. These include decreased concentrations of the NMDAR co-agonists, D-serine and 
glycine (Hashimoto et al., 2003, Neeman et al., 2005, Sumiyoshi et al., 2004) and increased levels 
of endogenous NMDAR antagonists such as kynurenic acid and N-acetylaspartylglutamate 
(NAAG) (Erhardt et al., 2007, Tsai et al., 1995). Genetic studies have also identified altered genes 
for the glutamate receptor subunits (Ripke et al., 2014) and post-synaptic complexes (Kirov et al., 
2012) in schizophrenic patients. As glutamate/NMDAR function is modulated by a multitude of 
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factors, these findings suggest there a number of potential therapies that could treat glutamatergic 
dysfunction in schizophrenia. 
Numerous clinical trials have explored the use of compounds that positively modulate 
glutamate/NMDAR neurotransmission in the treatment of schizophrenic symptoms. There has been 
notable inconsistency between individual reports. An early meta-analysis by Tsai et al., (2010) 
indicated improvement of positive, negative and cognitive symptoms in schizophrenic patients 
treated with positive glutamate modulators. However, two more recent, comprehensive meta-
analyses revealed that positive modulation of glutamate transmission did not lead to any significant 
improvements of cognitive deficits in schizophrenia (Choi et al., 2013, Iwata et al., 2015). It is 
therefore clearly evident that greater clarification of the role of glutamate/NMDAR dysfunction in 
schizophrenia is necessary (Goff, 2015, Lin et al., 2012). NMDAR antagonists reliably recapitulate 
schizophrenia-like deficits in clinical human studies, as well as in preclinical rodent/monkey animal 
studies (Section 1.5.1) (Bubenikova-Valesova et al., 2008). Therefore a better basic understanding 
of NMDAR dysfunction can be achieved through the study of pharmacologically induced rodent 
models (Javitt, 2015). This may facilitate the exploration of potential therapeutic targets and 
treatment options. (Abel et al., 2003) 
 
1.2.2 Schizophrenia, substance abuse and glutamate  
Compared to the general population, schizophrenic patients have a three to four-fold greater risk for 
substance abuse of alcohol and stimulants (Kavanagh et al., 2002) and up to 85% of patients have 
nicotine dependence (Cantor-Graae et al., 2001). Co-morbidity of schizophrenia and substance 
abuse is attributed to a shared dysfunction of the dopamine and glutamate neurotransmitter systems 
(Thoma and Daum, 2013). Firstly, the dysfunction of the dopamine system found in schizophrenia 
is primarily located within the reward circuitry, which is likely to modulate substance abuse 
behaviours (Chau et al., 2004). Secondly, NMDARs, which are dysfunctional in schizophrenia, are 
also critical in the mesocorticolimbic reward circuitry (Coyle, 2006). Though glutamatergic 
dysfunction has been attributed to the pathophysiology of schizophrenia (see above), and the 
pathophysiology of drug addiction (Tzschentke and Schmidt, 2003), there is currently still a lack of 
direct evidence for glutamate in the co-morbidity of these disorders. Some evidence arises from the 
reduction of substance abuse in schizophrenic patients receiving clozapine treatment (Coyle, 2006).  
The antipsychotic clozapine is thought to have positive modulatory effects on the NMDAR via the 
glycine modulatory site (GMS) (Coyle and Tsai, 2004). Clozapine is the most effective 
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antipsychotic medication for treatment-resistant schizophrenia, particularly in the treatment of 
negative symptoms (Meltzer, 2010). The efficacy in treating negative symptoms is thought to be 
partly due to the action of clozapine at the NMDAR that other antipsychotics do not possess (Kane 
and Correll, 2016). In schizophrenic patients, clozapine treatment has been found to greatly reduce 
the overall co-morbid substance abuse (Zimmet et al., 2000). This includes reductions in nicotine 
(i.e. cigarette) dependence (Procyshyn et al., 2001, Procyshyn et al., 2002), and alcohol and 
cannabis abuse (Drake et al., 2000, Green et al., 2003). Thus it appears that enhancing NMDAR 
function may be related to the reduction of substance abuse in schizophrenia (Coyle, 2006). The 
NMDARs play a central role in drug-induced sensitisation and drug-evoked neural plasticity 
(Luscher and Malenka, 2011, Wolf, 1998). Therefore studying animal models of NMDAR 
dysfunction could provide potential insight into not only schizophrenia pathophysiology, but also 
its co-morbidity with substance abuse. 
 
1.3 SENSITISATION AND SCHIZOPHRENIA  
Schizophrenia is a progressive disorder (Bilder et al., 1992, van Haren et al., 2008). Schizophrenia 
itself is typically diagnosed between late adolescence and early adulthood (Tandon et al., 2013). 
However, patients show accumulating ‘prodromal’ signs and symptoms that culminate in the ‘first-
episode’ psychosis, which is generally followed by a diagnosis of schizophrenia (McGlashan and 
Fenton, 1993). These prodromal signs typically become apparent during early adolescence 
(McGlashan and Fenton, 1993). Adolescence is a vulnerable period of brain development, in which 
critical events such as synaptic pruning occur (Feinberg, 1982). It is postulated that pre‐existing 
neural abnormalities may be “unmasked” as the brain develops during late‐adolescence (Lieberman 
et al., 1997). A process of sensitisation is proposed to account for the longitudinal course of 
schizophrenia and the varying propensity to relapse (Figure 1.3) (Lieberman et al., 1997). During 
the adolescent period of neural vulnerability, endogenous neurochemical sensitisation develops in 
response to stressful environmental factors and life events (Lieberman et al., 1997). After remission 
from neuroleptic treatment, schizophrenic patients may experience a psychotic relapse induced by 
discontinuation of medication or a stressor (a non-specific life event) (Gilbert et al., 1995, Kissling, 
1992). With each relapse that occurs, the disease severity increases and this results in longer 
recovery time (Ohmori et al., 1999). This implies that endogenous sensitisation occurs during the 
early stages of illness, and with each relapse (Ujike, 2002). The effects of amphetamine in 
schizophrenic patients support this hypothesis of endogenous sensitisation. In most schizophrenic 
patients, low doses of amphetamine that are without effect in healthy subjects, induces or worsens 
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the onset of positive symptoms (Lieberman et al., 1987a). This vulnerability to drug-induced 
psychosis is proposed to predict a vulnerability to relapse, and to indicate the stage of illness 
(Laruelle et al., 1996, Lieberman et al., 1987b). As this enhanced response is observed in patients 
who have not previously been exposed to psychostimulants, the state is referred to as endogenous 
sensitisation (Figure 1.3) (Laruelle, 2000). By comparison, exogenous sensitisation would refer to 
the sensitised state seen in subjects with a history of substance abuse (Figure 1.3), as discussed in 
the next section.  
Imaging studies have revealed that schizophrenia patients have a sensitised dopaminergic 
mesocorticolimbic system (Laruelle, 2000). Positron emission tomography (PET) and SPECT 
analyses have consistently revealed that patients with schizophrenia have enhanced dopamine 
release in response to low-dose amphetamine compared to ‘healthy’ individuals that can be directly 
correlated to the emergence of positive symptoms (Abi-Dargham et al., 1998, Breier et al., 1997b, 
Laruelle et al., 1996). This may reflect endogenous dopamine sensitisation in schizophrenic patients 
(Laruelle, 2000). Low doses of ketamine induce psychotic symptoms in schizophrenic patients to a 
greater degree than when administered healthy subjects (Lahti et al., 2001, Malhotra et al., 1997). 
The ability of ketamine to exacerbate existing symptomology suggests that schizophrenic patients 
are more sensitive to the effects of NMDAR antagonists (Javitt and Zukin, 1991).  
 
1.4 SENSITISATION AND DRUG ADDICTION   
The progressive and relapsing nature of drug addiction also forms the basis of the ‘incentive 
sensitisation’ theory first proposed by Robinson and Berridge (1993) (Figure 1.3). This theory 
posits that repeated exposure to drugs of abuse induces neuroadaptations in the mesocorticolimbic 
circuitry that regulates motivation and reward. Thus sensitisation of this system is proposed to 
increase the incentive salience or ‘wanting’ of drugs, leading to addictive behaviour i.e. compulsive 
drug seeking and drug taking (Robinson and Berridge, 1993). Longitudinal clinical studies have 
shown that abusers of drugs such as methamphetamine and cocaine show psychotic states closely 
resembling that of schizophrenia in response to an acute exposure (Satel and Edell, 1991, Sato et 
al., 1983). Even after years of abstinence low doses can induce a psychosis reminiscent to that 
observed with the initial exposure (Figure 1.3) (Satel and Edell, 1991, Sato et al., 1983). 
Furthermore, recurrences are induced not only by drug use but also external stressors such as life 
events (Sinha, 2008). Thus it would appear that an exogenous drug-induced sensitisation is 
occurring in the pathophysiology of substance abuse (Ujike, 2002).  
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Neuroimaging studies demonstrate that in healthy human subjects, repeated and intermittent 
administration of amphetamine leads to a sensitisation of the psychomotor response and ventral 
striatum dopamine release following challenge with amphetamine (Boileau et al., 2006). However, 
in cocaine, alcohol, methamphetamine and heroin addicts, striatal dopamine release is blunted in 
response to challenge with a dopamine-releasing agent such as amphetamine or methylphenidate 
(Martinez et al., 2011, Martinez et al., 2005, Martinez et al., 2012, Volkow et al., 2001, Wang et al., 
2012). As such, dopamine release in the nucleus accumbens (NAc) is thought to be responsible for 
inducing the rewarding properties of a drug, and for the development of addiction, but not for the 
reinstatement of drug craving (Kalivas and Volkow, 2005). In contrast, the long-lasting addiction, 
characterized by drug wanting and relapse, is likely to arise from alterations in neural plasticity of 
excitatory transmission (Kalivas and Volkow, 2005). 
Rodents develop sensitisation to the behavioural and neurochemical effects of drugs of abuse 
following repeated intermittent administration (Figure 1.3) (Stewart and Badiani, 1993). 
Behavioural sensitisation is typically measured as an augmentation of the locomotor activating 
effects of a psychostimulant (Stewart and Badiani, 1993). In experimental animals, psychomotor 
sensitisation is proposed to reflect a number of neuro-behavioural adaptations relevant to addiction 
(Robinson and Berridge, 1993, Robinson and Berridge, 2000, Robinson and Berridge, 2008). For 
example behavioural sensitisation can manifest as an increased propensity for drug self-
administration (Piazza et al., 1989, Pierre and Vezina, 1997, Valadez and Schenk, 1994), which can 
be driven by an acceleration for the escalation in level of drug intake (Ferrario and Robinson, 
2007), increased incentive to work for a drug in a progressive ratio scale (Lorrain et al., 2000), as 
well as drug place preference (Shippenberg and Heidbreder, 1995). As with any model there are 
evidently caveats in its validity to represent drug addiction. Perhaps most critically, research has 
demonstrated that psychomotor sensitisation can be dissociated from the compulsive escalation of 
drug taking (Ahmed and Cador, 2006, Lenoir and Ahmed, 2007) and compulsive drug seeking 
(Brown et al., 2010b). Albeit these limitations, psychomotor sensitisation has provided a useful 
model for identifying neural adaptations that may be implicated in the pathophysiology of addiction 
(Steketee and Kalivas, 2011). The aim of this thesis is not to develop a model of drug addiction. As 
such, there is extensive literature on behavioural locomotor sensitisation from studies targeted 
towards understanding the neural mechanisms of drug addiction. This review will focus on the 
mechanisms associated with locomotor sensitisation, as this is the behaviour most pertinent to the 
experiments conducted in this thesis. 
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Figure 1.3 Profiles of sensitisation  
The longitudinal profile of drug-induced behavioural sensitisation in rodents, the postulated endogenous sensitisation in 
schizophrenia pathophysiology and exogenous sensitisation occurring in human drug addicts. Adapted from Ujike 
(2002).  
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1.5 MK-801  
MK-801 is a potent, non-competitive antagonist of the NMDAR (Wong et al., 1986). The 
compound was first discovered in 1982 by a research team at Merck (Wong et al., 1986). MK-801 
binds within the ion channel of the NMDAR in a ligand- and voltage-dependent manner (Huettner 
and Bean, 1988). This binding site is also targeted by the dissociative anaesthetics ketamine and 
PCP (Wong et al., 1986). MK-801 selectively antagonises the effects of NMDA but not to kainate 
or quisqualate, which are the pharmacological agonists of kainate and AMPARs, respectively 
(Wong et al., 1986).  It should be noted that MK-801 is also reported to block nicotinic 
acetylcholine receptors (Amador and Dani, 1991, Ramoa et al., 1990). MK-801 binds preferentially 
to NMDARs in the open state (Figure 1.2c) (Huettner and Bean, 1988). Opening the channel 
requires binding of the glutamate neurotransmitter and glycine/serine co-agonist, and removal of the 
Mg2+ block by depolarization (Huettner and Bean, 1988). Since MK-801 binds within the ion 
channel, it blocks the influx of ions - mostly Ca2+ and Na+ - as well as the efflux of K+ (Huettner 
and Bean, 1988). 
MK-801 has been found to increase the efflux of glutamate in key regions associated with 
schizophrenia, including the prefrontal cortex (PFC) and striatum (Jonkers et al., 2002, Roenker et 
al., 2012, Zuo et al., 2006). Exposure to acute MK-801 also induces dopamine efflux in these same 
brain regions, as well in the hippocampus (Kretschmer, 1999, Mathe et al., 1999, Schmidt and 
Fadayel, 1996, Wedzony et al., 1993b, Whitton et al., 1992). Further investigation into the effects of 
MK-801 on dopamine release in the NAc revealed that this increase was specifically localized to 
the limbic-associated NAc shell sub-region, and not in the motor-associated NAc core sub-region 
(Marcus et al., 2001). The augmenting effect of MK-801 on the dopaminergic and glutamatergic 
systems has led to investigation into its effects on rodent behaviour, and especially in generating 
schizophrenia-like behaviours (Bubenikova-Valesova et al., 2008).  
1.5.1 Behavioural effects of MK-801  
MK-801 has anticonvulsant and potentially anaesthetic properties (Clineschmidt et al., 1982). 
However MK-801 is not used clinically in humans because when it was administered at high doses 
to rodents it was found to produce neurotoxic Olney’s lesions in the brain (Olney et al., 1989).  
Thus all behaviours described here refer to behavioural studies in rodents. As mentioned earlier, 
MK-801 is often utilized as a pharmacological tool for studying the role of NMDARs for various 
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drug-induced behaviours. In this section, I will describe the behavioural effects of MK-801 that 
have been studied, focusing on those with relevance to schizophrenia. 
Acute administration of MK-801 to rodents’ dose-dependently induces hyperlocomotion (Bubser et 
al., 1992, Kuribara et al., 1992b, Qi et al., 2008, Szabo et al., 2005, Zuo et al., 2006). With repeated 
administration, MK-801-induced locomotor activity can either become decreased - indicative of a 
tolerance-like effect - or increased, indicative of sensitisation (Kuribara et al., 1992a, Wolf et al., 
1993). Hyperlocomotion is frequently used as a behavioural read-out in rodent models with 
translational relevance to psychosis, particularly to the positive symptoms of schizophrenia (Jones 
et al., 2011). Acute MK-801 delivery also induces stereotypic behaviour such as head weaving 
(Sharkey et al., 1994) and turning (Qi et al., 2008) in a dose-dependent manner that is reversible by 
the co-administration of typical and atypical antipsychotics (Gattaz et al., 1994). This indicates that 
MK-801 exposure in rodents has some predictive validity in assessing antipsychotic drugs. At very 
high doses, MK-801 induces ataxia, resulting in the loss of motor co-ordination (Liljequist et al., 
1991). This is high dose induced ataxic behaviour and is not reflective of schizophrenia-like 
symptoms.  
In line with MK-801’s ability to induce a schizophrenia-relevant behavioural phenotype, MK-801 
has also been shown to disrupt the sensory gating of information, a robust phenotype in 
schizophrenia (Braff et al., 1978, Braff et al., 2001, Weike et al., 2000). One of the most 
translational measurements of sensory gating is a deficit in prepulse inhibition (PPI) (Green and 
Braff, 2001). Deficits in PPI of the ASR are reported after acute MK-801 exposure (Arai et al., 
2008, Bubenikova-Valesova et al., 2007). Sensitisation to PPI deficits is reported to accompany the 
development of locomotor sensitisation following repeated MK-801 exposure (Schulz et al., 2001).  
Social withdrawal, a feature of the negative symptoms of schizophrenia, is a symptom that persists 
throughout the course of the illness (Mueser et al., 1990). In response to acute MK-801 exposure 
rodents display deficits in social interaction (Zou et al., 2008) and social investigation (Rung et al., 
2005, van der Staay et al., 2011), reminiscent of human social withdrawal. By comparison, rats 
sensitised to MK-801 display social interaction deficits both in the absence and presence of an MK-
801 challenge, indicative of a long-term NMDAR dysfunction (Huang et al., 2012).  
Cognitive deficits are a core feature of schizophrenia and include deficits in general intelligence, 
attention, working memory, verbal fluency, verbal learning and memory and executive functioning 
(Bowie and Harvey, 2006). At low doses, acute MK-801 exposure induces impairments in spatial 
learning and short-term memory on tasks such as the Morris water maze (MWM) (Pitkanen et al., 
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1995, van der Staay et al., 2011). Following chronic administration of MK-801, rats show both 
short- and long-term deficits on the MWM test (Li et al., 2011).  The 5-choice serial reaction time 
task (5CSRTT) is a measure of attention in rodents (Robbins, 2002). Acute MK-801 treatment in 
rats produced a behavioural profile reflective of impaired attention in the 5CSRTT (Paine and 
Carlezon, 2009). In contrast, brief withdrawal from chronic MK-801 (24h) results in a behavioural 
profile reminiscent of reduced motivation, therefore reflecting negative schizophrenia-like 
symptoms (i.e. avolition) (Paine and Carlezon, 2009).   
Both the acute and subchronic/chronic effects of MK-801 described above recapitulate behaviours 
relevant to the positive, negative and cognitive symptoms of schizophrenia. MK-801 is therefore a 
well-accepted pharmacological tool for studying schizophrenia-like phenotypes in rodents 
(Bubenikova-Valesova et al., 2008, Meltzer et al., 2013). Together with research on PCP and 
ketamine, withdrawal from repeated NMDAR antagonist treatment in rodents has been proposed to 
mimic the neurochemical, neuroanatomical and behavioural alterations most closely correlated to 
clinical observations of schizophrenia (Bubenikova-Valesova et al., 2008, Jentsch and Roth, 1999, 
Mouri et al., 2007). Furthermore the effects of drug sensitisation on animal behaviours are 
considered a model for the worsening of symptoms in schizophrenia (Jentsch and Roth, 1999, 
Lieberman et al., 1997). Despite the apparent advantages a chronic or sensitised MK-801 animal 
model would have over an acute MK-801 animal model, there is limited knowledge on the 
mechanisms underlying sensitisation to MK-801 to apply to the potential neurobiology 
underpinning schizophrenia.  
 
1.6 NEUROBIOLOGY OF BEHAVIOURAL SENSITISATION  
As described earlier, MK-801 was first represented in behavioural sensitisation research as an 
inhibitor of the development of sensitisation to drugs of abuse. MK-801 has the ability to block 
sensitisation to another drug and still induce behavioural sensitisation to its own locomotor effects 
(Wolf and Khansa, 1991). This is the first indication that MK-801 may have a divergence between 
the neural mechanisms underlying its self-sensitisation and the sensitisation mechanisms for other 
drugs of abuse. As reviewed by Vandershuren and Kalivas (2000), the neural mechanisms 
underlying sensitisation to different drugs of abuse share some similarities, but are not identical 
between different drugs. A complete review of all the distinct mechanisms of behavioural 
sensitisation to different drugs of abuse is far beyond the scope of this thesis. As there is abundant 
literature on sensitisation to the psychostimulants amphetamine and cocaine (Steketee and Kalivas, 
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2011), I will primarily focus on these drugs to highlight the key pathways in behavioural 
sensitisation and contrast these with putative mechanisms in MK-801 induced sensitisation. In the 
remainder of this review, the emphasis will fall on the role of dopaminergic, glutamatergic and 
stress mechanisms in behavioural sensitisation to drugs of abuse, thus putting into context the small 
literature available on MK-801 induced sensitisation. 
Drug-induced behavioural sensitisation is predominately mediated by the mesocorticolimbic system 
(Steketee and Kalivas, 2011). The mesocorticolimbic system consists of the ventral tegmental area 
(VTA), and its major dopamine targets, the NAc and PFC (Beier et al., 2015). The NAc receives 
glutamatergic feedback from the PFC, as well as the hippocampus and amygdala, which regulate 
dopamine release (Friedman et al., 2002, Phillipson and Griffiths, 1985). The VTA also receives 
glutamatergic feedback from the PFC and NAc. The VTA is one of the central brain regions 
mediating the induction of sensitisation (Kalivas et al., 1993). The NAc also plays a key role in the 
induction of sensitisation (Heusner and Palmiter, 2005) and is also the central region mediating the 
expression of sensitisation (Kalivas et al., 1993). Other regions, in particular the PFC, play a 
modulatory role in both phases of sensitisation. Evidence for the involvement of these regions 
originates from a plethora of lesion and intra-cerebral microinjection studies and most recently, 
optogenetic stimulation studies (Li et al., 1999, Pierce et al., 1998b, Tzschentke and Schmidt, 
1998). Alterations in the dopaminergic and glutamatergic systems associated with behavioural 
sensitisation occur in both a brain region-dependent and phase-dependent manner.  
 
1.6.1 Dopamine in behavioural sensitisation  
1.6.1.1 Psychostimulant sensitisation and dopamine release  
The majority of drugs of abuse increase mesocorticolimbic dopamine signalling, either directly or 
indirectly (Dichiara and Imperato, 1988), though it is noted that hallucinogens such as Lysergic acid 
diethylamide (LSD) decrease mesocorticolimbic dopamine release (Hetey and Quiring, 1980). 
During the induction phase of behavioural sensitisation, dopamine signalling is primarily altered in 
the VTA. During the withdrawal phase, a transient switch is proposed to occur with dopamine 
signalling returning to normal in the VTA, and enhanced dopamine signalling occurring in the NAc 
during expression. Early reports indicated that cocaine-evoked dopamine release was augmented in 
the VTA of cocaine-sensitised animals (Kalivas and Duffy, 1993b). This effect was only transient, 
and dopamine levels in the VTA retuned to normal after withdrawal (Kalivas and Duffy, 1993b). 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme for dopamine synthesis. In contrast to 
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dopamine release, increased activity and levels of TH in the VTA are consistently elevated 
throughout both the induction and expression phases of psychostimulant-induced sensitisation 
(Beitnerjohnson et al., 1992, Beitnerjohnson and Nestler, 1991, Kalivas et al., 1988, Masserano et 
al., 1996, Sorg et al., 1993). The long-lasting increase in TH activity in the VTA may contribute to 
the increased release of dopamine in the NAc during the expression phase. In response to a drug 
challenge, animals sensitised to cocaine, amphetamine, morphine or nicotine all show enhanced 
dopamine release in the NAc (Addy et al., 2010, Johnson and Glick, 1993, Kalivas and Duffy, 
1990, Robinson et al., 1988, Shoaib et al., 1994). This is the most replicated finding associated with 
the expression of sensitisation to all drugs of abuse, which suggests this is a convergent mechanism 
mediating the expression of sensitisation (Ujike, 2002, Vanderschuren and Kalivas, 2000).  
In contrast to the robust reports on dopamine release in the NAc, the effects on dopamine release in 
the PFC following psychostimulant sensitisation is less clear. Cocaine pre-treated animals were 
reported to show attenuated dopamine release in the PFC in response to a cocaine challenge after a 
short withdrawal period (1, 6 and 7 days) (Sorg et al., 1997, Williams and Steketee, 2005). 
However, during a longer withdrawal period (30 days) dopamine release in the PFC is increased in 
response to a cocaine challenge in cocaine-sensitised animals (Williams and Steketee, 2005). 
Consistent with the observed effects in cocaine sensitisation, amphetamine sensitised animals show 
no change in PFC dopamine release during the early withdrawal period (Peleg-Raibstein and 
Feldon, 2008). Nicotine-induced sensitisation however is associated with enhanced PFC dopamine 
release during the early phase of withdrawal (Nisell et al., 1996). These studies would suggest that 
dopaminergic changes in the PFC are both drug-dependent and phase-dependent, and perhaps not a 
central mediator in the expression of drug-induced behavioural sensitisation.  
 
1.6.1.2 Psychostimulant sensitisation and dopamine receptors 
In accordance with alterations in mesocorticolimbic dopamine release, the dopamine receptors play 
a central role in drug-induced behavioural sensitisation. A transient subsensitivity of the dopamine 
D2 ‘autoreceptors’ is observed in the VTA immediately after repeated cocaine treatment 
(Ackerman and White, 1990, Henry et al., 1989, White and Wang, 1984). Inhibition of the 
dopamine D1 receptors (D1Rs) in the VTA attenuates the induction of sensitisation to 
amphetamine, but not to cocaine (Bjijou et al., 1996, Steketee, 1998, Stewart and Vezina, 1989). 
The same effect of D1R inhibition on amphetamine sensitisation is not observed with 
pharmacological inhibition of dopamine D2 receptors (D2Rs) (Bjijou et al., 1996). However, 
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repeated pharmacological inhibition of VTA D2Rs with eticlopride does result in a sensitised 
response to amphetamine challenge (Tanabe et al., 2004). Moreover, repeated intra-VTA 
administration of a D1R agonist results in a sensitised response to cocaine (Pierce et al., 1996b). 
Co-administration of less selective dopamine receptor antagonists such as haloperidol, which acts 
on D1Rs and D2Rs, has been found to block cocaine and amphetamine sensitisation (Mattingly et 
al., 1996, Meng et al., 1998). Overall, the induction of psychostimulant sensitisation appears to 
involve dampening of D2R signalling, allowing for enhanced signalling at the D1Rs. Due to their 
subsensitivity, the autoreceptors fail to suppress dopamine release, allowing cocaine to further 
enhance activation of dopamine projection neurons (Kalivas and Duffy, 1993b). 
Increased dopamine signalling from the VTA to the NAc has been proposed to alter the sensitivity 
of dopamine receptors on medium spiny neurons (MSNs) in the NAc (Henry and White, 1991). 
Specifically, ‘supersensitivity’ of the D1Rs in the NAc is associated with the expression of cocaine 
sensitisation (Henry and White, 1991). Consistent with the changes in D1R sensitivity, 
pharmacological inhibition of these receptors can block the expression of sensitisation following a 
psychostimulant challenge (White et al., 1998). Within the striatum, the MSNs are generally 
classified into D1 MSNs or D2 MSNs based on their expression of either of the dopamine receptor 
subtypes (Gerfen et al., 1990, Smith et al., 1998). It is estimated that approximately 6% of striatal 
MSNs co-express both the D1 and D2 receptor (Bertran-Gonzalez et al., 2008), therefore there is 
not complete distinction in the roles of the MSN subtypes.  Broadly however, D1 MSNs exert 
positive regulation on locomotor behaviour whereas D2 MSNs negatively regulate locomotor 
behaviour (Durieux et al., 2012). It has been shown that mice with hypofunctioning NMDARs on 
the D1 MSNs show a normal response to acute cocaine, but fail to sensitise following repeated 
cocaine exposure (Heusner and Palmiter, 2005). This study suggests NMDAR-mediated plasticity 
on D1 MSNs of the NAc are a critical component in the development of sensitisation. In vivo 
optogenetic inhibition of the D1 MSNs in the NAc alongside repeated cocaine exposure was found 
to inhibit locomotor sensitisation to cocaine (Chandra et al., 2013, Lobo et al., 2010). Congruent 
with this effect, optogenetic activation produced the opposite effect. Furthermore, optogenetic 
activation of D2 MSNs in the NAc was found to block cocaine sensitisation (Chandra et al., 2013, 
Lobo et al., 2010). Together these findings are indicative of a role for the enhancement of the D1 
MSNs, and attenuation of the D2 MSNs, in mediating behavioural sensitisation to drugs of abuse 
(Lobo and Nestler, 2011). 
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1.6.1.3 MK-801 sensitisation and dopamine release  
Whilst MK-801-induced sensitisation is associated with changes in dopamine signalling, it is 
important to note that in neonatal 6-hyrdoxydopamine (OHDA)- lesion rats, that have severely 
depleted dopamine levels, repeated MK-801 administration could still produce locomotor 
sensitisation (Criswell et al., 1993). This would suggest that, as is the case for acute MK-801 
locomotion (Carlsson and Carlsson, 1989), MK-801 locomotor sensitisation might not be reliant on 
dopamine. However, a number of alterations in the dopaminergic system are associated with MK-
801 sensitisation. For example, core features such as increased TH expression have been observed 
within the VTA during short-term expression (Huang et al., 2012). Furthermore, the expression of 
MK-801 sensitisation is associated with enhanced release of dopamine in the NAc in response to 
MK-801 challenge (Wolf et al., 1993). Augmented mesoaccumbal dopamine release is a core 
feature of sensitisation to all drugs of abuse (Ujike, 2002, Vanderschuren and Kalivas, 2000). 
Therefore MK-801 sensitisation appears to share enhanced mesoaccumbens dopamine signalling 
properties previously associated with the sensitisation induced by other drugs. Research from our 
lab has revealed that MK-801-sensitised rats show a delayed increase in PFC dopamine release in 
response to MK-801 challenge, when compared to non-sensitised rats (Cui et al., 2015). These 
effects in the PFC in MK-801 more closely resemble the dopaminergic changes reported during 
nicotine sensitisation in contrast to amphetamine and cocaine sensitisation, as described above 
(Section 1.6.1.1).  
 
1.6.1.4 MK-801 sensitisation and dopamine receptors  
During the induction of sensitisation to MK-801, the D2Rs appear to play a mediatory role, though 
the direction of action remains unclear. For instance, decreased density of the D2Rs is reported in 
the VTA following MK-801 sensitisation (Huang et al., 2012), which suggests a similarity to the 
D2R subsensitivity reported in psychostimulant sensitisation. However, repeated systemic 
administration of a D2R agonist, bromocriptine, was found to cross-sensitise with an MK-801 
challenge (Wise et al., 1996). This suggests that enhanced, rather than dampened D2R activity 
promotes the induction of MK-801 sensitisation. Pharmacological inhibition of the D1Rs has no 
effect on the induction of MK-801 sensitisation (Wolf et al., 1993). During the expression of MK-
801 sensitisation however, D1Rs in the NAc are supersensitive to dopamine stimulation (Wolf et 
al., 1993). Pharmacological inhibition of these D1Rs does not attenuate the sensitised locomotor 
response to MK-801 at expression (Wolf et al., 1993). Together this literature suggests that 
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dopaminergic signalling may be a part of the MK-801 sensitisation process, though is not 
necessarily required or sufficient for behavioural sensitisation to MK-801 to be observed.  
 
1.6.2 Glutamate and behavioural sensitisation  
1.6.2.1 Psychostimulant sensitisation and glutamate release  
Glutamatergic signalling plays a significant role in drug-induced behavioural sensitisation, 
particularly in mediating drug-evoked synaptic plasticity. An acute amphetamine injection has been 
shown to increase extracellular glutamate levels in the VTA (Xue et al., 1996), and both repeated 
systemic injections of cocaine or amphetamine increase extracellular VTA glutamate levels 
(Kalivas and Duffy, 1998, Xue et al., 1996). Additionally, repeated cocaine or amphetamine 
administration was found to increase sensitivity to glutamate in the VTA (White et al., 1995). In 
support of the role for VTA glutamate in sensitisation, repeated intra-VTA administration of the 
glutamate uptake inhibitor L-trans-pyrollidine-2,4-dicarboxylic acid (L-trans- PDC) lead to a 
sensitised behavioural response to amphetamine challenge (Aked et al., 2005). This indicates that 
enhancing glutamate levels in the VTA is sufficient to induce behavioural sensitisation.  
During the expression phase, glutamate release is enhanced in the NAc in response to a drug 
challenge in rodents sensitised to cocaine, amphetamine or ethanol (Kalivas and Duffy, 1998, 
Kapasova and Szumlinski, 2008, Pierce et al., 1996a, Reid and Berger, 1996, Zhang et al., 2001). 
Recent studies using a chronically implanted glutamate micro-biosensor demonstrated that repeated 
intravenous self-administration of cocaine or nicotine led to progressively increasing locomotor 
activity and progressively increasing glutamate release in the NAc (Lenoir and Kiyatkin, 2013, 
Wakabayashi and Kiyatkin, 2014). Increased glutamate release appears to be involved in both the 
induction and expression phases of drug-induced behavioural sensitisation, which is also reflected 
in the receptor systems mediating glutamatergic transmission.  
 
1.6.2.2 Psychostimulant sensitisation and glutamate receptors  
Glutamatergic signalling, particularly via ionotropic NMDA and AMPA receptors, plays a key 
mediatory role in behavioural sensitisation. Co-administration of NMDAR antagonists such as MK-
801, or AMPAR antagonists during the induction phase can block the development of sensitisation 
to drugs of abuse including amphetamine, cocaine, morphine, ethanol and nicotine (Karler et al., 
1994, Karler et al., 1989, Li et al., 1999, Li et al., 1997). NMDAR and AMPAR antagonists also 
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block the development of neuroadaptations associated with behavioural sensitisation. These include 
increased TH in the VTA (Masserano et al., 1996), D2 autoreceptor subsensitivity and NAc D1R 
supersensitivity (Li et al., 1999). These results indicate that (1) these neuroadaptations are required 
for the induction of sensitisation and (2) glutamatergic signalling via the ionotropic receptors may 
mediate dopaminergic adaptations.  
Drug-evoked plasticity in the VTA is a form of metaplasticity, thought to facilitate the further 
neuroadaptations induced by repeated drug exposure (Luscher, 2013). Following administration to a 
single dose of cocaine, the ratio between the amplitude of AMPAR- and NMDAR-mediated 
excitatory post-synaptic currents (EPSCs) (AMPAR/NMDAR ratio) is increased when measured in 
an ex-vivo VTA slice 24h later (Ungless et al., 2001). The increase in ratio is due to (1) decreased 
NMDAR current via recruitment of the NR2B subunit (Bellone and Luscher, 2012, Mameli et al., 
2011) and (2) increased AMPAR current via redistribution of the Ca2+ permeable GluR2-lacking 
subunit (Argilli et al., 2008, Bellone and Luscher, 2006). This increased AMPAR current occurs 
within 3h after exposure and lasts up to 5, but not 10, days (Argilli et al., 2008, Bellone and 
Luscher, 2006, Borgland et al., 2004, Saal et al., 2003b, Ungless et al., 2001). The transient nature 
of this alteration in AMPA/NMDA receptors in the VTA suggests that this may be an important 
factor for initiating sensitisation.  
In vivo optogenetic activation of dopamine neurons in the VTA mimics the acute effects seen with 
drugs of abuse, leading to an increased AMPAR/NMDAR ratio in the VTA (Brown et al., 2010a). 
Therefore, all drugs of abuse that stimulate mesolimbic dopamine release should be capable of 
enhancing excitatory synaptic plasticity. So far amphetamine, morphine, nicotine, ethanol, 
benzodiazepines and stress have all been shown to increase the AMPAR/NMDAR ratio in the VTA 
(Mao et al., 2011, Saal et al., 2003b, Tan et al., 2010). Importantly, non-abused psychoactive drugs, 
such as fluoxetine and carbamazepine that do not enhance mesolimbic dopamine release do not 
increase excitatory synaptic plasticity (Saal et al., 2003b). This indicates that changes in excitatory 
synaptic strength via mesolimbic dopamine overflow may be one specific alteration induced by 
substances of abuse.  
Drug-induced plasticity in the VTA and NAc are linked hierarchically (Creed and Luscher, 2013). 
Initial plasticity in the VTA sets the stage for synaptic plasticity in the NAc (Mameli et al., 2009).  
In the NAc, the AMPAR/NMDAR ratio is not altered by acute cocaine (Kourrich et al., 2007). One 
day after repeated cocaine treatment the AMPAR/NMDAR in the NAc is decreased and with 
increasing withdrawal from the induction phase the AMPAR/NMDAR ratio becomes increased 
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(Kourrich et al., 2007). Subsequent to a drug challenge the AMPAR/NMDAR ratio becomes 
rapidly ‘de-potentiated’, returning to the potentiated state after withdrawal from the challenge 
(Jedynak et al., 2016, Kourrich et al., 2007, Thomas et al., 2001). These changes in excitatory 
synaptic strength are reflective of altered synaptic plasticity mechanisms. The expression of 
behavioural sensitisation to amphetamine is blocked by the administration of a GluA23Y peptide that 
acts to inhibit AMPAR endocytosis and synaptic plasticity (Brebner et al., 2005, Choi et al., 2014a). 
Importantly, the reversal of cocaine-evoked synaptic plasticity in the NAc, via in vivo optogenetic 
depotentiation, abolishes locomotor sensitisation (Pascoli et al., 2012). These studies indicate that 
changes in excitatory synaptic strength are required for the expression of drug-induced sensitisation.  
In a cocaine-sensitised rodent, intra-NAc administration of AMPA, but not NMDA can elicit a 
hyperlocomotor response (Pierce et al., 1996). The ability of AMPA to elicit a sensitised response 
may stem from the increased AMPAR/NMDAR ratio in the NAc at expression of cocaine 
sensitisation (Wolf, 2010). Though there is some variation between studies based on the drugs of 
interest, both NMDAR and AMPAR antagonists have been shown to block the expression of 
behavioural sensitisation to drugs of abuse including amphetamine and cocaine (Li et al., 1997, Li 
et al., 1999b, Karler et al., 1994). Protracted withdrawal from the induction of cocaine sensitisation 
reveals enhanced synaptic plasticity and the recruitment of Ca2+- permeable, GluR2- lacking 
AMPARs into the NAc (Mameli et al., 2009, Kourrich et al., 2007). The increased Ca2+ 
permeability of the excitatory synapses enhances the responsiveness of MSNs in the NAc core to 
glutamate inputs from cortical and limbic regions (Mameli et al., 2009, Wolf and Ferrario, 2010).  
The application of optogenetics in ex vivo slices has revealed that the increase in excitatory synaptic 
strength is primarily driven by the ventral hippocampus, which has the strongest input to the NAc 
shell (Britt et al., 2012). In recent years, technical advancements have led to the development of 
Bacterial Artificial Chromosome (BAC) transgenic mice that express differentiating fluorescent 
proteins in the D1 and D2 MSNs (Shuen et al., 2008). Emerging evidence suggests that increases in 
synaptic strength and plasticity occur in a cell-type specific manner on the D1 ‘reward-promoting’ 
MSNs, following withdrawal from drugs of abuse including morphine (Hearing et al., 2016), 
cocaine (Pascoli et al., 2012) and ethanol (Jeanes et al., 2014, Renteria et al., 2016). Thus this 
suggests that drug-induced sensitisation is facilitated by enhanced glutamatergic synaptic input onto 
the ‘direct’ striatal dopaminergic pathway.  
There is also increasing evidence that by controlling glutamatergic transmission, the mGlu receptors 
play a critical role in drug-induced behavioural sensitisation. The presynaptic Group II mGlu 
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receptors, which decrease evoked presynaptic glutamate release in a negative feedback manner, are 
thought to be particularly critical. Firstly, in the NAc Group II mGlu receptor function and 
expression is decreased following repeated cocaine administration, leading to increased glutamate 
release in this region (Xi et al., 2002b). In amphetamine-sensitised animals, systemic injection of 
the mGlu2/3 agonist LY354740 prior to amphetamine challenge blocked the amphetamine-induced 
glutamate and dopamine overflow in the NAc, as well as the expression of amphetamine locomotor 
sensitisation (Kim et al., 2005, Kim and Vezina, 2002). Correspondingly, intra-NAc injection of 
Group II mGlu receptor antagonists in amphetamine-sensitised animals can elicit a sensitised 
locomotor response (Chi et al., 2006, Kim and Vezina, 1998). These data suggest the presynaptic 
group II mGlu receptors regulate the enhanced glutamatergic signalling in drug-induced 
behavioural sensitisation. Group I (mGlu1/5) receptors appear less likely to be involved in the 
development of drug-induced behavioural sensitisation. For example, in mGlu5 knock-out mice, 
repeated administration of cocaine led to a sensitised behavioural response (Bird et al., 2010). 
Interestingly, the authors found the behavioural sensitisation developed in the absence of 
AMPAR/NMDAR changes in the VTA (Bird et al., 2010). This would potentially suggest 
alternative mechanisms are capable of triggering cocaine induced behavioural sensitisation.  
 
1.6.2.3 MK-801 sensitisation and glutamate release  
Though there is a wealth of knowledge on the role of glutamate in behavioural sensitisation to other 
drugs of abuse, very little is known in regards to MK-801 sensitisation. Repeated administration of 
a high dose of MK-801 leads to a tolerance-like effect to the locomotor-stimulatory effects of MK-
801 (Zuo et al., 2006). This behavioural tolerance is associated with a decrease in the stimulatory 
effects of MK-801 on glutamate release in the PFC (Zuo et al., 2006). Therefore it is plausible that 
behavioural sensitisation, the opposing behaviour to tolerance, may be associated with increased 
glutamatergic transmission in the PFC. However, this is yet to be demonstrated.  
The PFC projects glutamatergic afferents to the NAc (Friedman et al., 2002, Phillipson and 
Griffiths, 1985). Glutamatergic feedback from the PFC to the NAc modulates the acute locomotor 
stimulatory effects of MK-801 (Tzschentke and Schmidt, 1998b, Scorza et al., 2008), as 
demonstrated with a quinolinic acid-induced lesion of the PFC. Following repeated MK-801 
administration, i.e. post-induction of sensitisation, this lesion of the PFC did not inhibit the 
expression of MK-801-induced sensitisation (Tzschentke and Schmidt, 2000). The lack of effect of 
the PFC is in stark contrast to the inhibiting effect a PFC lesion has on the induction and expression 
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of cocaine behavioural sensitisation (Li et al., 1999, Pierce et al., 1998b, Tzschentke and Schmidt, 
1998). This suggests that glutamatergic feedback from the PFC is not required for the expression of 
sensitisation to MK-801, and its role differs between drugs of abuse and MK-801.  
Repeated administration of high doses of methamphetamine can induce a cross-sensitisation to an 
MK-801 challenge (Ito et al., 2006a). During the repeated methamphetamine administration phase, 
glutamate release in the NAc is increased (Ito et al., 2006a). This suggests that enhanced NAc 
glutamate signalling may contribute to sensitisation to MK-801. In support of this idea, co-
administration of sodium valproate with methamphetamine during induction attenuated the levels of 
glutamate release in the NAc, and blocked the expression of cross-sensitisation to MK-801 
challenge (Ito et al., 2006b). Valproate is an anticonvulsant agent that exerts it effects primarily 
through potentiation of inhibitory GABAergic neurotransmission and inhibition of histone 
deacetylases (HDAC) (Gottlicher et al., 2001, Loscher, 1999). Co-administration of sodium 
valproate either at the induction phase or during the withdrawal phase was found to block MK-801-
induced sensitisation (Yang et al., 2002). Thus it is plausible that enhanced glutamate signalling, 
under GABAergic control, contributes to the induction and expression of MK-801 sensitisation. 
Evidently further investigation into the role of glutamatergic transmission in MK-801 sensitisation 
is required.  
 
1.6.2.4 MK-801 sensitisation and glutamate receptors  
The role of glutamatergic transmission via the various glutamate receptor subtypes in MK-801-
induced sensitisation is as equally elusive. Cross-sensitisation is the ability of one stimulus/drug to 
induce a sensitised response in animal previously sensitised to another stimulus/drug (Stewart and 
Badiani, 1993). Interestingly, asymmetric cross-sensitisation is observed between MK-801 and the 
non-competitive NMDAR antagonist PCP (Xu and Domino, 1994a). Repeated MK-801 
administration leads to a sensitised locomotor response to PCP challenge, whilst repeated PCP 
exposure does not induce a sensitised response to MK-801 challenge (Xu and Domino, 1994a). In 
contrast, repeated administration of ethanol, which reportedly has NMDAR antagonist properties, 
was found to increase the sensitivity to the locomotor effects of intra-NAc injected MK-801 
challenge (Abrahao and Souza-Formigoni, 2012). Furthermore, co-administration of PCP and MK-
801 did not block sensitisation to a PCP challenge, however no sensitisation to an MK-801 
challenge was observed (Xu and Domino, 1994b). This inhibitory effect of PCP on MK-801 
sensitisation may be attributed to its agonist action at the σ-receptor rather than the NMDAR, 
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though this has yet to be defined. Whilst it would seem self-evident that the antagonism of 
NMDARs is required for MK-801 sensitisation, the conflicting results with PCP make this 
hypothesis disputable. To the best of my knowledge there is currently no literature on the role of the 
AMPARs or mGlu receptors on MK-801-induced sensitisation.  
As described earlier, MK-801 is utilized in preclinical animal models of schizophrenia. Subchronic 
MK-801 rodent models describe positive modulation of the NMDARs in brains regions heavily 
associated with schizophrenia, the PFC and hippocampus. In the PFC, subchronic MK-801 dose-
dependently increased expression of all NMDAR subunits (Xi et al., 2009). Within the 
hippocampus there is a specific increase of the NR1 exon 5 splice variant, which increases 
glutamate sensitivity to NMDARs, and thereby increases excitatory transmission (Rujescu et al., 
2006). Repeated MK-801 exposure also increases recruitment of the NR2B subunit to synapses in 
the hippocampus (Rujescu et al., 2006). Recruitment of the NR2B subunit has previously been 
identified as a positive mediator of excitatory synaptic plasticity (Barria and Malinow, 2005, 
Bellone and Luscher, 2012, Mameli et al., 2011). Therefore, repeated MK-801 exposure may 
enhance excitatory synaptic plasticity in the hippocampus. It is possible then that one outcome of 
repeated MK-801 administration could be to alter the AMPAR/NMDAR ratio in the VTA or NAc. 
 
1.6.3 Stress and behavioural sensitisation  
It is well known that stress is linked to many neuropsychiatric conditions. Accordingly, 
epidemiological studies suggest that stressful life events contribute to the pathophysiology of 
schizophrenia, and that patients suffering from schizophrenia are more vulnerable to stress (Mura et 
al., 2012, Myin-Germeys and van Os, 2007, Norman and Malla, 1993). Stress is also a well-known 
risk-factor for vulnerability to drug addiction development and relapse (Sinha, 2008). A 
sensitisation of the stress signalling pathways is hypothesised to contribute to both the relapse of 
schizophrenia psychosis (Walker et al., 2008, Yuii et al., 2007) and relapse of drug addiction 
(Sinha, 2008). Overall stress, via sensitisation mechanisms, is hypothesised to contribute to the 
pathophysiology of schizophrenia and drug addiction. As such, many preclinical studies have 
focused on the contribution of stress, particularly via the hypothalamic-pituitary-adrenal (HPA) -
axis, to the development and expression of drug-induced behavioural sensitisation. 
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1.6.3.1 Psychostimulant sensitisation and stress  
Stress leads to activation of the HPA axis. Activation of the HPA axis produces increased levels of 
corticotrophin releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and 
glucocorticoids. Exogenous administration of corticosterone can enhance NAc dopamine release 
and increases the acute locomotor effects of psychostimulants (Cador et al., 1993, Deroche et al., 
1995, Piazza et al., 1996). Furthermore, repeated administration of exogenous corticosterone has 
been shown to cross-sensitise with psychostimulants such as amphetamine and cocaine (Deroche et 
al., 1992, Przegalinski et al., 2000). In rodents, a range of physiological stressors, such as foot 
shock, restraint, social defeat and food restriction have all been shown to cross sensitise to typical 
drugs of abuse (Covington and Miczek, 2001, DiazOtanez et al., 1997, Nikulina et al., 2004, 
Roberts et al., 1995). This stress-induced cross-sensitisation to psychostimulants is dependent on 
glucocorticoid levels, as this is blocked by adrenalectomy (Deroche et al., 1995). Together these 
studies show that stress, via glucocorticoids, enhances the sensitivity to psychostimulants.  
As reported in humans, the HPA axis is activated in rodents following acute exposure to drugs of 
abuse including cocaine (Nelson et al., 2010), amphetamine (Knych and Eisenberg, 1979), ethanol 
(Kakihana et al., 1968), and morphine (Milanes et al., 1993). In the absence of any additional 
stressors, glucocorticoids play a critical role in mediating drug-induced behavioural sensitisation. 
The glucocorticoids signal via the high-affinity mineralocorticoid receptors (MR) and low-affinity 
glucocorticoid receptors (GR) (Reul and de Kloet, 1985). A role for these receptors has been 
demonstrated during the induction phase of drug-induced sensitisation. For instance, co-
administration of GR or MR antagonists during the induction phase has been found to inhibit 
sensitisation to cocaine, amphetamine, morphine and ethanol (Prasad et al., 1996, Przegalinski et 
al., 2000, Roberts et al., 1995, van der Veen et al., 2013). In support of a role for the GR in 
psychostimulant sensitisation, mice with selective GR ablations show a blunted behavioural 
sensitisation to cocaine (Deroche-Gamonet et al., 2003). Conversely, overexpression of the GR was 
found to enhance behavioural sensitisation to cocaine (Wei et al., 2012). Furthermore, circulating 
corticosterone levels are crucial for the induction of sensitisation to cocaine. Adrenalectomy prior to 
drug treatment attenuates the development of sensitisation to cocaine, and this could be partially 
rescued by chronic re-introduction  (via pellet) of corticosterone (de Jong and de Kloet, 2009, 
Przegalinski et al., 2000). Taken together, drugs of abuse activate the HPA-axis, and this activation 
is subsequently required for the development of sensitisation.  
The endogenous opioid system, in addition to the HPA axis, regulates the neural response to stress 
(Knoll and Carlezon, 2010). There are a number of subtypes of endogenous opioids, each binding to 
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a specific receptor subtype. These are the endorphins and endomorphins, which act at the mu opioid 
receptor; dynorphin which acts at the kappa opioid receptor and enkephalins which act at the delta 
opioid receptor (Benarroch, 2012). In humans, the dynorphin/KOR system has been implicated in 
neuropsychiatric disorders including schizophrenia and drug addiction (Tejeda et al., 2012). For 
example, KOR agonists produce psychomimetic effects in humans similar to schizophrenia 
(Pfeiffer et al., 1986) and thereby similar to the psychomimetic effects of ketamine and PCP 
observed in humans. Polymorphisms in the prodynorphin promoter have also been associated with 
schizophrenia (Zhang et al., 2004) and polymorphisms in the KOR gene (OPRK1) have been 
reported in drug addicts (Chen et al., 2002). In rodents dynorphin/KOR activity is increased 
following social or physical stress, as well as exposure to drugs of abuse, through a CRF 
mechanism (Bruchas et al., 2010, Van't Veer et al., 2012). Through a dopamine-dependent 
mechanism CRF can induce increases in dynorphin release in striatal brain regions (Sirinathsinghji 
et al., 1990). KOR activation is thought to be a contributing mechanism for the pro-addictive effects 
of stress (Bruchas et al., 2010).  
KORs and dynorphin are densely expressed in the NAc (Svingos et al., 1999), particularly on D1 
GABAergic MSNs (Ma et al., 2003). KORs are also localized on the terminals of presynaptic 
excitatory synapses in the NAc (Meshul and McGinty, 2000, Svingos et al., 1999). Thus the KORs 
are locally poised to modulate excitatory transmission. KOR activation inhibits presynaptic 
glutamate release (Hjelmstad and Fields, 2003) and decreases evoked glutamate overflow in the 
NAc (Rawls et al., 1999). KOR activation also decreases dopamine release in the NAc (Di Chiara 
and Imperato, 1988). In the absence of stress, KOR agonists have been shown to block the 
development of sensitisation to morphine (Spanagel, 1995), as well as cocaine (Heidbreder et al., 
1993). Intriguingly, KOR antagonists have been found to block the potentiating effect stress has on 
drug-induced behavioural sensitisation (Allen et al., 2013, Jackson et al., 2013, McLaughlin et al., 
2003). The role of KORs in the development of drug-induced sensitisation therefore appears to be 
modulated by the presence of stress.  
 
1.6.3.2 MK-801 sensitisation and stress  
Acute exogenous administration of corticosterone in rodents enhances the acute locomotor 
stimulatory effects of MK-801 (Wedzony and Czyrak, 1994). Repeated physiological stress, such as 
food restriction, results in cross-sensitisation to the locomotor stimulatory effects of MK-801 (de 
Vaca and Carr, 1998). Other behavioural effects of MK-801, such as inducing memory deficits, are 
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also potentiated by physiological stressors (Castellano et al., 1999, Cestari et al., 1999). These 
isolated studies indicate that MK-801-induced behaviour is augmented by stress, most likely 
through enhanced corticosterone signalling.  
As described for other drugs of abuse, acute MK-801 administration also stimulates corticosterone 
release in rodents (Baumann et al., 2000, Pechnick et al., 1989, Wedzony and Czyrak, 1994). 
Corticosterone signalling is proposed to play a crucial role in the development of sensitisation to 
MK-801. This has been demonstrated in a two-injection sensitisation paradigm where a single acute 
administration of MK-801 is followed by an MK-801 challenge 48h later (Wedzony and Czyrak, 
1994). The authors showed that pre-treatment with either metyrapone (corticosterone synthesis 
inhibitor) or the GR antagonist RU486 had no effect on acute MK-801-induced locomotor activity. 
However, the sensitised response to the MK-801 challenge 48h later was attenuated in animals that 
had been pre-treated with either metyrapone or RU486 (Wedzony and Czyrak, 1994). Thus this 
study suggests that corticosterone signalling via the GR is required for the development of MK-801 
sensitisation. The role of the corticosteroids in the development of sensitisation to repeated MK-801 
administration is currently unknown.  
 
1.7 SUMMARY  
Drug-induced behavioural sensitisation involves a tapestry of several intertwined signalling 
pathways. Despite decades of research the precise nature of these mechanisms is still poorly 
understood. These pathways act in complex cascades, triggering neuroadaptative processes that are 
critical for the phenomena of behavioural sensitisation. Here I have focused on three key 
mechanistic pathways (dopamine, glutamate and stress) in behavioural sensitisation and how they 
may mediate MK-801-induced sensitisation. Dopaminergic adaptations that occur during MK-801-
induced behavioural sensitisation appear to occur in a similar manner to that described for 
sensitisation to other drugs of abuse. For reasons discussed earlier however, these dopaminergic 
adaptations are not thought to be pertinent to the downstream mechanisms underlying MK-801 
sensitisation. Sensitisation to drugs of abuse is thought to involve mechanisms that enhance 
glutamatergic signalling in the mesocorticolimbic system. This includes both presynaptic glutamate 
release mechanisms as well as postsynaptic functional receptor adaptations. There is a lack of 
understanding on both the presynaptic and postsynaptic glutamatergic mechanisms involved in MK-
801 sensitisation. Since MK-801 acts to inhibit the glutamatergic NMDAR function, glutamatergic 
mechanisms are a primary target. The last mechanistic pathway discussed in this review is the 
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stress-related factors contributing to drug-induced behavioural sensitisation. Perhaps most critically, 
corticosterone signalling via the GRs has been shown to mediate the development of behavioural 
sensitisation to a number of different drugs of abuse. A single administration of MK-801 produces a 
sensitised response to a subsequent MK-801 challenge, and this sensitisation is dependent on 
corticosterone signalling via the GR. However, the role of GR activation in the development of 
sensitisation to repeated MK-801 administration is unknown.  
 
 
Figure 1.4  Model of the excitatory synapse and the targets of interest investigated in this thesis 
(1) Ex vivo slice electrophysiology was used to determine the ratio of AMPAR to NMDAR mediated excitatory post-
synaptic currents (EPSCs). This provides a measure of the synaptic strength between the excitatory afferents to the NAc 
arising from the PFC, hippocampus (Hipp) or amygdala (AMY) (2) Changes in protein expression in the NAc were 
measured using SWATH proteomics. (3) Radioligand binding assessed for changes in dopamine D1R density in the 
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NAc. (4) The role of corticosterone signalling via the glucocorticoid receptor (GR) was evaluated by systemic injection 
of the GR antagonist RU486 during the induction phase. (5) The role of dynorphin (DYN) signalling via the kappa 
opioid receptor (KOR) was also investigated by pharmacological antagonism with nBNI. (6) Lastly, stimulation of the 
mGlu2/3 receptors reduces presynaptic glutamate release. Therefore to see if increased glutamate signalling was required 
for the expression of MK-801 sensitisation, these mGlu2/3 receptors with stimulated with the pharmacological agonist 
LY354740.   
 
1.8 AIMS AND OUTLINE  
As outlined in the previous paragraphs, there is a substantial knowledge gap regarding the neural 
mechanisms underlying sensitisation to MK-801. MK-801 is a common agent used to 
pharmacologically induce NMDAR dysfunction in animal models relevant to schizophrenia. 
Sensitisation is one proposed mechanism in schizophrenia pathophysiology. Therefore 
understanding the neural changes that lead to a ‘sensitised NMDAR dysfunction’ in an animal 
model may be informative for understanding the shared pathways between addiction and mental 
disorders such as schizophrenia. The main hypothesis of this thesis postulates that mechanisms and 
neuroadaptations previously identified in dopaminergic psychostimulant behavioural sensitisation, 
will differ greatly from those identified in sensitisation to the NMDAR antagonist MK-801. The 
overarching aim of this thesis was to further illuminate mechanisms and neuroadaptations 
associated with behavioural sensitisation to MK-801 in rodents (Figure 1.4). To develop a 
comprehensive rodent model of MK-801-induced sensitisation, a number of external factors known 
to modulate drug-induced behavioural sensitisation were investigated. The varying impact of MK-
801 dose, environmental context, withdrawal period and rat strain on the development and 
expression of MK-801 behavioural sensitisation are reported in Chapter 2. A multidisciplinary 
approach was utilized in Chapter 3 to identify functional and molecular changes in the NAc 
associated with the expression of MK-801 sensitisation. Ex vivo slice electrophysiology was 
implemented to investigate whether MK-801 sensitisation induced alterations in excitatory synaptic 
strength, in a manner similar to reports for sensitisation to other drugs of abuse. A proteomics 
approach was used to address whether MK-801-induced sensitisation caused protein alterations 
relevant to synaptic plasticity. Radioligand binding was used to determine if the density of D1Rs 
reflected changes in D1R sensitivity previously linked with MK-801 sensitisation. Chapter 4 
examined whether MK-801 sensitisation shared similar stress-related mechanisms as sensitisation 
to other drugs of abuse. A pharmacological approach was used, by co-administration of the GR 
antagonist RU486 to investigate whether corticosterone signalling via the GR was required for the 
development of sensitisation to MK-801. Plasma corticosterone levels were assessed with mass-
spectrometry, examining how these changes related to the induction and expression phases of MK-
801 sensitisation. Dopamine and metabolite tissue levels were also quantified in the NAc.  Finally, 
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in Chapter 5 this pharmacological approach was extended to test the role of two different receptor-
signalling pathways in the induction or expression of MK-801 sensitisation. The role of the stress-
related kappa opioid receptors (KORs) during the induction phase was assessed by pre-treatment 
with the KOR antagonist nor-Binaltorphimine. The second part of the chapter assessed whether the 
sensitised response to MK-801 challenge could be attenuated by pre-treatment with the Group II 
mGlu receptor agonist LY354740.  
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Chapter 2  External factors modulating behavioural 
sensitisation to MK-801  
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2.1 INTRODUCTION 
Animal models of behavioural sensitisation have predominately focused on the psychostimulants 
amphetamine and cocaine, and have led to a substantial understanding of the neural mechanisms 
involved in this phenomenon. The impact of external factors such as pattern of administration and 
length of withdrawal, drug dosage, environmental context and genetic background on modulating 
the onset of tolerance or sensitisation to these commonly abused stimulants has been extensively 
characterised. For example, continuous intravenous cocaine administration in rodents has been 
shown to induce tolerance to the behavioural effects of cocaine, whereas intermittent intraperitoneal 
administration led to behavioural sensitisation (Calipari et al., 2013, King et al., 1998, Reith et al., 
1987). Furthermore, higher levels of drug intake appear to induce tolerance and lower levels induce 
sensitisation (Calipari et al., 2013).  
Sensitisation to a number of drugs, such as amphetamine, cocaine, morphine and nicotine, can be 
facilitated or modulated by environmental context (Badiani and Robinson, 2004). Rodents display a 
greater sensitisation when repeated drug administration occurs in a context-paired environment 
(novel test cage) compared to when drug administration occurs in a context-unpaired environment 
(home cage) (Badiani et al., 1995, Badiani et al., 1997, Badiani et al., 2000). Studies also report 
context-paired drug administration produces a conditioned response when a saline injection is given 
in the drug-associated context (Badiani et al., 1995, McPherson and Lawrence, 2006, Ohmori et al., 
2000). Therefore, contextual conditioning is proposed to have an enhancing effect on locomotor 
sensitisation to drugs of abuse. Few studies have investigated MK-801-induced behavioural 
sensitisation. However, MK-801- induced behavioural sensitisation in rodents is proposed to 
recapitulate aspects of the NMDAR hypofunction hypothesis of schizophrenia, warranting further 
investigation using this agent. In order to investigate the neural mechanisms of MK-801 
sensitisation, and its potential relevance to schizophrenia, it is first critical to characterize external 
factors that may modulate sensitisation. 
Studies examining the effect of MK-801 on methamphetamine (Kuribara et al., 1992a) or morphine 
(Jeziorski et al., 1994)-induced behavioural sensitisation give an indication to the role of drug dose 
on the induction or expression of MK-801 sensitisation. In a paradigm used to induce 
methamphetamine sensitisation, mice repeatedly injected with MK-801 every few days were shown 
to develop a progressive tolerance to a high dose of MK-801 (1mg/kg), locomotor sensitisation with 
an intermediate dose (0.3mg/kg) and no behavioural change with a low dose of MK-801 (0.1mg/kg) 
(Kuribara et al., 1992a).  Although this study did not demonstrate whether this dose response 
persists subsequent to drug withdrawal, Jeziorski et al (1994) reported the expression of behavioural 
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sensitisation was evident in rats after 5 days withdrawal from repeated daily (7-10) administrations 
of 0.25mg/kg but not 0.1mg/kg MK-801. No studies to date have examined the role of 
environmental context on the induction and expression of MK-801-induced sensitisation. The 
modulatory effect of environmental context is thought to involve associative learning via activation 
of the NMDARs (Gronig et al., 2004). Behavioural sensitisation to PCP, which acts as an 
antagonist at NMDARs and agonist at σ-receptors, was previously found to be independent of 
environmental context (Clark et al., 2002, Xu and Domino, 1994b). Additionally, behavioural 
sensitisation to ethanol, which acts indirectly as an NMDAR antagonist, was recently reported to be 
independent of environmental context (Didone et al., 2008). Therefore I sought to test the 
hypothesis that behavioural sensitisation to a drug that antagonizes NMDARs, such as MK-801, 
may not be affected by environmental context. 
The expression phase of drug-induced behavioural sensitisation has previously been classified into 
two broadly defined phases. Short-term sensitisation is the behavioural sensitisation observed 
within a short period of withdrawal (days), and long-term sensitisation refers to the behavioural 
sensitisation observed after weeks to months of withdrawal from drug treatment. The 
neuroadaptations that occur during short-term withdrawal are thought to be transient factors that are 
required to evoke the long-lasting neuroadaptations mediating persistent drug-induced behavioural 
sensitisation (Vanderschuren and Kalivas, 2000). Psychostimulant-induced sensitisation is not 
always observed during short-term withdrawal, particularly in paradigms in which a high dose is 
used (Vanderschuren and Kalivas, 2000).  By comparison, opioid-induced sensitisation is more 
typically observed during short-term withdrawal (Vanderschuren and Kalivas, 2000). The limited 
literature on MK-801 sensitisation has generally employed short-term withdrawal periods 
(Wedzony and Czyrak, 1994, Wolf and Khansa, 1991, Yang et al., 2002). Jeziorski et al (1994) 
reported that sensitisation to repeated administration of a low dose of MK-801 (0.1mg/kg) could be 
observed in response to a higher dose challenge (0.25mg/kg) after both short-term withdrawal (3 
days) and long-term withdrawal (17 days). However, neither short-term nor long-term sensitisation 
was elicited when challenged with the same low dose (0.1mg/kg) of MK-801 (Jeziorski et al., 
1994). In contrast, O’Neill et al., (1999) found that sensitisation to a single administration of a high 
dose of MK-801 (1mg/kg) could be elicited by a lower challenge dose (0.3mg/kg) after short-term 
withdrawal (4 and 7 days) and long-term withdrawal (14 days). Therefore the literature suggests 
MK-801 sensitisation may follow a more similar pattern to opioid-induced sensitisation, where it 
emerges during short-term withdrawal and is observed in a paradigm-dependent manner following 
long-term withdrawal.  
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Another question that has not been extensively studied is the role of the rodent background strain in 
MK-801 sensitisation. The magnitude or propensity to develop behavioural sensitisation to other 
drugs of abuse is shown to be substantially distinct between rodent strains (Bailey et al., 2010, 
Cailhol and Mormede, 1999, Iyaniwura et al., 2001, Mouri et al., 2012, Tolliver et al., 1994, 
Yetnikoff and Arvanitogiannis, 2013). Investigations using different rodent strains have led to the 
identification of genetic variations that contribute to the development of behavioral sensitisation, 
such as differences in the mesoaccumbens dopamine release and dopamine transporter density 
(Bailey et al., 2010, Iyaniwura et al., 2001). As behavioural sensitisation is a proposed mechanism 
in both drug addiction and schizophrenia, these genetic differences may provide clues to the 
mechanisms contributing to vulnerability to these neurological disorders. Most of the studies 
published on MK-801-induced sensitisation have used Sprague Dawley (Wolf and Khansa, 1991, 
Wolf et al., 1993, Yang et al., 2002) and Wistar (Wedzony and Czyrak, 1994, Wedzony et al., 
1993a) rats or selected mouse strains (Kuribara et al., 1992a). Thus far, no studies have compared 
the same MK-801 sensitisation paradigm on different background strains. Because there is wider 
variation in behavioural responses to stimulants and psychotropic drugs in different rodent strains, 
genotype can aid in identifying biological substrates for inter-individual variability in the propensity 
to develop behavioural sensitisation.  
The experiments described in this chapter determined the modulatory role of drug dose, 
environmental context, withdrawal phase and rat strain on the development and expression of MK-
801-induced sensitisation. The first experiment manipulated the doses of MK-801 in the 
sensitisation paradigm. I identified an inverted-U dose response in the development of behavioural 
sensitisation, whereby only the intermediate dose was sufficient to induce sensitisation. The dose 
that induced sensitisation was selected to assess whether MK-801-induced sensitisation was 
dependent on environmental context. In the second experiment, this was achieved by treating 
separate groups of rats in one of two environments during the induction phase. The third experiment 
utilized the intermediate dose to determine whether extending the length of the withdrawal phase 
would increase the expression of behavioural sensitisation. The first three experiments described 
were performed in the Sprague Dawley rat strain. For the last experiment, Wistar rats underwent the 
sensitised paradigm optimized for dose, context and withdrawal period.  
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2.2 MATERIALS AND METHODS  
2.2.1 Animals 
Sprague Dawley and Wistar rats were imported from an outbred colony at the Animal Resources 
Centre (ARC), Western Australia. In all experiments rats were of an ‘adult’ (at least 70 days) age 
and male. Animals were housed at the Australian Institute for Bioengineering and Nanotechnology 
(AIBN) animal facility. They were given a minimum one-week acclimatization period to their 
homeroom at the AIBN animal facility after import.  The rats were housed in a temperature-
controlled room (Room Temp. 24°C, 40-60% Humidity) on a constant 12h light/dark cycle (light 
phase 0600-1800h). Rats were provided with standard rat chow (Specialty Feeds, Glen Forrest, 
Western Australia, Australia) and water ad libitum. Rats were pair-housed in opaque Makrolon wire 
topped cages (38x23.5x16cm), lined with Sani chip bedding. The animal facility technicians 
performed daily health checks and cleaned cages weekly. All procedures were performed with the 
approval from The University of Queensland Animal Ethics Committee, and followed the 
Australian code for the care and use of animals for scientific purposes (NHMRC, 8th Ed, 2013). 
 
2.2.2 Behavioural Testing  
Behavioural testing was conducted in a room separate to the homeroom at the AIBN animal facility. 
The behavioural room was also temperature controlled to the same conditions as the homeroom 
(room temperature 24° C, 40-60% humidity). Rats were transported from the East wing homeroom 
to the West wing behavioural room of the animal facility, a distance of approximately 100m. The 
rats were transported in their home cages on a trolley, which was uncovered to maintain similar 
lighting conditions during transport. They were transported to the behavioural room at least half an 
hour prior to behavioural testing commencement to allow them to habituate to the new 
environment. Behavioural testing was conducted after at least 2h into the light phase (0800h-
1800h). 
 
2.2.3 Apparatus  
The locomotor activity was assessed in twelve black Perspex chambers, 45cm x 45cm wide and 
60cm deep. The chambers were illuminated by a central strip of light emitting diodes (LEDs) with 
an illumination of approximately 17 lux. The locomotor activity was recorded via a centrally placed 
video camera (IP8152 Vivotek, Taiwan). The total locomotor distance travelled was calculated 
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using the Ethovision automated video tracking software (Noldus Information Technology, 
Wageningen, Netherlands) using differencing background subtraction to identify the rat. All test 
cages were cleaned with 70% ethanol between animals.  
 
2.2.4 Preparation of drugs and administration procedure  
(+) MK-801 maleate was supplied by Sigma (Sigma, MO, USA) and made into a stock solution of 
1mg/ml in 0.9% saline then stored under dark conditions at -20°C until use. To obtain the desired 
concentrations, the stock was further diluted with 0.9% saline. All solutions were administered via 
intraperitoneal (i.p.) injection using a 1mL insulin syringe with a 29-gauge needle (Terumo, Japan). 
Injections were administered at a volume of 1ml/kg. Rats were weighed each experimental day to 
calculate the amount of solution required for each injection. To administer the injections rats were 
gently restrained with a towel and the process took no more than 2 min. 
 
2.2.5 Sensitisation paradigm   
Except when otherwise stated in the following sections, the same experimental protocol was used to 
induce and test the behavioural sensitisation to MK-801 in male Sprague Dawley rats. The general 
sensitisation paradigm was similar to protocols utilised by Yang et al. (2002) and Jeziorski et al. 
(1994). The behavioural sensitisation paradigm consists of three key phases; induction, withdrawal 
and expression. The induction phase involved once-daily injections for 7 consecutive days in the 
test cage. Over the 5-day withdrawal phase, rats were left untreated in their home cages. On day 13 
of the behavioural paradigm, the expression of locomotor sensitisation was observed by challenging 
rats with MK-801 in the test cage. Once acclimatised to the behavioural room, rats were placed 
individually into a test cage. After a 30min period of habituation to the test cage, rats were injected 
with either saline or MK-801. MK-801 has an elimination half-life in plasma and brain of 1.9 and 
2.05hr, respectively (Vezzani et al., 1989).  MK-801-induced locomotor activity lasts 
approximately 2-3h (Andine et al., 1999); therefore MK-801-induced locomotor activity was 
recorded for 3h post-injection.  
 
2.2.6 Experiment 2.1: Dose-dependent effects on MK-801-induced sensitisation  
The first experiment was designed to determine at which dose MK-801 induces behavioural 
sensitisation in male Sprague Dawley rats. The rats were divided into four dose treatment groups 
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(n=7-8/group). The four treatment groups were saline, low dose MK-801 (0.1mg/kg), intermediate 
dose MK-801 (0.25mg/kg) and high dose MK-801 (0.5mg/kg). The dose used within each group 
remained constant between the induction and expression phases (see Figure 2.1a for experimental 
timeline). Behavioural sensitisation paradigms to other stimulant drugs may often use a lower dose 
for challenge. Due to the hyperlocomotor inducing effects of MK-801 occurring within a tight range 
window (Andine et al., 1999), a lower dose challenge was not ideal in this paradigm. This design 
has previously been implemented in other research inducing MK-801 locomotor sensitisation 
(Wedzony et al., 1993a, Wolf and Khansa, 1991, Yang et al., 2002).  
 
2.2.7 Experiment 2.2: Effect of environmental context on MK-801-induced 
sensitisation 
Experiment 2.2 aimed to test whether the behavioural sensitisation to MK-801 (0.25mg/kg) in 
Sprague Dawley male rats was altered by environmental context. Saline and MK-801-treated rats 
were subdivided into two context groups (n=20/group); home and test. During the induction phase 
the test group received the 7 daily injections in the test chamber as described above. The home 
group however, received the same 7 daily injections in the homeroom and were placed immediately 
back into their home cage after injection. On day 13, both context groups were placed in the test 
cage and challenged with MK-801 (0.25mg/kg). Experiment 2.2 also examined whether repeated 
administration of MK-801 (0.25mg/kg) in the test cage produces a conditioned response upon re-
exposure subsequent to withdrawal (see Figure 2.2a for experimental timeline). This phenomenon 
has previously been observed in sensitisation to other stimulant drugs. A simultaneous separate 
cohort was also treated with saline or MK-801 under home or test conditions (n=8/group). On day 
13, all rats were challenged with a saline injection in the test cage to assess for a conditioned 
locomotor response.  
 
2.2.8 Experiment 2.3: Effect of extended withdrawal on MK-801-induced 
sensitisation  
The aim of Experiment 2.3 was to determine whether behavioural sensitisation to MK-801 
(0.25mg/kg) could be observed after an extended withdrawal period. Sprague Dawley rats were 
administered with saline or MK-801 (0.25mg/kg) once daily over the 7-day induction phase in 
either the home or test cage (n=8/group). The withdrawal phase, in which rats were drug-abstinent 
and left in their home cages, lasted for 14 days in this experiment instead of 5 days. All rats were 
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then challenged with MK-801 (0.25mg/kg) in the test cage on Day 22 (see Figure 2.3a for 
experimental timeline). Increasing withdrawal is hypothesised to increase the stimulatory effects of 
MK-801. Therefore levels of ataxia were recorded to determine whether ataxia was compromising 
locomotor activity using a previously described method (Cui et al., 2015). Ataxia was scored using 
a ‘scan sampling’ technique at 60-65min after MK-801 injection. The 60min time point for ataxia 
scoring was selected to match with the peak MK-801 induced locomotor activity time point. Within 
this 5-min time bin, rats were scored every 30s with a total of 10 observations. Rats were scored, 
blind to treatment, using the rating scale developed by Cho et al (1991). The rating scale is as 
follows (0) inactive or coordinated movements, (1) awkward or jerky movements or loss of balance 
while rearing, (2) frequent falling or partial impairment of antigravity reflexes, (3) the inability to 
move beyond a small area and to support body weight and (4) inability to move except for twitching 
movements. Therefore the maximum score that could be obtained using this protocol was 40, which 
would be indicative of a total loss of movement. Ataxia was preliminarily assessed during this short 
5-min time window. From this analysis (Figure 2.3c), in addition to an overall video observation, it 
was concluded that there was little incidence of ataxia or stereotypies in these rats. Therefore, 
manual scoring by a blind observer was not conducted at subsequent time points.  
 
2.2.9 Experiment 2.4: Effect of rat strain on MK-801-induced sensitisation  
After establishing a sensitisation paradigm in Sprague Dawley rats, with the dose, context and 
withdrawal parameters optimised, the last experiment sought to determine if MK-801 sensitisation 
was strain dependent. During the induction phase, Wistar rats were administered with saline or MK-
801 (0.25mg/kg) once daily over the 7-day induction phase. After 5 days withdrawal in the home 
cage, both treatment groups (n=12/group) received a challenge injection of MK-801 (0.25mg/kg) in 
the test cage (see Figure 2.4a for experimental timeline).  
 
2.2.10 Statistical Analysis 
Statistical analysis was performed using the SPSS statistics program (version 20, Armonk, NY: 
IBM Corp.). Data were analysed using the repeated measures analysis of variance (ANOVA) when 
appropriate or the one-way ANOVA. MK-801 treatment and environmental context pre-treatment 
served as between-subjects factors. Day served as a within-subjects factor. The presence of 
sensitisation from Day 1 to Day 13 (or Day 22) was computed using repeated measures ANOVA. 
Sensitisation is also defined between-subjects, with MK-801 drug treatment and saline drug 
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treatment serving as the between-subjects factors on the response to MK-801 challenge. A 
Bonferroni correction was used to control for multiple comparisons where appropriate. A Pearson 
correlation analysis was performed for locomotor activity on Day 1 and Day 13. Statistical 
significance was set at p<0.05. All data are reported as mean ± SEM.  
 
2.3 RESULTS  
2.3.1 Experiment 2.1: Dose-dependent effects on MK-801-induced sensitisation  
Male Sprague Dawley rats were administered either saline or one of three doses of MK-801 (0.1, 
0.25 and 0.5mg/kg) once daily for 7 days. Subsequent to a 5-day period of abstinence, rats were re-
exposed to the same dose of saline or MK-801 (Figure 2.1a). On day 1, a significant effect of MK-
801 Dose on locomotor activity was observed (F(3, 28) = 8.8 p<0.01). The highest dose, 0.5mg/kg, 
elicited hyperlocomotion compared to saline (Figure 2.1b,c). Neither of the lower doses (0.1 and 
0.25mg/kg) significantly increased locomotor activity on the first day of induction. To determine 
the presence of sensitisation, repeated measures ANOVA was performed on the total distance 
travelled between Days 1 and 13 (Figure 2.1b) revealing a main effect of Dose (F(3, 27) = 5.16 
p=0.006). Sensitisation defined as a significant increase in locomotor activity on Day 13 compared 
to Day 1, was only evident in rats treated with the intermediate dose (0.25mg/kg) of MK-801 (t6= 
2.5, p<0.05). There was a significant positive correlation (R2=0.84, p=0.001) between the acute 
response to 0.25mg/kg MK-801 on Day 1 and the sensitised response on Day 13. There was no 
significant increase (or decrease) in locomotor activity from Day 1 to Day 13 in rats treated with 
0.1mg/kg and 0.5mg/kg MK-801 (Figure 2.1c). This indicates that neither locomotor sensitisation 
nor tolerance developed to these doses of MK-801. Overall, the development of MK-801-induced 
sensitisation displayed an inverted-U dose response. Therefore, the subsequent experiments utilised 
only the 0.25mg/kg dose of MK-801.  
 
2.3.2 Experiment 2.2: Effect of environmental context on MK-801-induced 
sensitisation 
The main aim of this experiment was to characterize the effect environmental context had on the 
development of MK-801-induced sensitisation. Sprague Dawley rats received saline or MK-801 
(0.25mg/kg) injections in either the home or test environment during the induction phase. At 
expression, all rats were challenged with MK-801 in the test environment and locomotor activity 
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assessed (Figure 2.2a). Two-way ANOVA revealed a significant effect of Drug treatment (saline vs. 
MK-801; F(1, 76) = 5.23, p=0.023). In contrast, there was no significant main effect of 
Environmental context and no significant interaction between Drug treatment and Environmental 
context. The expression of locomotor sensitisation to MK-801 was not significantly different 
between MK-801 groups treated in either the home or test Environmental context (Figure 2.2b).  
Repeated administration of drugs of abuse has been shown to potentiate the response to saline 
challenge given in the same environment (McPherson and Lawrence, 2006). Therefore, the 
secondary aim of this experiment was to determine whether repeated MK-801 injections in the test 
cage would enhance response to saline challenge. Thus a second cohort of rats was treated with 
saline or MK-801 in the home or test environmental context during induction. At expression, this 
cohort was instead challenged with saline in the text environment and locomotor activity assessed 
(Figure 2.2c).  The two-way ANOVA revealed no significant main effects of Drug treatment or 
Environmental context and no significant interaction between the two factors. Sprague-Dawley rats 
treated with MK-801 in the test cage did not produce a conditioned response to saline challenge 
compared to either their MK-801 treated home cage counterparts (Figure 2.2c). Furthermore, there 
was no difference in response to saline challenge between rats treated with MK-801 or saline in the 
test environment.  
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Figure 2.1 Role of MK-801 dose on behavioural sensitisation  
(a) Experimental timeline to investigate effect of MK-801 dose on sensitisation. (b) Acute response (± SEM) to 
increasing doses of MK-801 (0, 0.1, 0.25 and 0.5mg/kg) on day 1 of induction. Rats were injected with saline or MK-
801 (n=7-8/group) after a 30 min habituation period to the novel environment. A steep dose –response curve to the 
locomotor stimulating effects of MK-801. *p<0.01 significantly different to saline controls. (c) Comparison of total 
distance travelled over the 180min post-injection testing period (mean response ± SEM post-injection) on Day 1 of 
induction (white bars) and Day 13 at expression (dark grey bars). *p<0.05 significantly different between test days. 
#p<0.05 significantly different from the saline control group.  
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Figure 2.2 Role of environmental context on MK-801 sensitisation  
(a) Experimental timeline for Experiment 2.2. (b) Locomotor response to MK-801 challenge on Day 13 at the 
expression phase. Rats that were previously treated in the home (white bars) or test (grey bars) context (n=20/group) 
were challenged with 0.25mg/kg MK-801 to test for sensitisation (c) Locomotor response to Saline challenge on Day 13 
at the expression phase. Rats that were previously treated in the home (white bars) or test (grey bars) context 
(n=8/group) were challenged with Saline to test for contextual conditioning. *p<0.05 compared to Saline treated 
controls. Data are presented as the mean ± SEM.  
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2.3.3 Experiment 2.3: Effect of extended withdrawal on MK-801-induced 
sensitisation  
This experiment examined whether a sensitised locomotor response was observable after 14 days 
withdrawal from MK-801 treatment in both the home and test cage (Figure 2.3a). Two-way 
ANOVA revealed there was no significant effect of Environmental context on the locomotor 
response to MK-801 challenge (Figure 2.3b). This result was consistent with that observed in 
Experiment 2.2. Statistical analysis also revealed there was no significant effect of Drug treatment 
on the locomotor response to MK-801 challenge, indicating no sensitisation was present in the MK-
801 treated rats after 14 days withdrawal. There was no significant interaction between 
Environmental context and Drug treatment.  
 
2.3.4 Experiment 2.4: Effect of rat strain on MK-801-induced sensitisation  
This experiment explored whether the sensitisation paradigm optimized for Sprague Dawley rats, 
could also induce locomotor sensitisation in the outbred albino Wistar rat strain (Figure 2.4a). One-
way repeated measures ANOVA on the locomotor activity during the induction phase revealed a 
significant effect of Drug treatment (F(1, 22) = 61.19 p<0.001), Day (F(6, 132) = 6.98 p<0.001) and a 
Drug treatment x Day interaction (F(6, 132) = 3.65 p<0.01). The hyperlocomotor effects of MK-801 
significantly decreased across the 7 days of induction, indicative of a tolerance-like phenomenon 
(Figure 2.4b). On day 13, both saline and MK-801 treated Wistar rats received an MK-801 
challenge. One-way ANOVA revealed there was no significant effect of Drug treatment, indicating 
there was no behavioural sensitisation to MK-801 in Wistar rats (Figure 2.4c). 
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Figure 2.3 Effect of extended withdrawal on MK-801 sensitisation 
(a) Experimental timeline for Experiment 2.3 with the extended withdrawal period of 14 days. (b) Total distance 
travelled in response to the MK-801 challenge on Day 22. Rats treated with MK-801 during the induction phase did not 
show a sensitised locomotor response compared to saline treated rats, irrespective of environmental context 
(n=8/group). (c) Ataxia levels were not significantly different between groups in response to MK-801 challenge. Data 
are presented as the mean ± SEM.  
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Figure 2.4 Role of rodent strain on MK-801 sensitisation  
(a) Experimental timeline for Experiment 2.4 in Wistar rats. (b) Total distance travelled following MK-801 or saline 
injection (n=12/group) during days 1-7 of the induction phase. MK-801 significantly increased locomotor activity 
compared to saline injection. Repeated measures indicated MK-801-induced locomotor activity decreased across the 
induction phase. (c) Total distance travelled on Day 13 in response to MK-801 challenge was not different between 
Wistar rats treated with saline or MK-801 during induction. The response to MK-801 challenge on Day 13 is 
comparable to the total distance travelled on Day 1 (b). Statistical significance is set at p<0.05. Data are presented as the 
mean ± SEM. 
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2.4 DISCUSSION  
Our results show that adult male Sprague Dawley rats develop behavioural sensitisation after 
repeated MK-801 exposure. Sensitisation occurred when an intermediate dose of 0.25mg/kg MK-
801 was repeatedly injected. It was found that using a lower or higher MK-801 dose did not induce 
locomotor sensitisation, at least in the current paradigm. The results of the second experiment 
demonstrate that the expression of sensitisation to MK-801 was unaltered between rats treated in 
two different environmental contexts. The magnitude of locomotor sensitisation was similar 
between Sprague Dawley rats receiving MK-801 treatment in the home or test cage during the 
induction phase. To the best of our knowledge this is the first study to assess whether MK-801-
induced sensitisation is modulated by environmental context. The third experiment revealed that 
behavioural sensitisation was not observed following an extended withdrawal period of two weeks 
from repeated administration of the intermediate dose of 0.25mg/kg MK-801. The results of the 
final study demonstrated that the administration paradigm used to induce sensitisation in outbred 
albino Sprague Dawley rats, did not induce sensitisation in outbred albino Wistar rats.  
In Experiment 2.1, a steep dose-response curve to the acute locomotor stimulatory effects of MK-
801 is observed and this finding was consistent with a multitude of acute MK-801 studies (Druhan 
et al., 1996, Hiramatsu et al., 1989, Irifune et al., 1995, Kuribara et al., 1992b, Rung et al., 2005). 
This experiment also found the development of sensitisation to MK-801 in Sprague Dawley rats 
showed an inverted-U shape dose response curve, similar to what has been reported in mice 
(Kuribara et al., 1992a). Kuribara et al (1992a) demonstrated that in the ddY mouse strain, an 
intermittent sensitisation paradigm only resulted in locomotor sensitisation with an intermediate 
dose of MK-801 (0.3mg/kg), compared to low (0.1mg/kg) or high (1mg/kg) doses. Furthermore, 
Jeziorski et al (1994) reported that locomotor sensitisation was observed in Sprague Dawley rats 5 
days after repeated daily (7-10 days) administrations of 0.25mg/kg but not 0.1mg/kg MK-801. In 
the current study, repeated administration of 0.1mg/kg or 0.5mg/kg did not produce sensitisation, 
nor was there a significant decrease in response to indicate the development of tolerance. This 
would suggest tolerance was not a competing mechanism.  
In Experiment 2.2 there was no evidence to suggest that behavioural sensitisation to MK-801 was 
dependent on, or modulated by, environmental context. Firstly, rats treated with the sensitising dose 
(0.25mg/kg) of MK-801 in the home cage developed locomotor sensitisation to the same extent as 
the rats treated in the test context. Secondly, MK-801 sensitised rats did not display a conditioned 
hyperlocomotor response to a saline challenge when re-exposed to the drug-paired context. This 
study is the first to report a lack of environmental dependency for MK-801 sensitisation and is 
 
 
50 
consistent with that described for sensitisation to another NMDAR antagonist, PCP (Clark et al., 
2002, Xu and Domino, 1994b).  Taken together, these results suggest that sensitisation to MK-801 
is not influenced by the environmental context in which the drug is administered, contrary to the 
literature on behavioural sensitisation to other drugs of abuse. However, a limitation of this 
experiment is the difference in group number between those challenged with MK-801 (n=20) and 
those challenged with saline (n=8). Additional numbers of animals were required for the MK-801 
challenge group based on G*Power statistical analysis. The n=8 was sufficient for a saline 
challenge as there is little variation in the behavioural response, this number was deemed 
appropriate by G*Power statistical analysis.  
A number of studies have demonstrated that environmental context modulates the susceptibility to 
sensitisation induced by psychostimulant drugs including amphetamine, cocaine and morphine 
(Badiani et al., 1995, Badiani et al., 1997, Badiani et al., 2000). Pairing the repeated drug exposure 
with a novel context was found to further augment the sensitised response in rodents compared to 
the drug treatment occurring in the home cage (Badiani and Robinson, 2004). Although not 
completely understood, the modulatory role of environmental context is thought to involve a 
number of factors including associative learning, as well as gene expression and synaptic plasticity 
in brain regions associated with reward (Badiani and Robinson, 2004, Ohmori et al., 2000). These 
processes involve NMDAR activation. As such, NMDAR activation has been shown to play a 
critical role in context-dependent sensitisation (Battisti et al., 2000, Battisti et al., 1999) and 
contextual conditioning (Quinn et al., 2005, Xie et al., 2013).  For example, co-administration of 
MK-801 with amphetamine during the induction phase was shown to specifically attenuate the 
development of amphetamine sensitisation in a context-dependent paradigm, without affecting 
sensitisation in a context-independent paradigm (Battisti et al., 2000). Thus it would appear that 
antagonism of the NMDAR abolishes contextual conditioning. In mice, the development of 
behavioural sensitisation to ethanol, an indirect NMDAR antagonist, was also reported to be 
independent of environmental context (Didone et al., 2008) as has been observed with the direct 
NMDAR antagonists MK-801 (present study) and PCP (Clark et al., 2002, Xu and Domino, 
1994b). Overall, the absence of environmental contextual modulation on MK-801 sensitisation 
reported in this study is congruent with the literature.  
In the third experiment, increasing the length of the withdrawal phase was found to have a negative 
impact on the expression of locomotor sensitisation to MK-801. The longer withdrawal period of 14 
days appeared to abolish the locomotor sensitisation observed with the shorter 5-day withdrawal 
period. In drug-induced behavioural sensitisation, longer withdrawal periods are generally thought 
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to enhance the sensitivity to drug, eventually leading to increased stereotypic behaviour (Paulson et 
al., 1991). Therefore, ataxia scores were measured to assess whether sensitisation to MK-801 was 
perhaps expressed as an increase in the response to the ataxia inducing effects of MK-801. 
However, ataxia was not increased in MK-801 treated animals and therefore was not a confounding 
factor on the locomotor response. Thus it is not immediately clear why MK-801-induced 
sensitisation in this paradigm is not long-lasting. The short withdrawal period of 5 days was 
selected for the first and second experiment, as this was similar to other MK-801 sensitisation 
reports (Jeziorski et al., 1994, O'Neill and Sanger, 1999, Wolf and Khansa, 1991, Yang et al., 
2002). Sensitisation to MK-801 has previously been observed after a longer withdrawal period of 
17 days, though a higher challenge dose was required (Jeziorski et al., 1994). Additionally, the 
authors reported that at least one-third of the rats did not display behavioural sensitisation (Jeziorski 
et al., 1994). Previous work from our laboratory demonstrated that behavioural sensitisation to MK-
801 could be observed in response to an MK-801 challenge after two weeks withdrawal from a 
single acute administration of a high dose of MK-801 (0.5mg/kg) (Cui et al., 2015). With this 
paradigm a large level of individual variation was also identified (Cui et al., 2015). With a large 
population sample size, the previous study was able to statistically categorise rats into ‘sensitisers’ 
and ‘non-sensitisers’. In Experiment 2.3, there was not a large level of individual variation therefore 
it does not seem likely that this was the causative factor in the absence of locomotor sensitisation at 
a population level. Comparison of the neuroadaptations identified in the subsequent experiments 
(Chapter 3) after 5 days withdrawal with neuroadaptations after this longer withdrawal period could 
aid in identifying key pathways that lead to the sensitised behavioural response. Though beyond the 
scope of this thesis, this would be a warranted future line of research.  
In the last experiment, rat strain was found to have a significant impact on the development of MK-
801-induced behavioural sensitisation. Whilst this MK-801 administration protocol induced 
behavioural sensitisation in Sprague-Dawley rats, a tolerance-like effect was observed in the Wistar 
rats. After 5 days withdrawal, the response to MK-801 returned to acute levels in Wistar rats. It is 
well documented that rodent strain significantly affects the acute sensitivity, and propensity, to 
develop behavioural sensitisation to several drugs of abuse (Bailey et al., 2010, Cailhol and 
Mormede, 1999, Iyaniwura et al., 2001, Mouri et al., 2012, Yetnikoff and Arvanitogiannis, 2013). 
Comparing the acute MK-801-induced locomotor activity in Wistar rats, appears to be nearly twice 
that observed in Sprague Dawley rats in Experiments 2.1 and 2.2. This could be evident of a 
heightened sensitivity to the effects of MK-801 in Wistar rats. Therefore the lack of sensitisation 
may due to a ceiling effect on the behavioural response to MK-801 at this dose that could not be 
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further elevated. One limitation of these experiments is that the Wistar cohort of rats was run 
separately to the Sprague Dawley rats. Thus no direct statistical comparisons can be made, as there 
is no Sprague Dawley control group. Despite this limitation however, it is clear that rats of the 
Wistar strain do not develop a sensitised locomotor behavioural response to MK-801.  
It is possible that these two rat strains metabolise MK-801 at different rates and as such the 
sensitisation paradigm employed did not result in similar plasma concentration temporal profiles in 
the Sprague Dawley and Wistar strains. Sprague Dawley and Wistar rats have previously shown 
strain differences in the ability of MK-801 to disrupt prepulse inhibition (van den Buuse, 2003, 
Varty et al., 1999). These two rat strains also show differences in other behavioural features such as 
their anxiolytic profile (Rex et al., 2004), and the behavioural, neurochemical and physiological 
response to stress (Bekris et al., 2005). The underlying neurobiological substrate for MK-801-
induced sensitisation is not clear. Therefore to understand the strain differences in MK-801 
sensitisation, specific neurobiological targets must first be identified. Future studies however could 
utilise this strain difference to identify neurobiological substrates that mediate resilience or 
vulnerability in the propensity to develop behavioural sensitisation.  
In conclusion, the present report demonstrates that sensitisation to repeated administrations of MK-
801 in male Sprague Dawley rats develops at selective doses. Sensitisation was only observed with 
an intermediate MK-801 dose of 0.25mg/kg, whereas repeated injections of a lower dose 
(0.1mg/kg) or higher (0.5mg/kg) produced neither sensitisation nor tolerance. In this paradigm, 
behavioural sensitisation is not modulated by the environmental context in which drug 
administration occurs. Critically, it was found that sensitisation to MK-801 was observed during 
short-term withdrawal (5 days) but not during long-term withdrawal (14 days). The absence of 
long-term sensitisation in the current paradigm has implications for its potential in modelling the 
pathophysiology of disorders such as schizophrenia and drug addiction, which have a long 
trajectory. As will be addressed in Chapter 6, there are further investigations that may aid to address 
whether MK-801 sensitisation was truly absent at the longer withdrawal period. As it currently 
stands, the MK-801 sensitisation paradigm is presented as a useful tool for investigating the neural 
mechanisms that lead to an enhanced behavioural response to the psychomimetic MK-801, with 
further query into the transience of the neural adaptations.  
In this study, I have established a model of MK-801-induced sensitisation incorporating both 
features of repeated intermittent exposure and short-term withdrawal. This administration paradigm 
only induced sensitisation in the Sprague Dawley and not the Wistar rat strain. This suggests that 
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the acute and long-term responses to MK-801 are under distinct genetic factors. The antagonist 
effect of MK-801 at NMDARs decreases GABAergic transmission and has the capacity to increase 
neurotransmitter release of glutamate, dopamine, serotonin and acetylcholine. Thus genetic 
variations in the density and distribution of the receptors of these neurotransmitters are potential 
mediators of the behavioural differences reported here. The MK-801 sensitisation paradigm 
employed in the subsequent chapters of this thesis is as follows. Sprague Dawley rats are 
administered the 0.25mg/kg dose of MK-801 administered in the test cage environmental context 
for 7 days. This is followed by a 5-day withdrawal period in the home cage prior to an MK-801 
(0.25mg/kg) challenge.  
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Chapter 3 Functional and molecular changes in the 
nucleus accumbens of MK-801 sensitised rats 
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3.1 INTRODUCTION 
Behavioural sensitisation in rodents is considered a form of drug-evoked synaptic plasticity that is 
relevant to progressive and relapsing neural disorders such as drug addiction and schizophrenia 
(Kauer and Malenka, 2007, Ujike, 2002). The neural circuitry underlying drug-induced behavioural 
sensitisation is the mesocorticolimbic system, consisting of dopaminergic projections from the VTA 
to the NAc, and excitatory input from associated limbic structures, including the PFC, hippocampus 
and amygdala (Kalivas et al., 1993). GABAergic medium spiny neurons (MSNs) are the majority 
cell type of the NAc (Tepper and Bolam, 2004). Accumulating evidence indicates that, in the NAc 
shell, excitatory synaptic plasticity is increased during the expression of behavioural sensitisation 
(Jedynak et al., 2016, Kourrich et al., 2007, Wu et al., 2012). The ratio of AMPAR to NMDAR 
evoked synaptic currents is a widely used assay of excitatory synaptic strength (Bellone and 
Luscher, 2006, Saal et al., 2003a, Thomas et al., 2001, Ungless et al., 2001). As there is a large 
body of research related to excitatory synaptic strength in cocaine sensitisation, this provides the 
most useful basis for comparison (Jedynak et al., 2016, Kourrich et al., 2007, Thomas et al., 2001). 
Withdrawal from repeated cocaine is associated with an increased AMPAR/NMDAR ratio in the 
NAc shell (Kourrich et al., 2007). The increase in synaptic strength however is reversed, or 
depressed, when measured after a cocaine challenge, indicative of a bidirectional synaptic plasticity 
(Jedynak et al., 2016, Kourrich et al., 2007, Thomas et al., 2001).  
In contrast to cocaine, the changes in NAc excitatory synaptic strength associated with MK-801 
sensitisation are currently unknown. However, indirect evidence comes from a study in which MK-
801 was used to block both morphine-induced behavioural sensitisation, and increases in NAc 
excitatory synaptic strength (Wu et al., 2012). In the study, a subgroup of rats received repeated 
administration (twice daily x 5d) of MK-801 alone. After 10 days withdrawal from this MK-801 
treatment no changes in NAc excitatory synaptic strength were observed (Wu et al., 2012). The 
authors did not assess whether this administration paradigm resulted in behavioural sensitisation to 
MK-801.  Given the ability of MK-801 to block drug-induced alterations in excitatory synaptic 
strength, it is postulated that this phenomenon is dependent on NMDAR activation (Luscher and 
Malenka, 2011). Therefore, one would hypothesise that MK-801-induced sensitisation would not be 
associated with altered NAc excitatory synaptic strength. 
Drug-induced behavioural sensitisation is associated with changes in intrinsic membrane 
excitability, dendritic and spine structural plasticity and glutamate availability in the NAc (Russo et 
al., 2010, Wolf, 2010). Together with alterations in synaptic strength, these changes are causally 
linked to one another in mediating behavioural sensitisation (Wolf, 2010). Repeated drug exposure 
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activates a series of intracellular cascades leading to changes in protein expression and subsequent 
long lasting biochemical, physiological and morphological adaptations in the NAc (Nestler, 2001). 
Various molecular techniques have been used to identify the signalling pathways involved in 
behavioural sensitisation and, proteomics can provide the ability to measure global changes in 
protein abundance in response to drug administration (Abul-Husn and Devi, 2006). Behavioural 
sensitisation to psychostimulants and opiates is associated with protein changes in the NAc that are 
involved in cytoskeletal modification, energy metabolism, neurotransmission and synaptic function 
(Abul-Husn et al., 2011, Iwazaki et al., 2007, Li et al., 2006, Romanova et al., 2012). Adaptations in 
the ERK, CaMKII and PKA signalling pathways in the NAc have also been tightly associated with 
sensitisation to cocaine and are thought to be critical in glutamate receptor function and trafficking 
(Boudreau et al., 2009).  While many studies have described proteomic changes in different brain 
regions following chronic MK-801 administration (Joo et al., 2013, Paulson et al., 2007, Paulson et 
al., 2004, Paulson et al., 2003, Zhou et al., 2012), these were not examined in the context of MK-
801 induced behavioural sensitisation or the proteome of the NAc. Aside from changes in proteins 
related to energy metabolism in the cerebral cortex (Zhou et al., 2012), the available literature 
suggests there is little overlap between the signalling pathways affected by repeated MK-801 
exposure and repeated exposure to other drugs of abuse.    
Drug-induced behavioural sensitisation is associated with both altered glutamatergic and 
dopaminergic signalling pathways. In the NAc, MSNs are subtyped based on their expression of 
dopamine D1 and D2 receptors (Gerfen et al., 1990, Smith et al., 1998). The D1 MSNs form the 
direct pathway and are thought to promote reward related behaviours whilst the D2 MSNs that form 
the indirect pathway oppose reward related behaviour (Kupchik et al., 2015). Several lines of 
evidence imply D1R signalling mediates the expression of drug induced behavioural sensitisation. 
For example, alterations in changes in excitatory synaptic strength occur in a cell-type specific 
manner on the D1 MSNs (MacAskill et al., 2014), NAc D1Rs show a long-lasting supersensitivity 
(Henry and White, 1991, Wolf et al., 1994) and D1R antagonists block expression of locomotor 
sensitisation (White et al., 1998). In MK-801 sensitisation, D1Rs in the NAc were found to be 
supersensitive (Wolf et al., 1993). Pharmacological inhibition of these D1Rs though did not block 
expression of sensitisation to MK-801 (Wolf et al., 1993).  
Although drug-induced behavioural sensitisation is thought to be NMDAR dependent, behavioural 
sensitisation occurs in response to repeated administration of the NMDAR antagonist MK-801 
(Wolf et al., 1993). Drug-induced alterations in synaptic strength associated with behavioural 
sensitisation are purportedly NMDAR dependent (Luscher and Malenka, 2011). Since repeated 
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MK-801 can induce behavioural sensitisation, the aim was to determine whether MK-801 
sensitisation would induce alterations in synaptic strength. To test this hypothesis, whole-cell 
recordings were made on MSNs from NAc shell brain slices and measured the ratio of 
AMPAR/NMDAR mediated excitatory postsynaptic currents (EPSCs). The NAc shell subregion 
was selected over the core, as it has previously been the predominant target region in cocaine 
sensitisation synaptic plasticity literature (Jedynak et al., 2016, Kourrich et al., 2007, Thomas et al., 
2001).  Secondly, an established SWATH proteomics approach was used to elucidate signalling 
pathways in the NAc that may contribute to MK-801-induced alterations in synaptic strength and 
behavioural sensitisation. Thirdly, single-concentration radioligand binding was used to determine 
whether this MK-801 sensitisation paradigm altered the density of dopamine D1 receptors in the 
NAc.  
 
3.2 MATERIALS AND METHODS  
3.2.1 Animals  
Adult male Sprague Dawley rats (ARC, Western Australia) were housed at the AIBN animal 
facility. They were given a minimum one-week acclimatization period to their homeroom at the 
AIBN animal facility after import.  The rats were housed in a temperature-controlled room (Room 
Temp. 24°C, 40-60% Humidity) on a constant 12h light/dark cycle (light phase 0600h-1800h). Rats 
were provided with standard rat chow (Specialty Feeds, Glen Forrest, Western Australia, Australia) 
and water ad libitum. Rats were pair-housed in opaque Makrolon wire topped cages 
(38x23.5x16cm), lined with Sani chip bedding. The animal facility technicians performed daily 
health checks and cleaned cages weekly. All procedures were performed with the approval from 
The University of Queensland Animal Ethics Committee, and followed the Australian code for the 
care and use of animals for scientific purposes (NHMRC, 8th Ed, 2013). 
 
3.2.2 Behavioural Testing  
Behavioural testing was conducted in a room separate to the homeroom at the AIBN animal facility. 
The behavioural room was also temperature controlled to the same conditions as the homeroom 
(room temperature 24° C, 40-60% humidity). Rats were transported in their home cages on a trolley 
from the East wing homeroom to the West wing behavioural room. They were transported to the 
room at least half an hour prior to behavioural testing commenced to allow them to habituate to the 
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new environment. Behavioural testing was conducted after at least 2 h into the light phase (0800h-
1800h). 
 
3.2.3 Apparatus  
The locomotor activity was assessed in twelve black Perspex chambers, 45cm x 45cm wide and 
60cm deep. The chambers were illuminated by a central strip of LEDs (17 lux). The locomotor 
activity was recorded via a centrally placed video camera (IP8152 Vivotek, Taiwan). The total 
locomotor distance travelled was calculated using the Ethovision automated video tracking software 
(Noldus Information Technology, Wageningen, Netherlands) using differencing background 
subtraction to identify the rat. All test cages were cleaned with 70% ethanol between animals.  
 
3.2.4 Preparation of drugs and administration procedure  
(+) MK-801 maleate was supplied by Sigma (Sigma, MO, USA) and made into a stock solution of 
1mg/ml in 0.9% saline then stored under dark conditions at -20°C until use. The stock was further 
diluted to 0.25mg/ml in 0.9% saline. All solutions were administered via intraperitoneal (i.p.) 
injection using a 1mL insulin syringe with a 29-gauge needle (Terumo, Japan). Injections were 
administered at a volume of 1ml/kg. To administer the injections rats were gently restrained with a 
towel and the process took no more than 2 min. 
 
3.2.5 Sensitisation paradigm  
A total of 40 rats were used in this study including Naïve (n=12), MK-801 acute (n=14) and MK-
801 sensitised (n=14). Rats in the MK-801 acute group received once-daily saline injections during 
the induction phase and an MK-801 (0.25mg/kg) challenge at the expression phase. Rats in the MK-
801 sensitised group received once daily MK-801 (0.25mg/kg) injections during the induction 
phase and an MK-801 (0.25mg/kg) challenge at the expression phase. All injections were 
administered in the test cage. The Naïve group was both behaviourally- and drug-naïve. 
Electrophysiological recordings, proteomic analysis and radioligand binding was conducted on 
tissue collected one day after MK-801 challenge in the acute and sensitised animals (see Figure 3.1 
for experimental timeline).  
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Figure 3.1 Experimental timeline  
MK-801 Acute rats received saline during induction phase and MK-801 Sensitised rats received MK-801 during the 
induction phase. Electrophysiology recordings, SWATH proteomics or radioligand binding was performed on tissue 
collected 24h after MK-801 challenge.  
 
3.2.6 Electrophysiology  
Following isoflurane anaesthesia, animals were decapitated and the brain was rapidly removed and 
submerged in ice-cold, pH balanced and oxygenated artificial cerebrospinal fluid (aCSF), 
containing (in mM): NaCl 87, NaHCO3 25, Glucose 25, Sucrose 50, KCl 2.5, NaH2PO4.H2O 1.2, 
MgCl2.6H2O 4, CaCl2 0.5. Brains were hemisected sagittally in a Perspex mold (prepared in-house). 
Sagittal slices containing NAc shell (300-400 µm) were prepared with a vibratome (VT1000S, 
Leica, Nussloch, Germany) and incubated at 32°for 30 min in aCSF, containing (in mM): NaCl 
118, NaHCO3 25, Glucose 10, KCl 2.5, NaH2PO4.H2O 1.2, MgCl2.6H2O 1.3, CaCl2 2.5. Slices (2-3 
per animal) were equilibrated to room temperature for at least 30 min, before being transferred to 
the recording chamber. During recording, slices were continuously perfused with oxygenated aCSF 
at room temperature, and secured with a platinum harp strung with parallel nylon threads. 
Recording pipettes were fabricated from borosilicate glass and pulled to a tip resistance between 3-
6 MΩ (GC150F, Harvard Apparatus, UK) when filled with the caesium-based internal solution, 
containing (in mM): CsMeSO4 135, NaCl 8, NaCl 8, HEPES 10, Na-phosphocreatine 7, Mg2-ATP 
2, Na3-GTP 0.3, EGTA 0.3, spermine 0.1 (pH 7.3 with CsOH; Osmolarity ~290 mOsm). Picrotoxin 
(100μM; Sigma) was added to the perfusing aCSF to block GABAA receptor-mediated inhibitory 
postsynaptic currents (IPSCs). Whole-cell recordings of EPSCs onto neurons in the NAc shell were 
made using a patch-clamp amplifier (Multiclamp 700A; Axon Instruments, Burlingame, CA). The 
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NAc shell was visualized under low magnification using an upright microscope (5x magnification; 
BX50WI, Olympus). MSNs were identified by their high resting membrane potential (-75 to -85 
mV) and their morphology at high magnification (40x) using differential interference contrast 
(DIC) optics combined with infrared illumination. EPSCs were evoked within MSNs of the NAc 
shell (Figure 3.2) by the placement of a concentric bipolar electrode (World Precision Instruments) 
at the prelimbic cortex – NAc border (0.1 Hz). Data were filtered at 4-8 kHz and digitized at 20 kHz 
using an Instrutech ITC-18 interface, and acquired on an iMac using Axograph X. Access resistance 
was monitored throughout the experiment, and data was excluded from analysis if it exceeded 20 
MΩ, or changed by more than 20% throughout the recording. AMPAR/NMDAR ratios were 
computed from EPSCs recorded in voltage-clamp at holding potential +40 mV. Following 
acquisition of a stable EPSC amplitude baseline, the NMDAR antagonist D-APV (50μM; Sigma) 
was bath-applied within the perfusing aCSF solution to isolate the AMPAR-mediated EPSC 
component. The NMDAR-mediated EPSC component was calculated through the digital 
subtraction of an averaged AMPAR EPSC trace from an averaged total EPSC trace, requiring a 
minimum of 10 synaptic responses per condition. The peak amplitude of the AMPAR EPSC was 
divided by the peak amplitude of the NMDAR EPSC to yield the AMPAR/NMDAR ratio.  
 
 
Figure 3.2 Location of recorded neurons in NAc 
Diagram of the sagittal slice showing the location of the bipolar stimulating electrode on excitatory afferents at the 
prelimbic cortex – NAc border and the recording electrode in the NAc shell.  
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3.2.7 Tissue Collection for Proteomics  
NAc tissue was collected from 4 Naive, 4 MK-801 acute and 3 MK-801 sensitised rats. The n/group 
for the MK-801 sensitised rats was originally n=4. However, a technician error with the mass 
spectrometry wiff file led to the data from one animal being lost. The animals were euthanized 
using Lethabarb (4ml/kg, i.p.) (Virbac Pty. Ltd., Australia) and decapitated. The brain was 
immediately removed and placed in an ice-chilled petri dish. The NAc was isolated by micro-
dissection, snap frozen in liquid nitrogen and stored at -20° C. The NAc tissue was dispersed by 
sonication in Lysis buffer (8M urea, 20mM Tris, 4% Chaps and 1% DTT) with 1X protease and 
phosphatase inhibitors (Roche Diagnostics). The samples were subsequently extracted with 200 µL 
of RIPA buffer (50mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 
100).  The sample was clarified by centrifugation at 15° C for 30 min at 13,000g and the 
supernatant collected. Protein concentration of the supernatant was determined by Bradford assay 
following kit instructions (Bio-Rad, CA, USA). 
 
3.2.8 Filter Assisted Sample Preparation (FASP) and tryptic digest 
For each sample, 100 µg of protein was transferred to a NanoSep 10K Omega ultrafiltration device 
(PALL Life Sciences) and processed according to the FASP protocol (Wisniewski et al., 2009). 
Briefly, samples were diluted to 200 uL in reduction buffer (100 mM Tris, 8M urea containing 20 
mM DTT) and incubated for 1h at room temperature on a Bioshake XP orbital shaker (900 rpm).  
Reduction buffer was removed by centrifugation at 14,000g for 30 min.  Alkylation buffer (100 mM 
Tris, 8M urea containing 50 mM iodoacetamide) was added and the samples incubated as above for 
15 min at room temperature.  Following alkylation, the sample was washed with 3 x 200µL aliquots 
of 100 mM Tris/8M urea to facilitate detergent removal.  Buffer was exchanged to 100 mM 
ammonium bicarbonate and sequencing grade trypsin (Promega) was added at a 1:100 substrate to 
enzyme ratio.  The centrifugal units were sealed with Parafilm and incubated overnight at 37°C.  
Following trypsin digestion, the centrifugal unit was transferred to a fresh collection tube and the 
peptides collected by centrifugation at 14,000g for 30 min. 
 
3.2.9 Peptide Clean-up and SCX Fractionation 
Peptides were desalted using Empore C-18 7mm/ 3 mL SPE cartridges according to the 
manufacturers instructions and dried in a speed-vac overnight at 30°C.  SCX fractionation was 
performed using OASIS MCX 3cc 60 mg extraction cartridges.  Briefly, peptides were resuspended 
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in 25% acetonitrile containing 0.05% formic acid in an ultrasonic waterbath for 15 min. Cartridges 
were conditioned as recommended by the manufacturer and the peptides loaded using gravity 
filtration.   Peptides were step eluted from the cartridge using 1 mL aliquots of 50, 100, 150, 200 
and 400 mM ammonium formate in 25% acetonitrile respectively.  Eluted peptides were speed-vac 
to dryness and stored at -20° C until MS analysis. 
 
3.2.10 SWATH Mass spectrometry  
For 1D LC-MS/MS analysis peptides were dissolved in 0.1% formic acid and injected onto an 
Eksigent nanoLC-Ultra system (AB Sciex) at a flow rate of 300 nL/min onto a cHiPLC-Nanoflex 
75 x 150 mm column ChromXP C18-CL 3µm 120 Å phase (Eksigent, USA) configured in trap and 
elute mode.  Chromatographic separation was performed using a linear gradient 1 – 60% solvent B 
over 90 min. Mobile phases consisted of solvent A (1% acetonitrile, 0.1% formic acid) and solvent 
B (0.1% formic acid, 90% acetonitrile). The HPLC eluent was interfaced to a TripleTOF 5600 
LC/MS/MS system using a Nanospray III ionisation source (Applied Biosystems, Forster City CA). 
Source conditions included an ion spray voltage of 2700 V, nebulizer gas flow of 10, curtain gas 
flow of 30, interface heater temperature at 150° C and collision-induced dissociation settings 
included CAD gas of 10 and a declustering potential of 80 V. MS TOF spectra were acquired across 
the range m/z350 – 1800 for 0.5 s followed by 20 data-dependent MS/MS measurements on 
precursor ions (100 counts/s threshold, +2 to +5 charge state, collision energy of 40 with collision 
energy spread of 15).  For SWATH (Sequential Window Analysis of all Theoretical fragment-ion 
spectra) analysis, a second injection was performed in a data independent mode stepped at 25amu 
across the same mass range.  Data was acquired and processed using Analyst TF 1.6™ software. 
 
3.2.11 Protein identification and quantification 
ProteinPilot™ v4.5 software (Applied Biosystems, Forster City CA) utilising the Paragon 
Algorithm was used for the identification of proteins. MS/MS data was searched against the Uniprot 
FASTA formatted database (January 2014 release). Search parameters included trypsin as the 
digestion enzyme, iodoacetamide as cys-modification, biological modifications allowed (using the 
set provided with the software) and ‘thorough’ search setting. The criterion for a positive 
identification was a confidence score of ≥ 95% and a minimum of 3 transitions per peptide and 2 
peptides per protein. For SWATH analysis, the data was initially processed using Peak View 1.2 
software (Applied Biosystems, Forster City CA).  The ion library was generated from the Protein 
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Pilot data file; filters included 5 peptides per protein, 3 transitions per peptide, modified peptides 
and shared peptides excluded from the analysis.  The filtered ion library was then exported to the 
MSstats package using the R platform (Choi et al., 2014b).  
 
3.2.12 Molecular Pathway And Network Analysis 
The lists of significant (p<0.05) differentially expressed proteins (UniProt) and the fold change of 
these proteins was uploaded to the Ingenuity Pathway Knowledge Base (Ingenuity System Inc, 
Redwood City, CA). The two lists used were proteins altered in MK-801 acute rats compared to 
Naïve Control and proteins altered in MK-801 sensitised rats compared to Naïve Control. Ingenuity 
Pathway Analysis (IPA) was used to identify significant canonical pathways, bio functions and 
networks (p<0.05). 
 
3.2.13 Tissue collection for radioligand binding  
NAc tissue was collected from 5 Naive, 7 MK-801 acute and 7 MK-801 sensitised rats. The animals 
were euthanized using Lethabarb (4ml/kg) (Virbac Pty. Ltd., Australia) and decapitated. The brain 
was immediately removed and placed in an ice-chilled petri dish. The NAc was isolated by micro-
dissection, snap frozen in liquid nitrogen and stored at -20° C. Tissue was homogenized in 50 
volumes of ice-cold 50-mM Tris-HCl buffer (pH7.4) using an Ultra-Turrax homogenizer. 
Homogenates were centrifuged at 48,000g for 10 min at 4°C. The pellets were resuspended in 20 
volumes of washing buffer containing (in mM): Tris-HCl 50, EDTA 5, and EGTA 1) and 
centrifuged again at 48,000g for 10 min at 4°C. The washing was repeated twice, and the final 
pellet was resuspended in ten volumes of assay buffer containing (in mM): Tris-Hcl 50, NaCl 120, 
KCl 5, CaCl2 2, MgCl2 1, EDTA 1 and 0.1% Ascorbic acid). Protein concentration of the crude 
synaptosome was determined by Bradford assay following kit instructions (Bio-Rad, CA, USA). 
 
3.2.14 Dopamine D1 Receptor Radioligand Binding Assay  
Crude synaptosomes were incubated at 37°C for 1h in the presence of 5 nM [3H] SCH23390 
(Amersham Biosciences, NJ, USA). Nonspecific binding was determined with the addition of 1μM 
cis-flupenthixol (Sigma Aldrich). Due to limitations with the amount of NAc tissue available, only 
a single concentration instead of a range of concentrations could be assessed. The single 
concentration used was a saturating concentration previously established and published in our 
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laboratory (Kesby et al., 2012). For each sample, total binding was measured in triplicate and non-
specific binding was measured in duplicate. Incubations were terminated and the bound radioligand 
was filtered on 0.6% polyethylenimine pre-treated glass fibre filters (Whatman GF/B) using a cell 
harvester (Tomtec, Hamden, CT, USA), with subsequent rapid washing. Bound radioactivity was 
determined by liquid scintillation (Wallac MicroBeta 1450 JET, USA) with an efficiency of 56%.  
 
3.2.15 Statistical Analyses  
Behavioural data and D1R radioligand binding data was analysed using the SPSS statistics program 
(version 20, Armonk, NY: IBM Corp.). Data were analysed using the repeated measures or one-
way ANOVA with Drug treatment as the between-subjects factor. The electrophysiology data was 
analysed using the GraphPad Prism software (CA, USA) with an unpaired Student’s t-test. 
Proteomics data was analysed in the MSstats package (Bioconductor) using the R platform. The 
statistical significance was set as p<0.05.  
 
3.3 RESULTS  
3.3.1 Behavioural sensitisation  
Rats assigned to the MK-801 acute group were treated with saline once daily for 7 consecutive days 
and rats assigned to the MK-801 sensitised group were treated with MK-801 for 7 days. After 5 
days withdrawal, both groups were challenged with MK-801 (0.25mg/kg). As previously observed, 
the locomotor response to MK-801 challenge was significantly augmented in rats previously treated 
with MK-801 compared to those previously treated with saline (F 1, 26 = 10.2, p<0.01) (Figure 
3.3a,b). Repeated measures ANOVA confirmed the MK-801 sensitised group had an increased 
locomotor response to MK-801 challenge compared to their response on Day 1 (F 1, 26 = 11.1, 
p<0.01) (Figure 3.3a). 
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Figure 3.3 Behavioural sensitisation to repeated MK-801 
Rats were divided into two treatment groups; MK-801 Acute (n=14) and MK-801 Sensitised (n=14).  MK-801 Acute 
rats were injected intraperitoneal (i.p.) with saline (1ml/kg) and MK-801 Sensitised rats were injected with MK-801 
(0.25mg/kg) once daily over 7 consecutive days. Following 5 days withdrawal, both groups received an MK-801 
(0.25mg/kg) challenge injection (i.p.). (a) An augmented locomotor response to MK-801 challenge was observed in the 
MK-801 Sensitised group compared to the MK-801 Acute group. Furthermore, the MK-801 Sensitised group showed 
an enhanced response to the MK-801 challenge compared to locomotor activity on Day 1. (b) Time course of locomotor 
activity of MK-801 Acute and MK-801 Sensitised rats over 3h following MK-801 challenge. Repeated measures 
ANOVA revealed MK-801 Sensitised rats had a significantly enhanced locomotor response from 50-110min after 
challenge. Data are presented as mean ± SEM. *p<0.05.  
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3.3.2 Excitatory synaptic strength in the NAc 
To evaluate changes in excitatory synaptic strength on MSNs in the NAc shell, comparisons were 
made from the relative contributions of AMPARs and NMDARs to EPSCs. One-way ANOVA 
revealed a main effect of group (F 2, 9 = 19.5, p<0.001) on the AMPAR/ NMDAR ratio in MSNs in 
the NAc shell. Post-hoc Dunnett test revealed MK-801 sensitised rats (n=5 cells, 4 rats) was 
significantly decreased compared to naïve rats (n=3 cells, 3 rats) (p=0.0001; Figure 3.4). Post-hoc 
Dunnett test also revealed that compared to the naïve controls, there was no change in the 
AMPAR/NMDAR ratio in MK-801 acute treated rats (n=4 cells, 3 rats)  (p=0.412; Figure 3.4). An 
unpaired t-tests also indicated there was a significant difference in the AMPAR/NMDAR ratio 
between acute and sensitised rats (p=0.0009; Figure 3.4). This indicates that a single MK-801 
injection in MK-801-treated animals during withdrawal triggered synaptic depression whereas a 
single MK-801 injection in saline- treated animals did not.  
 
 
Figure 3.4 Sensitisation to MK-801 decreases AMPAR/NMDAR ratio in the NAc. 
Summary EPSCs from (a) naïve rats, (b) Acute MK-801 rats and (c) Sensitised MK-801 rats. Calibration: 25ms, 50pA. 
(d) Mean AMPAR/NMDAR ratio in naïve (n=3 cells, 3 rats), Acute MK-801 (n=4 cells, 3 rats) and Sensitised MK-801 
(n=5 cells, 4 rats). *** Significantly different between groups (p<0.001).  Data is presented as mean ± SEM.   
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3.3.3 Differentiated proteins  
SWATH proteomics identified in excess of 10,000 proteins in the NAc samples. After the protein 
grouping algorithm was applied a total of 1,026 unique proteins that had 2 or more peptides were 
identified with >95% confidence. Using the MSstats software 18 proteins were classified as 
significantly (p<0.05) altered in the MK-801 Acute group compared to Naïve controls. Of these 
proteins, 13 were up regulated and 5 were down regulated (Figure 3.5a). In the MK-801 
Sensitisation group 131 proteins were classified as significantly (p<0.05) altered compared to Naïve 
controls. Of these proteins, 129 were up regulated and 2 were down regulated (Figure 3.5b). Of the 
18 altered proteins in the MK-801 Acute group, 9 of these were also found to be significantly 
altered in the MK-801 Sensitisation group. Table 3.1 lists the most significantly (p<~0.01) altered 
proteins with a fold change >1.5. For the full list of significantly altered proteins see Appendix I. A 
literature search of the 131 proteins altered in the MK-801 sensitisation group revealed 9 proteins 
that had previously been identified in chronic MK-801 animal models (Table 3.5).  Using the 
MSstats software, 22 proteins were found to be significantly altered in the MK-801 sensitisation 
group relative to the MK-801 acute group. Table 3.2 lists all of these significantly altered proteins 
(p<0.05). Of these proteins, 21 were up-regulated and 1 was down-regulated (Figure 3.6).  
 
 
 
 
 
 
 
 
Figure 3.5 Volcano plot of the differentiated proteins  
Volcano plots of all mapped proteins in (a) MK-801 Acute rats (n=4) compared to Naïve Controls (n=4) and (b) MK-
801 Sensitised (n=3) compared to Naïve Controls. The red points indicate proteins that were significantly up regulated 
in the treatment groups and the green points indicate proteins that were significantly decreased. The cut-off line for 
significance was set at p<0.05.  
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Table 3.1 Significantly altered proteins in the NAc 
List of significantly (p<0.01, uncorrected) altered proteins with fold change (FC>1.5) in the (A) MK-801 Acute model 
and (B) MK-801 Sensitised model.  
 
 
 
 
 
 
 
 
 
 
Gene 
Name 
UniProt 
ID 
Protein Name FC p-value 
(A) MK-801 Acute model 
TLN1 P54939 talin 1 2.095 0.00031 
TWF1 Q5RJR2 twinfilin actin-binding protein 1 1.82 0.00518 
CLDN12 Q9ET43 claudin 12 2.139 0.00972 
CBR1 P47727 carbonyl reductase 1 -1.604 0.012 
(B) MK-801 Sensitisation model 
ETFB Q9DCW4 electron-transfer-flavoprotein, beta polypeptide 4.123 0.001 
CRYL1 Q811X6 crystallin, lambda 1 1.694 0.002 
CLDN12 Q9ET43 claudin 12 1.899 0.004 
RAB1A Q6NYB7 RAB1A, member RAS oncogene family 1.511 0.006 
RGS7 P49803 regulator of G-protein signaling 7 2.189 0.006 
FAM49A Q9H0Q0 family with sequence similarity 49, member A 1.532 0.009 
PSMD3 Q2KJ46 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 3 
1.863 0.009 
MYH9 Q62812 myosin, heavy chain 9, non-muscle 1.632 0.009 
CAMK2A Q9UQM7 calcium/calmodulin-dependent protein kinase II 
alpha 
1.54 0.011 
Fus Q28009 fused in sarcoma 1.861 0.012 
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Table 3.2 Significantly altered proteins between MK-801 Acute and MK-801 Sensitised 
List of all the proteins significantly different (p<0.01, uncorrected) in the MK-801 Sensitised animals relative to the 
MK-801 acute animals.  
 
 
 
 
 
 
Gene 
Name  
UniProt 
ID 
Protein Name FC p-value 
PHB2 Q5XIH7 Prohibitin-2 1.246 0.0136 
PEPD Q5I0D7 Xaa-Pro dipeptidase 1.885 0.0181 
DDAH1 O08557 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 1.794 0.0184 
TIM8A Q9WVA1 Mitochondrial import inner membrane 
translocase subunit Tim8 A 1.251 0.0187 
SRR Q76EQ0 Serine racemase 1.365 0.0190 
LRRC7 P70587 Leucine-rich repeat-containing protein 7 1.872 0.0228 
SEPT7 Q9WVC0 Septin-7 1.257 0.0248 
ES1 P56571 ES1 protein homolog, mitochondrial 1.223 0.0260 
1433E P62260 14-3-3 protein epsilon 1.407 0.0267 
RAP2B P61227 Ras-related protein Rap-2b 1.704 0.0295 
ATP5H P31399 ATP synthase subunit d, mitochondrial 1.349 0.0303 
TRXR1 O89049 Thioredoxin reductase 1, cytoplasmic 2.599 0.0312 
WDR7 Q9ERH3 WD repeat-containing protein 7 1.742 0.0395 
LDHB P42123 L-lactate dehydrogenase B chain 1.188 0.0400 
PFKAM P47858 ATP-dependent 6-phosphofructokinase, muscle 
type 1.358 0.0410 
RL18A P62718 60S ribosomal protein L18a 1.176 0.0412 
DNM1L O35303 Dynamin-1-like protein 1.472 0.0434 
TCTP P63029 Translationally-controlled tumor protein 1.359 0.0441 
LETM1 Q5XIN6 LETM1 and EF-hand domain-containing protein 
1, mitochondrial -1.413 0.0463 
STXB1 P61765 Syntaxin-binding protein 1 1.372 0.0468 
PRDX1 Q63716 Peroxiredoxin-1 1.084 0.0485 
GRIA2 P19491 Glutamate receptor 2 1.453 0.0486 
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Figure 3.6 Volcano Plot of differentiated proteins between MK-801 treatment groups 
Volcano plots of all mapped proteins in MK-801 Sensitised (n=3) compared to MK-801 Acute rats (n=4). The red 
points indicate proteins that were significantly up regulated in the MK-801 sensitisation group and the green points 
indicate proteins that were significantly decreased. The cut-off line for significance was set at p<0.05.  
 
 
3.3.4 In Silico Pathway and functional analysis  
3.3.4.1 Canonical pathways  
IPA identified 3 significant canonical pathways in the NAc of MK-801 acute animals. They were 
Protein Ubiquitination pathway (p=0.0204), IL-15 Production (p=0.0233) and Regulation of 
Cellular Mechanics by Calpain Protease (p=0.0486).  In the MK-801 sensitised group, IPA analysis 
identified 71 significant canonical pathways (p<0.05) (Appendix II). The top 10 canonical pathways 
are listed in Table 3.3, in order of statistical significance. The two most significantly affected 
canonical pathways were Calcium signalling (p= 1.76 x 10-7) and Calcium transport I (p= 1.78 x 10-
7).  Other identified significant canonical pathways of interest were CREB signalling in neurons 
(p=4.3x10-3), ERK/MAPK signalling (p=2.93x10-2), synaptic long-term potentiation (p=3.8x10-2) 
and glutamate receptor signalling (p=4.89x10-2).  
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Table 3.3 Canonical pathways 
List of the top 10 significantly affected canonical pathways in MK-801 sensitisation animals identified by Ingenuity 
Pathway Analysis.  
 
 
3.3.4.2 Biological Functions  
Altered proteins from each dataset were mapped to a number of “Molecular and Cellular Functions” 
and “Diseases and Disorders” in IPA. The top 5 biological functions affected in the MK-801 acute 
and MK-801 sensitised groups are listed in Table 3.4. Within each bio function, IPA analysis 
identifies biological processes likely to be impacted on by the altered protein expression. In the 
MK-801 acute model these include ‘paired-pulse facilitation of synapse’, ‘size of synaptic vesicles 
pool’ and ‘endocytosis of synaptic vesicles’. In the MK-801 sensitisation model significant 
biological processes of interest include ‘morphology of neurons’, ‘plasticity of synapse’, 
‘microtubule dynamics’, ‘transport of synaptic vesicles’, ‘neuritogenesis’, ‘size of dendritic spines’, 
‘paired-pulse facilitation of synapse’, ‘efflux of Ca2+’ and ‘proliferation of cells’. 
 
 
 Ingenuity Canonical Pathways p-value Ratio Molecules 
1 Calcium Signaling 0.000000168 10/178 
(5.6%) 
AKAP5,MYH10,CAMK2A,
MYH9,ATP2B3,ATP2B1,TP
M3,MCU,ATP2B4,ATP2B2 
2 Calcium Transport I 0.000000289 4/10 
(40%) 
ATP2B3,ATP2B1,ATP2B4,A
TP2B2 
3 Phagosome maturation 0.00000999 7/120 
(5.8%) 
DYNC1H1,ATP6V1H,TUBA
4A,NAPG,RAB7A,CANX,A
TP6V1A 
4 Oxidative Phosphorylation 0.000061 6/109 
(5.5%) 
ATP5J,NDUFS1,NDUFS8,A
TP5A1,CYC1,UQCRB 
5 Mitochondrial Dysfunction 0.000097 7/171 
(4.1%) 
ATP5J,NDUFS1,NDUFS8,A
TP5A1,CYC1,VDAC1,UQC
RB 
6 Mechanisms of Viral Exit from 
Host Cells 
0.00012 4/41  
(9.8%) 
SH3GL1,SH3GL2,PRKCG,P
RKCB 
7 Glycolysis I 0.000486 3/25 
(12%) 
 
ENO1,ENO2,Tpi1 (includes 
others) 
8 Remodeling of Epithelial 
Adherens Junctions 
0.000848 4/68 
(5.9%) 
DNM1,TUBA4A,RAB7A,M
APRE2 
9 Superpathway of Methionine 
Degradation 
0.00101 3/32 
(9.4%) 
PCCB,GOT2,AHCY 
10 Clathrin-mediated Endocytosis 
Signaling 
0.00105 6/185 
(3.2%) 
SH3GL1,DNM1,SYNJ1,PIP5
K1C,RAB7A,SH3GL2 
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Table 3.4 Top affected biological functions  
Significantly affected ‘Disease and disorders’ and ‘Molecular and cellular functions’ identified by IPA in the (a) MK-
801 acute model and (b) MK-801 sensitised model.  
 
 
 
 
 
 
 
 
(a) MK-801 Acute model (b) MK-801 Sensitisation model 
Diseases and disorders 
 p-value range No. of 
Molecules 
 p-value range No. of 
Molecules 
Developmental 
disorder 
4.36e-03 to 
8.73e-4 
2 Neurological 
disease 
1.66e-2 to 
4.58e-17 
63 
Hereditary 
disorder 
3.45e-3 to 
8.73e-4 
4 Psychological 
disorders 
1.66e-2 to 
1.05e-13 
43 
Metabolic 
Disease 
8.73e-4 to 
8.73e-4 
1 Hereditary 
disorder 
1.39e-2 to 
4.41e-12 
50 
Organismal 
Injury and 
Abnormalities 
3.52e-2 to 
8.73e-4 
7 Organismal 
injury and 
abnormalities 
1.48e-2 to 
4.41e-12 
79 
Renal and 
Urological 
Disease 
2.59e-2 to 
8.73e-4 
2 Skeletal and 
muscular 
disorders 
1.50e-2 to 
4.41e-12 
49 
Molecular and Cellular Functions 
Cell Death and 
Survival 
3.94e-2 to 
8.73e-4 
5 Cell 
morphology 
1.58e-2 to 2e-
10 
55 
Cell-to-cell 
signalling and 
interaction 
3.86e-2 to 
8.73e-4 
2 Cellular 
assembly and 
organization 
1.58e-2 to 
1.88e-9 
56 
Cellular 
assembly and 
organization 
2.67e-2 to 
8.73e-4 
5 Cellular 
function and 
maintenance 
1.58e-2 to 
1.88e-9 
59 
Cellular 
function and 
maintenance  
3.86e-2 to 
8.73e-4 
6 Cellular 
development 
1.46e-2 to 
2.53e-9 
37 
Cell 
morphology  
3.1e-2 to 
1.74e-3 
2 Cellular 
growth and 
proliferation  
1.46e-2 to 
2.53e-9 
58 
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Table 3.5 List of proteins in MK-801 sensitised animals previously described in MK-801 models 
 
 
 
 
 Gene 
name 
Swiss 
Protein 
ID 
Protein Name FC p-
value 
Described in Chronic 
MK-801 animal model 
1 CAMK2A 
 
Q9UQM7 
 
Calcium/calmodulin-
dependent protein 
kinase II alpha 
 
!1.540 
 
0.011 " Cerebral cortex 
(Zhou et al., 2012) 
 
2 ENO1 P04764 
 
enolase 1, (alpha) !1.413 0.048 " Cerebral cortex 
(Paulson et al., 2003) 
"Thalamus      
(Paulson et al., 2004) 
3 ENO2 P07323 
 
enolase 2 (gamma, 
neuronal) 
 
!1.506 0.036 " Cerebral cortex  
(Paulson et al., 2003)  
!Cerebral cortex 
(Zhou et al., 2012) 
 
4 DNM1 P21575 dynamin 1 !1.330 
 
0.041 !Cerebral cortex 
(Zhou et al., 2012) 
 
5 NDUFS1 Q66HF1 NADH 
dehydrogenase 
(ubiquinone) Fe-S 
protein 1, 75kDa 
!1.362 0.019 "Cerebral cortex 
(Zhou et al., 2012) 
6 FSCN1 P85845 fascin actin-bundling 
protein 1 
1.683 0.017 "Cerebral cortex 
(Zhou et al., 2012) 
7 SH3GL2 Q62420 SH3-domain GRB2-
like 2 
1.409 
 
0.018 
 
!Cerebral cortex 
(Zhou et al., 2012) 
 
8 ACTR1B 
 
P42025 
 
ARP1 actin-related 
protein 1 homolog 
B, centractin beta 
(yeast) 
1.383 0.006 !Cerebral cortex 
(Zhou et al., 2012) 
 
9 IDH3A 
 
Q99NA5 isocitrate 
dehydrogenase 3 
(NAD+) alpha 
1.261 0.006 " Cerebral cortex 
(Zhou et al., 2012) 
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3.3.5 Dopamine D1 receptor binding density 
Single concentration radioligand binding revealed there was no significant effect of Drug treatment 
on the density of D1R in the NAc compared to Naïve controls. There was no significant difference 
between MK-801 acute and MK-801 sensitised rats (Figure 3.6).  
 
 
 
Figure 3.7 Dopamine D1 receptor density  
Radioligand binding indicated dopamine D1 receptor binding density is unchanged in the NAc of MK-801 Acute (n=7) 
and MK-801 Sensitised (n=7) rats compared to Naïve controls (n=5).  
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3.4 DISCUSSION  
There is currently little knowledge of the neural mechanisms underpinning behavioural sensitisation 
to MK-801. The results of this study shed some light on neural changes in the NAc, a central brain 
region implicated in expression of drug-induced behavioural sensitisation (Kalivas et al., 1993). 
Here it is shown that the administration of an MK-801 challenge to rats sensitised to MK-801 
decreases the NAc AMPAR/NMDAR ratio, indicative of decreased excitatory synaptic strength. 
This effect is postulated to be dependent on prior MK-801 administration because acute exposure to 
MK-801 had no effect on excitatory synaptic strength in the NAc. This is consistent with previous 
reports indicating that acute drug exposure does not affect synaptic strength in the NAc (Kourrich et 
al., 2007, Wu et al., 2012). SWATH proteomics was utilised to determine the biological processes 
that may be involved in mediating MK-801 evoked changes in synaptic strength and behavioural 
sensitisation.  Finally, the radioligand binding revealed no change in dopamine D1R density in the 
NAc of MK-801 sensitised rats compared to both MK-801 acute and naïve rats.  
This study provides the first electrophysiological evidence that MK-801 sensitisation induces a 
depression in MSN excitatory synaptic strength in the NAc. The AMPAR/NMDAR ratio was 
decreased 24h after an MK-801 challenge in rats that were in withdrawal from repeated MK-801 
administration. Rats in withdrawal from repeated saline administration had no change in synaptic 
strength 24h after MK-801 challenge. That the decrease in synaptic strength was restricted to 
animals with prior drug exposure is reflective of the observations made in cocaine sensitisation 
(Jedynak et al., 2016, Kourrich et al., 2007, Thomas et al., 2001). The initial study by Thomas et al 
(2001) demonstrated a depressed synaptic strength following cocaine challenge in cocaine-treated 
but not saline-treated animals. However, subsequent research suggests that this depression is a 
reversal of the increase in synaptic strength seen in unchallenged cocaine-sensitised animals 
(Jedynak et al., 2016, Kourrich et al., 2007). An important methodological difference to take into 
consideration is that the synaptic strength in this study was not examined in MK-801 treated 
animals in the absence of an MK-801 challenge. Notwithstanding this limitation, the current 
electrophysiological results are indicative of a role for synaptic plasticity in MK-801 sensitisation.  
In support of the electrophysiological findings, the preliminary proteomics data reveals MK-801 
sensitisation induces protein changes that are related to calcium and glutamate signalling, 
mitochondrial dysfunction, clathrin mediated endocytosis and CaMKII and PKC pathways. The 
decrease in AMPAR/NMDAR ratio is thought to be mediated by an decrease in AMPAR function 
and/or number, an increase in NMDAR function or number, or a combination of these (Perkel and 
Nicoll, 1993). The molecular changes observed in the NAc of MK-801 sensitised rats may 
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synergistically contribute to the observed functional change through various mechanisms described 
below.  
In MK-801 sensitised rats, an increase in the expression of Ca2+/calmodulin kinase IIα (CaMKIIα
) and serine/ threonine protein kinase C subunits (PKCβ and PKCγ) was observed.  These 
enzymes target numerous phosphorylation sites on the both the NMDAR NR1 subunit and AMPAR 
GluR1 subunit (Barria et al., 1997, Dingledine et al., 1999, Roche et al., 1996). Phosphorylation by 
enzymes such as CaMKII and PKC signals trafficking of AMPARs and NMDARs in the 
postsynaptic membrane of excitatory synapses (Wang et al., 2006). Thus the phosphorylation status 
of the AMPARs or NMDARs could contribute to the decrease in excitatory synaptic strength 
observed in MK-801 sensitisation (Figure 3.7). Furthermore, pharmacological inhibition reveals 
that both CaMKII and PKC activity in the NAc are critical for the expression of cocaine 
sensitisation (Pierce et al., 1998a). Therefore future investigation into whether pharmacological 
inhibition of these proteins blocks sensitisation to MK-801 is warranted.  
A number of the proteins identified in the MK-801 sensitised rats are involved in glutamate 
signalling, particularly in the glutamate release mechanisms from the synapse. In MK-801 
sensitised rats a significant up-regulation of the glutamate transporter (SLC1A2 or EAAT2) was 
observed (Figure 3.7). Increased expression of EAAT2 leads to increased glutamate uptake into 
astrocytes, thereby reducing extracellular glutamate (Fattorini et al., 2008, Vallejo-Illarramendi et 
al., 2006).  The proteomics also identified an increase in LGI1, a gene whose role in vivo has only 
recently been defined (Zhou et al., 2009) and has previously been associated with epilepsy 
(Anderson, 2010). This gene encodes a secreted protein that localises to the glutamatergic synapse 
and interacts with membrane-anchored proteins such as ADAM22 (A Disintegrin And 
Metalloprotease domain) (Sirerol-Piquer et al., 2006) (Figure 3.7). LGI1 expression increases 
during postnatal development in the rodent brain during a period when glutamatergic synapses are 
functionally down regulated and pruned (Zhou et al., 2009). Overexpression of this protein was 
found to decrease glutamate release probability (Zhou et al., 2009). Decreases in presynaptic 
glutamate release probability are postulated to contribute to decreases in excitatory synaptic 
strength (Thomas et al., 2001). Taken together, up regulation of EAAT2 and LGI1 in MK-801 
sensitised animals suggest there may be decreased glutamate release probability a factor that could 
be examined in further electrophysiological studies.  
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Figure 3.8 Model showing the proposed mechanisms underlying MK-801-induced behavioural sensitisation. 
Model showing the proposed mechanisms underlying MK-801-induced behavioural sensitisation. In MK-801 sensitised 
animals, presynaptic glutamate release probability and availability is decreased by increased expression of excitatory 
amino acid transporter 2 (EAAT2) (A) and Leucine-rich, glioma inactivated 1 (LGI1)  (B). Disturbed calcium (Ca2+) 
signalling induced by MK-801 sensitisation leads to alterations of Ca2+/calmodulin kinase IIα (CaMKIIα) and protein 
kinase C (PKC) (C). Alterations of these proteins are thought to lead to phosphorylation of the AMPAR and NMDAR 
triggering trafficking of the receptors via dynamin (DNM1) mediated endocytosis (D). The alterations in ionotropic 
receptor number or function are observed as the decreased ratio of AMPAR to NMDAR mediated EPSCs (E). Post-
synaptically, dopamine D1R density is unaltered in MK-801 sensitised animals, however increased expression of G-
proteins may lead to altered dopamine receptor function (F). Altered function of the ionotropic receptors affects 
mitochondrial function  (G) and changes in amino acid metabolism via up-regulated expression of glutamic-oxaloacetic 
transaminase 2 (GOT2).  
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The plasticity of the synapse architecture is postulated to contribute to drug-induced alterations in 
synaptic strength and behavioural sensitisation (Russo et al., 2010). In MK-801 sensitised animals 
there was an up regulation of cytoskeletal and cell adhesion molecules including NCAM1, tenascin 
R, myosin 9 and 10, annexin A7 and cytoplasmic linker associated protein (CLASP2). Therefore it 
is plausible to suggest that modifications to synaptic architecture could also contribute to MK-801 
sensitisation. Proteins associated with various steps of synaptic vesicle trafficking, including 
transport (calnexin), exocytosis (spectrin), endocytosis (dynamin 1) and recycling (SH3GL 1 and 2) 
were also up regulated in MK-801 sensitised animals. Of particular interest is dynamin 1, a GTPase 
protein that is phosphorylated by PKC, which is another protein also up regulated in MK-801 
sensitised animals. Up regulation of dynamin 1 has previously been observed following chronic 
exposure to MK-801 (Zhou et al., 2012), as well as also nicotine (Hwang and Li, 2006) and 
morphine (Moron et al., 2007). Dynamin 1 is involved in clathrin-mediated endocytosis (CME) an 
identified canonical pathway affected in MK-801 sensitisation. CME regulates the number of 
glutamate receptors at the postsynaptic site (Lau and Zukin, 2007) and may therefore be a 
contributing mechanism towards decreased synaptic strength in MK-801 sensitisation (Figure 3.7).  
Energetic mechanisms are critical for structural and synaptic plasticity activity (Li et al., 2004b). 
Two of the major canonical pathways affected in the MK-801 sensitisation model were oxidative 
phosphorylation and mitochondrial dysfunction. Mitochondrial dysfunction is the top canonical 
pathway affected in an animal model of behavioural sensitisation to methamphetamine (Wearne et 
al., 2015) suggestive of mechanistic overlap between MK-801 sensitisation. The proteomics results 
also detected changes in subunits of the electron transport chain (NDUFS1, NDUFS8, CYC1 and 
UQCRB) in the NAc tissue of MK-801 sensitised animals. It was also found that this treatment 
group had increased expression of aspartate aminotransferase, an enzyme involved in the 
production of glutamate in mitochondria (Fonnum, 1984). This could be indicative of an increased 
capacity for glutamate production in the NAc, a possible compensatory adaptations in response to 
decreased glutamatergic transmission. Mitochondria also regulate many other functions including 
calcium homeostasis, apoptosis, ATP production, neurite outgrowth and synaptic plasticity (Manji 
et al., 2012). Thus the mitochondrial dysfunction might be causative to the abnormalities in synaptic 
strength observed in MK-801 sensitised animals (Figure 3.7). 
In this study, the density of dopamine D1 receptors in the NAc of sensitised animals was not 
altered. MK-801 sensitisation has previously been associated with supersensitivity of D1R’s, in the 
NAc (Wolf et al., 1993). Our results suggest the previously observed changes in D1R sensitivity do 
not reflect a change in receptor density. Consistent with our findings, other studies have shown that 
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at these doses chronic MK-801 does not increase D1R mRNA in the NAc (Al-Amin et al., 2003, 
Healy and Meador-Woodruff, 1996). The proteomics data revealed an increase in the expression of 
guanine nucleotide binding protein α-subunit (GNAZ) and guanine nucleotide binding protein β-
subunit (GNB1). These heterotrimeric proteins are coupled to dopamine receptors and therefore 
may possibly mediate dopamine receptor function even though D1R density is normal (Figure 3.7). 
Together with previous literature, these results suggest that dopamine receptor function rather than 
expression is altered in MK-801 sensitisation. Altered dopamine receptor function, via G-protein 
signalling pathways, is postulated to influence cell excitability and the phosphorylation of AMPARs 
and NMDARs (Cahill et al., 2014). Thus future research should be targeted to the downstream 
signalling pathways of the dopamine receptors. 
In conclusion our results demonstrate MK-801 sensitisation induces a decrease in synaptic strength 
in the NAc, which is a key brain region for behavioural sensitisation and mechanisms of addiction 
(Steketee and Kalivas, 2011). Preliminary analysis using proteomics identified a number of proteins 
altered by repeated MK-801 administration that were not previously identified in chronic MK801 
proteomic reports of other brain regions (Joo et al., 2013, Paulson et al., 2007, Paulson et al., 2004, 
Paulson et al., 2003, Zhou et al., 2012). An important future direction will be to determine if these 
molecular changes are pathogenic mediators that contribute to both the observed changes in 
synaptic strength and behavioural sensitisation. Our functional results suggest MK-801-induced 
sensitisation is associated with synaptic depression, rather than potentiation as observed in cocaine 
sensitisation. It cannot be excluded at this point that synaptic potentiation may also be associated 
with MK-801 sensitisation. Further studies to identify and confirm the synaptic alterations and their 
molecular basis are warranted, given the relevance of behavioural sensitisation to drug addiction 
and schizophrenia. 
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sensitisation  
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4.1 INTRODUCTION  
The hypothalamic-pituitary-adrenal (HPA) axis is activated in response to stress. Acute 
administration of drugs of abuse including cocaine (Nelson et al., 2010), amphetamine (Knych and 
Eisenberg, 1979), ethanol (Kakihana et al., 1968), morphine (Milanes et al., 1993) and MK-801 
(Baumann et al., 2000) can also lead to HPA axis activation. Upon activation of the HPA axis 
corticosterone is released from the adrenal glands and signals at the high-affinity mineralocorticoid 
receptors (MR) and low-affinity glucocorticoid receptors (GR) (Reul and de Kloet, 1985). Low 
basal corticosterone levels are believed to preferentially bind MR, whereas under stressful 
conditions increased corticosterone levels progressively saturate the GR (Moldow et al., 2005, Reul 
and de Kloet, 1985). Research suggests that stress, via increased corticosterone signalling at the 
GRs, facilitates behavioural sensitisation to psychostimulant drugs.  
The role of the glucocorticoids is thought to be predominately involved in the induction rather than 
expression phase of behavioural sensitisation. For instance it has been shown that adrenalectomy or 
the co-administration of the GR antagonist RU486 can block the induction of behavioural 
sensitisation to drugs of abuse (Prasad et al., 1996, Przegalinski et al., 2000, Roberts et al., 1995, 
van der Veen et al., 2013). However, once sensitisation is established, adrenalectomy past the 
induction phase has no effect on the expression of behavioural sensitisation (Prasad et al., 1996, 
Przegalinski et al., 2000). In agreement with these findings, co-administration of RU486 with drug 
challenge does not attenuate the expression of behavioural sensitisation (de Jong and de Kloet, 
2009) (though see (Rivet et al., 1989)). The glucocorticoids are postulated to exert their effects on 
behavioural sensitisation through modulation of mesoaccumbens activity. For example, increased 
dopamine release in the NAc has been observed in the cross-sensitisation between stress and 
psychostimulant drugs in a glucocorticoid dependent manner (Deroche et al., 1995, Garcia-Keller et 
al., 2013, Rougepont et al., 1995). Furthermore, the removal of corticosterone by adrenalectomy, or 
ablation of the GR has been shown to reduce psychostimulant-induced increases of dopamine 
release in the NAc (Barik et al., 2010, Barrot et al., 2000). 
Corticosterone signalling via the GRs is thought to play a critical role in the induction of 
sensitisation to MK-801 (Wedzony and Czyrak, 1994). Co-administration of the corticosterone 
synthesis inhibitor, metyrapone, was found to block induction of a sensitised locomotor response to 
a subsequent MK-801 challenge after two days withdrawal (Wedzony and Czyrak, 1994). The 
authors also demonstrated that in their acute MK-801 sensitisation paradigm, co-administration of 
RU486 with the first injection MK-801 blocked the development of sensitisation (Wedzony and 
Czyrak, 1994). Furthermore, acute administration of exogenous corticosterone can increase the 
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hyperlocomotor stimulatory effects of MK-801 (Wedzony and Czyrak, 1994). The manipulation of 
GRs during the induction of repeated MK-801 exposure has not previously been examined until 
now. Since acute MK-801 has activating effects on the HPA axis, this may, in part, mediate the 
ability of repeated MK-801 to induce behavioural sensitisation. Therefore, the primary objective of 
this chapter was to determine whether sensitisation to repeated MK-801 injections could be 
inhibited by co-administration of the GR antagonist RU486. In addition, how the induction and 
expression of MK-801 sensitisation interacted with GR antagonism to affect plasma corticosterone 
levels was examined. The mechanism by which glucocorticoids modulate NAc dopamine in a 
model of MK-801-induced sensitisation is currently unknown. Therefore, it was also determined 
whether long-term changes in NAc dopamine were altered by MK-801 and/or RU486 
administration.   
 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Adult (~70 days of age) male Sprague Dawley rats (ARC, Western Australia) were utilised in this 
study. Rats were pair-housed in standard Makrolon wire-top cages (38x23.5x16cm), kept on a 
constant 12h light/dark cycle (light phase 0600h-1800h), and provided with standard rat chow 
(Specialty Feeds, Glen Forrest, Western Australia, Australia) and water ad libitum. Rats were 
acclimatized to these living conditions for a minimum period of one week prior to any behavioural 
testing. Both the homeroom and behavioural testing room were located in the same animal facility 
(Room Temp. 24°C, 40-60% Humidity). All testing was conducted during the light phase and at the 
same time of day across the sensitisation paradigm. Two separate cohorts of rats were used for the 
behavioural testing and plasma corticosterone analysis. All procedures were performed with the 
approval from the University of Queensland Animal Ethics Committee, and followed the Australian 
code for the care and use of animals for scientific purposes (NHMRC, 8th Ed, 2013).  
 
4.2.2 Behavioural testing  
Behavioural testing was conducted in a room separate to the homeroom at the AIBN animal facility. 
The behavioural room was also temperature controlled to the same conditions as the homeroom 
(room temperature 24° C, 40-60% humidity). Rats were transported in their home cages on a trolley 
from the East wing homeroom to the West wing behavioural room. They were transported to the 
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room at least half an hour prior to behavioural testing commenced to allow them to habituate to the 
new environment. Behavioural testing was conducted after at least 2 h into the light phase (0800h-
1800h). 
 
4.2.3 Apparatus 
The locomotor activity was assessed in twelve black Perspex chambers, 45cm x 45cm wide and 
60cm deep. The chambers were illuminated by a central strip of LEDs (17 lux). The locomotor 
activity was recorded via a centrally placed video camera (IP8152 Vivotek, Taiwan). The total 
locomotor distance travelled was calculated using the Ethovision automated video tracking software 
(Noldus Information Technology, Wageningen, Netherlands) using differencing background 
subtraction to identify the rat. All test cages were cleaned with 70% ethanol between animals.  
 
4.2.4 Preparation of drugs and administration procedure 
MK-801 (Sigma) was dissolved in 0.9% NaCl to a concentration of 0.25mg/ml. MK-801 was 
administered at a dose of 0.25mg/kg body weight. Animals were weighed daily and the injection 
volume was adjusted to body weight with 1ml/kg body weight. The GR antagonist RU486 
(mifepristone; Cayman Chemicals, MI, USA) was dissolved in dimethyl sulfoxide (DMSO) to a 
concentration of 80mg/ml. This solution was administered at 0.25ml/kg body weight in order to 
give a dose of 20mg/kg body weight. DMSO (100%) was delivered as the vehicle control for 
RU486 and was also administered at 0.25ml/kg body weight. All solutions were administered via 
intraperitoneal (i.p.) injection using a 29-gauge needle (Terumo, Japan). Analytical reference 
solutions of corticosterone and the internal standard corticosterone-[9,11,12,12-2H4] were obtained 
from IsoSciences (King of Prussia, PA, USA). Stripped human plasma (VD-DC Mass Spec Gold) 
was obtained from Golden West Biologicals Inc. (Temecula, CA, USA).  All solvents and reagents 
were of HPLC grade.  
 
4.2.5 Behavioural effects of RU486 in MK-801 sensitisation   
The behavioural sensitisation paradigm is as described in Chapter 2 and with the modifications 
depicted in Figure 4.1a. Briefly, rats were injected once daily with MK-801 (0.25mg/kg) or saline 
(1ml/kg) over a 7-day induction phase.  This was followed by a 5-day withdrawal phase in which 
rats were left untreated. Following this, at the expression phase (Day 13) all rats received a 
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challenge injection of MK-801 (0.25mg/kg). On each day of the induction phase, rats were 
habituated to the behavioural testing room for 30min. Once placed in the locomotor chamber, they 
were allowed another 30min habituation period. To investigate the role of GR in MK-801 
sensitisation, the antagonist RU486 (20mg/kg) (n=8/group) or a DMSO vehicle (n=4/group) was 
administered on each day of the induction phase. RU486 or vehicle was administered after the 
30min habituation phase and rats were immediately returned to the test chamber. After a further 
30min, by which time RU486 concentrations were maximal (Baulieu and Segal, 1985), rats 
received the MK-801 or saline injection as per the sensitisation protocol. Locomotor activity was 
recorded for a further 120min. At the expression phase rats were habituated to the behavioural 
testing room for 30min followed by 30min habitation to the locomotor chamber. All rats were then 
challenged with an injection of MK-801 (0.25mg/kg) and locomotor activity recorded for 120min. 
 
4.2.6 Corticosterone effects of RU486 in MK-801 sensitisation  
In a separate cohort of animals (n=12/group), the effects of MK-801 and RU486 on plasma 
corticosterone signalling were examined in the same sensitisation protocol as described above 
(Section 4.2.5). Corticosterone levels were assessed from blood samples taken on Day 1, 4, 7 of the 
induction phase and at the expression phase (Day 13) (Figure 4.1b). On Days 1, 4 and 7 blood was 
collected at three different time points, T-60, T0 and T60. As per the above protocol, rats were 
habituated to the behavioural testing room for 30min. Subsequent to this initial habituation period to 
the behavioural testing room, a baseline blood sample was collected (T-60). Rats were placed into 
the test cage and allowed a 30min habituation period. They were then administered an RU486 or 
DMSO vehicle injection and returned to the test cage. After 30min, the second blood sample was 
collected at the time point denoted as T0. Immediately after the blood sample was taken, rats 
received their MK-801 or saline injection. They were then returned to the test cage. At T60, the 
third blood sample was taken, hence 1h following MK-801 or saline administration and 1.5h after 
RU486 or vehicle administration.  
 
4.2.7 Blood sampling  
Blood samples were collected from the saphenous vein by making a small prick with a needle (23 
gauge, Nipro, NSW, Australia). The blood sample was taken while rats were gently restrained, the 
procedure took a maximum of 2min. Approximately 100ul of blood was collected into EDTA-
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coated tubes (Sarstedt, Nümbrecht, Germany). Samples were placed on ice and plasma was 
obtained by centrifugation at 1000RPM at 4°C for 10min. Plasma was stored at -20°C until assayed. 
 
 
Figure 4.1 Timeline of the study  
Timeline of the study. Behavioural testing was completed on the first cohort of animals (a) and corticosterone analysis 
on the second cohort (b). During the induction phase (Days 1-7) rats were sensitised with injections of MK-801 
(0.25mg/kg) or Saline. Thirty min prior to these injections  either RU486 (20mg/kg) or Vehicle (DMSO) was 
administered. In the second cohort blood samples were collected from the saphenous vein on Days 1, 4 and 7. The time 
points are relative to the MK-801 or saline injection at T0. The first sample was collected at T-60 min prior to 
habituation to the test chamber. After 30 min habituation (T-30) rats were injected with RU486 or Vehicle and the next 
sample was taken after 30min at T0. Rats were then injected with MK-801 or Saline and the third blood sample was 
collected 60min later at T60. At day 13, all rats were administered MK-801 to test for the expression of sensitisation. 
The first blood sample was taken at T-30, prior to habitation to the test chamber. At T0 rats were administered with 
MK-801 and the second blood sample was collected 60min later at T60.  
 
4.2.8 Plasma corticosterone quantification 
Corticosterone levels were quantified by an in-house Liquid Chromatography/ Tandem Mass 
Spectrometry (LC-MS/MS) technique. The system consisted of a Shimadzu Nexera® UPLC system 
with a Phenomenex Kinetex® 1.7u XB-C18 100Å (50x2.1mm) column attached to an ABSciex 
QTrap-5500® triple-quadrupole mass spectrometer. To 20µL aliquots of plasma,  20µL of internal 
standard (500 nM corticosterone-[²H4] in 1:1 acetonitrile : water), 10µL of 1M ZnSO4 and 600µL 
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9:1 ethyl-acetate : acetonitrile was added.  After mixing, 500µL of the organic phase was decanted, 
dried under vacuum and reconstituted in 50µL of 1:1 methanol : water. 20µL of extract was then 
injected.  A gradient elution method at 0.5mL/min was used with the mobile phases A= 0.1% 
aqueous formic acid and B= 0.1% formic acid in 9:1 acetonitrile : water. The mixture was increased 
from 50%B to 95%B over 2 min, held at 95%B for 0.5 min and then returned to 50%B for 1min.  
This resulted in a retention time of 1.2min. The mass-spectrometer detection was by way of 
positive-mode, scheduled multiple reaction monitoring with electrospray ionisation. The mass 
spectrometer parameters were as follows:  for corticosterone: m/z= 247.1 → 329.1, declustering 
potential (DP)=100V, exit potential (CXP)=12, collision energy (CE)= 23V; for corticosterone-
[2H4]: m/z= 351.1 → 333.0, DP=100, CXP=15, CE=23. Calibration standards over the range 1000 – 
10nM and quality controls at three levels were prepared in stripped plasma.  Differential quality 
control samples were prepared by spiking rat serum with 75nM of corticosterone.   A ±15% 
acceptance criterion was applied to all quality controls. 
 
4.2.9 Dopamine and metabolites 
Animals were euthanized with an overdose of Lethabarb (4ml/kg, i.p.) (Virbac Pty. Ltd., Australia) 
on Day 14. Tissue was collected 24h after the challenge injection of MK-801 to allow sufficient 
drug-washout (Vezzani et al., 1989). The brains were dissected on an ice-chilled petri dish to collect 
the NAc region according to the method described by Carlsson and Lindqvist (Carlsson and 
Lindqvist, 1973), then snap frozen in liquid nitrogen and stored at -80°C pending analysis. The NAc 
tissue was dispersed by sonication in 0.1M Perchloric acid. Dopamine and the metabolites 3,4-
Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were analysed by high 
performance liquid chromatography (HPLC) as described previously (Cui et al., 2015). The HPLC 
system used was an Agilent 1100 Series system (Agilent Technologies, Inc., CA, USA) containing 
a temperature- controlled autosampler. Mobile phase consisted of 75mM NaH2PO4, 1.4mN octane 
sulfonate, 1mM EDTA and 12% acetonitrile (adjusted to pH 4.13 using phosphoric acid). Mobile 
phase was delivered at a flow rate of 1mL/min to a Kinetex 5µm C18 column, 150mm x 4.6mm 
(Phenomenex Inc., CA, USA).  Dopamine, DOPAC and HVA were detected using a Coulochem III 
electrochemical detector (ESA Laboratories, Inc., MA, USA). The detector settings were as 
follows: conditioning cell (Model 5020, ESA Laboratories, Inc.) at +300 mV, analytical cell (Model 
5014B, ESA Laboratories, Inc.) with the first and second electrodes maintained at −150 and +250 
mV, respectively. Data were quantified by calculating peak-height ratios for each specific analyte 
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relative to the internal standard, deoxyepinephrine. Data were stored and processed with 
Chemstation software (Rev B.01.03, Agilent Technologies, Inc.).  
4.2.10 Statistical Analyses  
Statistical analysis was performed using SPSS statistics program (IBM, version 20). Locomotor 
activity is presented as the total distance travelled over the 2h of measurement following MK-801 
or saline injection. Locomotor activity during the induction phase was analysed with a two-way 
repeated measures ANOVA with Day (Days 1 -7) as within-subjects factors and Pre-treatment 
(RU486 or vehicle) and Drug treatment (MK-801 or saline) as between-subjects factors. Locomotor 
activity was further analysed with a repeated measures ANOVA for both the vehicle- and RU486- 
pre-treated rats with Day (Days 1 -7) as within-subjects factors and Drug treatment (MK-801 or 
saline) as between-subjects factors. To determine whether animals had sensitised, factorial ANOVA 
was performed on locomotor activity at challenge with treatment (MK-801 or saline) as the 
between-subjects factor. The effect of RU486 and MK-801 on corticosterone and neurotransmitter 
levels were analysed by factorial ANOVA. Repeated measures ANOVA were performed on 
corticosterone levels between the days of induction with Day (Days 1, 4, 7) as the within-subjects 
factor and Group as the between-subjects factor. Statistical significance was set at p<0.05 and when 
found, post-hoc testing was performed using a Dunnett’s test, to correct for multiple comparisons.  
 
4.3 RESULTS 
4.3.1 Behavioural effects of RU486 on induction of MK-801 sensitisation    
Figure 4.2a shows the locomotor response, post MK-801 or saline injection, across Days 1-7 of the 
induction phase of our sensitisation protocol. It can be seen that pre-treatment with RU486 elevated 
MK-801-induced locomotor activity. The repeated measures ANOVA conducted on this data 
revealed significant effects of Day (F 6, 120 = 6.79, p<0.001), Pre-treatment (F 1, 20 = 9.53, p<0.01), 
Drug treatment (F 1, 20 = 49.56, p<0.01), and a Pre-treatment x Drug treatment interaction (F 1, 20 = 
8.72, p<0.01). Further analysis indicates that in the vehicle pre-treated rats, MK-801-induced 
locomotor activity was increased compared to saline-induced locomotor activity (F 1, 6 = 30.3, 
p<0.001). In the vehicle pre-treated rats there was no significant Day x Drug treatment interaction, 
indicating that MK-801-induced locomotor did not increase over the induction phase (Figure 4.2a). 
In the RU486 pre-treated rats, MK-801-induced locomotor activity was increased compared to 
saline-induced locomotor activity (F 1, 14 = 55.88, p<0.001). In the RU486 pre-treated rats, repeated 
measures ANOVA revealed a significant Day x Drug treatment interaction (F 1, 14 = 59.5, p<0.001).  
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This indicates that RU486 pre-treatment selectively and progressively increased MK-801-induced 
locomotor activity over the induction phase.  
 
4.3.2 Behavioural effects of prior RU486 treatment on expression of MK-801 
sensitisation    
As expected, when rats that had gone through our induction regime were challenged with MK-801 
after 5 days drug withdrawal, the locomotor response was higher in the prior MK-801 treated rats 
compared to their saline controls (F 1, 20 = 5.12, p<0.05) (Figure 4.2b). No significant interaction 
between RU486 pre-treatment and MK-801 treatment was identified on the locomotor response to 
MK-801 challenge. This indicates that co-administration of RU486 with MK-801 during the 
induction phase, did not have a long lasting effect sufficient to block the expression of MK-801 
sensitisation. However, as evident from Figure 4.2b, prior treatment with RU486 produced an 
enduring enhancing effect on the locomotor sensitivity to MK-801 (F 1, 20 = 6.5, p<0.05), even after 
a withdrawal period of 5 days.  
 
Figure 4.2 Effect of RU486 on MK-801 behavioural sensitisation  
MK-801-induced locomotor sensitisation. (a) During the induction phase, rats received daily administration of RU486 
(20mg/kg) (grey symbols) or DMSO vehicle (white symbols). Thirty minutes later they were injected with MK-801 
(triangles)(0.25mg/kg) or saline (circles) (n=4-8/group). Locomotor activity is recorded as the distance travelled over 
120min. Not surprisingly locomotion was increased by repeated MK-801 but not saline.  RU486 had no effect on the 
saline exposed animals but produced an additive locomotor effect in the MK-801 treated animals that progressively 
increased across the induction phase (*p<0.05)  (b) At the expression phase all animals received a single challenge dose 
of MK-801 (0.25mg/kg) and again distance travelled over 120min was measured. Rats previously treated with MK-801 
displayed a sensitised locomotor response compared to saline treated controls. Expression of MK-801-induced 
sensitisation was preserved in rats previously exposed to RU486 (*p<0.05). Overall rats previously treated with RU486 
(dark bars) during the induction phase displayed a heightened response to MK-801 challenge #p<0.05 compared to 
vehicle treated controls (white bars). Data are presented as the mean ± SEM 
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4.3.3 Plasma corticosterone levels at induction 
Blood was collected from a second cohort of rats for corticosterone analysis on Days 1, 4 and 7 of 
induction (Figure 4.1).  Baseline measures of corticosterone (T-60) decreased with each subsequent 
day of sampling  (F 1, 36 = 94, p<0.001) likely indicating a habituation to the procedure (Figure 
4.3a). At T0 (30min after RU486 or vehicle injection) there was a significant effect of Day on 
corticosterone levels (F 1, 30 = 15.7, p<0.001). This decrease across days is further indication of 
habituation to procedure. As shown in Figure 4.3b, RU486 significantly increased corticosterone 
levels (F 1, 30 = 14.3, p<0.001). At T60 (60min after MK-801 or saline injection) on Day 1, 
corticosterone levels were significantly increased by MK-801 (F 1, 33 = 4.2, p<0.05) and RU486 (F 
1, 33 = 7.1, p<0.05). This effect by each individual drug was no longer observed on Day 4 and Day 7. 
Repeated measures ANOVA on T60 corticosterone levels indicated no significant effect of Day but 
a significant effect of RU486 Pre-treatment (F 1, 33 = 10.6, p<0.01) and MK-801 Drug treatment (F 
1, 33 = 7.1, p<0.05). A post-hoc Dunnett’s test revealed that only corticosterone levels in the 
RU486+MK-801 group were significantly higher than the Vehicle+Saline control group (p<0.01, 
Figure 4.3c). Thus, when given together, the two antagonists had an additive effect on 
corticosterone levels on the first day of induction. However, as there is no individual effect of each 
antagonist on Day 4 and 7 of the induction phase, the nature of the interaction has been altered.  
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Figure 4.3 Plasma corticosterone at induction   
Plasma corticosterone levels throughout induction were measured every third day. (a) Rats (n=12/group) were bled 
prior to treatment (T-60) for baseline measures. Corticosterone levels at baseline decreased over the 7-day induction 
period. (b) After 30min habituation to the chamber half the animals were injected with RU486 and half with vehicle. 
Animals were then bled 30min later (T0). At this time point RU486 was shown to increase plasma corticosterone levels 
compared to vehicle groups across all days. (c) Immediately after being bled at T0 rats were injected with MK-801 (or 
saline) and a final blood sample was collected 60min later (T60). RU486 and MK-801 individually increased 
corticosterone on day 1 (#p<0.05). RU486 and MK-801 had an additive increase on corticosterone across Days 1, 4 and 
7 (*p<0.05). Data are presented as the mean ± SEM  
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4.3.4 Plasma corticosterone levels at expression 
The corticosterone levels measured during the expression of sensitisation on Day 13 are depicted in 
Figure 4.4. At baseline (T-30) there was no effect of any prior treatment on corticosterone levels. 
Administration of an MK-801 challenge injection after 5 days washout had no effect on 
corticosterone levels at T60 and was not affected by any prior treatment.  
 
 
Figure 4.4 Plasma corticosterone at expression  
Plasma corticosterone levels at the expression phase.  All groups (n=12) were habituated to the chamber for 30 min 
prior to receiving a challenge injection of MK-801. Corticosterone levels were unaltered by any prior treatment either at 
baseline (T-30) or 60min after MK-801 challenge (T60). Corticosterone levels did not significantly increase from 
baseline and were not affected by prior induction treatment of RU486 or MK-801. Data are presented as the mean ± 
SEM.  
 
4.3.5 Neurotransmitters and metabolites in the nucleus accumbens 
RU486 pre-treated animals had significantly increased dopamine levels (F 1, 44 = 4.6, p<0.05) in the 
NAc compared to vehicle controls (Fig 4.5a). This increase in dopamine was not affected by prior 
MK-801 treatment. Compared to the Vehicle+Saline control group, DOPAC (Figure 4.5b) and 
HVA (Figure 4.5c) tissue levels were significantly elevated in RU486 pre-treated groups treated 
with either Saline (DOPAC; t22=-2.1, p=0.041, HVA; t16.5=-3, p=0.008) or MK-801 (DOPAC; t22=-
2.4, p=0.024, HVA; t15.3=-2.1, p=0.047). Since DOPAC and HVA levels were both increased in 
RU486 pre-treated animals there was no difference in the DOPAC/HVA ratio (Figure 4.5d).  
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Figure 4.5 Dopamine and metabolite levels in the NAc  
Nucleus accumbens tissue samples were collected one day after the final MK-801 challenge (n=12/group). Dopamine 
(a) and its major metabolites DOPAC (b) and HVA (c) were significantly elevated in RU486 pre-treated rats (grey 
bars). Since DOPAC and HVA were both increased there was no difference in the DOPAC/HVA ratio between groups 
(d). Data are presented as the mean ± SEM *p<0.05 
 
4.4 DISCUSSION  
This study investigated the role of GR signalling in MK-801 sensitisation in male Sprague Dawley 
rats. This was achieved by co-administration of the GR antagonist RU486 with MK-801 during the 
induction phase. The study found that RU486-treated rats did not differ from vehicle controls in the 
initial response to MK-801 injection. However, there was a progressive increase in the locomotor 
response across the induction phase and, contrary to our initial hypothesis, prior treatment with 
RU486 did not block the development of MK-801 sensitisation. In addition to the augmenting effect 
of RU486 on MK-801-induced behaviour, RU486 was found to have an additive effect on MK-801-
induced plasma corticosterone levels.  
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Based on previous studies demonstrating a role for glucocorticoids in behavioural sensitisation to 
psychostimulants, including cocaine (de Jong et al., 2009), amphetamine (van der Veen et al., 
2013), and ethanol (Roberts et al., 1995), it was hypothesised that the co-administration of the GR 
antagonist would block the development of MK-801 sensitisation. The present results did not 
support this hypothesis. These results also contradict those of the one study to date that investigated 
GR function in MK-801 sensitisation (Wedzony and Czyrak, 1994). The authors reported that when 
RU486 was given in conjunction with a single MK-801 administration, the sensitised response to 
the MK-801 challenge 48h later was inhibited (Wedzony and Czyrak, 1994). The most critical 
difference between the present study and that of Wedzony and Czyrak (1994), is that this study 
implemented a repeated MK-801 exposure paradigm rather than a single MK-801 exposure. The 
effects of RU486 may differ significantly between acute and chronic administration of the NMDAR 
antagonist.  
Acute RU486 was found to have potentiating effects on corticosterone production. This is 
consistent with previous reports of the effects of RU486 on corticosterone levels (Dalm et al., 2008, 
Roberts et al., 1995). This is thought to occur via disinhibition of the negative feedback of 
corticosterone from higher components of the HPA axis (Dayanithi and Antoni, 1989). 
Corticosterone synthesis is self-regulated through suppression of corticotropin-releasing hormone 
(CRH). Blocking GRs with RU486 would attenuate this negative feedback, allowing CRH to 
stimulate the release of adrenocorticotropic hormone (ACTH), which results in increased 
corticosterone synthesis (Dayanithi and Antoni, 1989). Consistent with previous studies (McCullers 
and Herman, 2001, Roberts et al., 1995), the present study demonstrated that repeated 
administration of RU486 resulted in a tolerance-like response to its corticosterone-inducing effects.  
Congruent with past reports, MK-801 was also shown to acutely increase corticosterone levels 
(Baumann et al., 2000, Pechnick et al., 1989, Wedzony and Czyrak, 1994). This lead to a tolerance-
like response with repeated exposure, which has also previously been demonstrated (Pechnick et al., 
1989). The precise mechanism by which MK-801 stimulates the secretion of corticosterone is still 
unclear. MK-801 has been shown to increase the biosynthesis of CRH from the parvocellular 
neurons of the paraventricular nucleus (PVN) in the hypothalamus (Lee et al., 1994) and to 
stimulate the release of ACTH (Pechnick et al., 1989). The stimulatory effects of NMDAR 
antagonism on the HPA axis are therefore centrally mediated. This is further supported by early 
findings demonstrating that the NMDAR antagonist PCP has no direct stimulatory effects at the 
level of the pituitary or adrenal glands (Pechnick et al., 1990).  
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Consistent with its effect of increasing MK-801-induced locomotor behaviour, RU486 also 
potentiated the corticosterone-inducing effects of MK-801. When either antagonist was given alone 
(i.e. RU486+Saline or Vehicle+MK-801) corticosterone was only elevated on Day 1 of induction. 
In contrast, the combined administration of RU486 and MK-801 lead to consistently increased 
levels of plasma corticosterone until the end of the induction phase (Day 7). RU486 has previously 
been reported to potentiate the corticosterone-inducing effects of other drugs such as ethanol 
(Roberts et al., 1995). The effect of RU486 on ethanol-induced corticosterone levels showed a 
similar pattern to that shown in the current experiment, with an enhancing effect on acute ethanol-
induced corticosterone and maintaining this effect across the induction of ethanol sensitisation 
(Roberts et al., 1995). Despite the enhancing effect on ethanol-induced corticosterone, Roberts et al. 
(1995) reported that, in mice, the co-administration of RU486 with ethanol for 10 days blocked the 
development of a sensitised locomotor response to the ethanol challenge one day later. The study 
did not monitor locomotor activity during the induction phase. Thus it is unknown whether the 
augmenting effect RU486 had on ethanol-induced plasma corticosterone during induction was also 
reflected in behavioural locomotor activity. It is well known that ethanol, in addition to stimulating 
GABAA receptor function (Mihic, 1999), can also inhibit the function of NMDARs (Hoffman et al., 
1989, Lovinger et al., 1989a). Together with the results of Roberts et al., (1995), our results suggest 
that the potentiating effect of RU486 on MK-801-induced corticosterone release may be due to an 
effect of RU486 on the NMDARs and/or glutamatergic transmission.  
Corticosteroids, like all other nuclear steroids, exert their effects through rapid, non-genomic and 
slower, genomic processes (de Kloet et al., 2008). Both the MR and GR reside in the cytoplasm, 
until they are ligand-bound whereupon they translocate to the nucleus to exert genomic actions 
(Beato and SanchezPacheco, 1996). Non-genomic actions occur predominately via receptors bound 
to the plasma membrane and can affect the ion channels, receptors and neurotransmitters (de Kloet 
et al., 2008). Corticosterone exerts rapid non-genomic effects on glutamatergic transmission and 
synaptic plasticity (Joels et al., 2012). Within minutes, corticosterone has been found to induce 
increases in miniature EPSC frequency (Karst et al., 2010, Karst et al., 2005) and AMPAR mobility 
(Groc et al., 2008). Importantly, even though RU486 is a GR antagonist, most studies are in 
agreement that it does not block non-genomic actions occurring via the GR (Di et al., 2005, Joels et 
al., 2012). The effects of RU486 observed in these experiments during the induction and expression 
of MK-801-induced sensitisation may be reflective of both non-genomic and genomic 
corticosterone actions. 
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The effect of RU486 on MK-801 locomotor activity may occur via corticosterone induced non-
genomic such as a rapid increase in glutamatergic transmission (Figure 4.6) (Groc et al., 2008, 
Martin et al., 2009, Yuen et al., 2009). The system could be therefore be considered ‘primed’ for an 
agent such as MK-801 that produces a short term elevation in glutamate release (Lopez-Gil et al., 
2007, Zuo et al., 2006). Additionally, an increase in glutamate release would allow for more 
NMDARs to be in the open state, to which MK-801 preferentially binds (Huettner and Bean, 1988). 
This provides a plausible mechanism for the interaction between RU486 and MK-801 on enhancing 
locomotion during the induction phase observed in this study. Non-genomic effects of RU486 on 
glutamatergic transmission would not be expected to affect the locomotor response to saline 
injection, consistent with our findings during the induction phase. The effects of corticosterone in 
the brain are also ‘state-dependent’ based on the prior stress history of an animal (Karst et al., 
2010). Repeated co-administration of RU486 and MK-801 each day may also induce genomic 
actions that further prime the glutamatergic system, hence the ‘snowball-like’ effect of RU486 and 
MK-801 co-administration on locomotor activity during the induction phase.  
 
Figure 4.6 Model of the postulated non-genomic and genomic actions of corticosterone. 
Non-genomic actions: Excess corticosterone release stimulates the mineralocorticoid receptor (MR). MR increases 
presynaptic glutamate release enhancing the acute effects of MK-801 locomotor activity. Genomic actions: Increased 
corticosterone release induced by RU486 and MK-801 leads to longer term changes in glutamate receptor function 
further enhancing the locomotor response to MK-801.  
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Though locomotor sensitisation to MK-801 was present at the expression phase, there was no 
sensitised corticosterone response. This finding is consistent with previous reports demonstrating 
that repeated ethanol (Roberts et al., 1995) or cocaine (Borowsky and Kuhn, 1991, Levy et al., 
1992) administration sensitises the behavioural, but not the neuroendocrine response. Prior RU486 
treatment had long-term effects on locomotor behaviour (observed after MK-801 challenge), but not 
corticosterone levels. The effect of RU486 on augmenting MK-801-induced corticosterone levels is 
evidently short-term, since it is dependent on the presence of RU486. An increase in corticosterone 
levels however cannot explain the longer-term effects of RU486 on the sensitivity to the locomotor 
activating effects of MK-801.  
Increased dopamine release in the NAc during challenge has been demonstrated in MK-801 
sensitised animals by microdialysis (Wolf et al., 1993). In the vehicle pre-treated animals that were 
sensitised to MK-801, tissue levels of dopamine and its metabolites in the NAc were not increased 
when measured 24h after exposure to MK-801. However, dopamine, DOPAC and HVA were all 
increased in animals that had previously been treated with RU486 during the induction phase, even 
after 6 days withdrawal. Tissue levels of dopamine typically reflect presynaptic storage. Thus, it is 
plausible that, when challenged with MK-801, RU486 pre-treated animals had a greater available 
pool of dopamine within the NAc that could be released upon exposure to MK-801. It is therefore 
possible that a dopaminergic mechanism also underlies the enhanced locomotor response to MK-
801 challenge in the RU486 treated rats.   
 
Figure 4.7 Model of the postulated genomic action of corticosterone on dopamine  
Corticosterone signalling via the GR stimulates the glucocorticoid responsive element (GRE) on the tyrosine 
hydroxylase (TH) promoter region. This leads to increased TH mRNA allowing enhanced synthesis of dopamine and its 
metabolites in the RU486 treated animals.  
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To the best of our knowledge this is the first study to show that repeated RU486 administration 
induces a persistent increase in dopamine levels in the NAc. Substantial evidence indicates that 
glucocorticoid hormones regulate the mesolimbic dopamine system (Joels et al., 2009). The 
mechanism by which chronic GR antagonism results in increased dopamine is currently unknown. 
One potential mechanism for the increase in dopamine and metabolites observed in this study is 
through increased expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in 
catecholamine synthesis (Flatmark and Stevens, 1999). Through a glucocorticoid-responsive 
element on the promoter region of the TH gene, corticosterone has been shown to directly increase 
TH transcription (Fossom et al., 1992, Hagerty et al., 2001). Thus, in the present study, RU486 
induced corticosterone release occurring during the induction phase could exert long-term genomic 
effects on TH mRNA (Figure 4.7). Because an increase in TH could produce the long-term increase 
in dopamine and its metabolites in the NAc further investigation into this mechanism is warranted.  
In summary, our data indicates that the GRs are a potential moderator in the development of MK-
801-induced locomotor sensitisation. The increased dopamine tissue levels induced by RU486 are 
suggestive of a potential mechanism involved in the interaction between RU486 and MK-801. 
Future studies could address this through pharmacological manipulation of the dopamine receptors 
or 6-OHDA lesions of the dopaminergic terminals. MK-801 behavioural sensitisation is purportedly 
independent of dopamine release and occurs in 6-OHDA lesion animals (Criswell et al., 1993). 
Therefore co-administration of RU486 in 6-OHDA lesion animals during the induction of MK-801 
sensitisation, could determine if the effect of RU486 is dependent on dopamine release. 
Furthermore, it was shown that the corticosterone inducing effects of the NMDAR antagonist MK-
801 is potentiated by GR inhibition, similar to the effects observed with ethanol.  Once again my 
findings indicate there is a clear distinction between mechanisms related to behavioural 
sensitisation to MK-801, compared to behavioural sensitisation to other drugs of abuse.  
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5.1 INTRODUCTION  
Drug-induced behavioural sensitisation involves the complex interplay of many signalling pathways 
(Chapter 1). Pharmacological manipulation of receptor targets is a widely used preliminary tool for 
identifying the role of specific signalling pathways. My previous experiments indicate that stress-
mediated signalling pathways modulate the induction of MK-801 sensitisation (Chapter 4). I have 
also shown that the expression of sensitisation to MK-801 involves glutamate-signalling pathways 
(Chapter 3). In this study, I have used pharmacological manipulation of selected receptor targets to 
investigate 1) the role of certain stress-mediated signalling pathways during the induction phase and 
2) the role of glutamate signalling in the expression phase of MK-801 sensitisation.  
In addition to activation of the HPA axis, stress is mediated by endogenous opioids (Knoll and 
Carlezon, 2010). Opioid signalling consists of at least four types of neuropeptides. These are 
endorphins and endomorphins, enkephalins, and dynorphins and their respective receptor subtype 
targets, mu opioid receptors (MORs), delta opioid receptors (DORs) and kappa opioid receptors 
(KORs). Activation of the HPA axis, and subsequent release of corticotropin releasing hormone 
(CRH) induces dynorphin release (Sirinathsinghji et al., 1990). Correspondingly, dynorphin/KOR 
activity is increased in rodents following physiological stress (Donahue et al., 2015, Nabeshima et 
al., 1992). Stress-induced behavioural sensitisation (Allen et al., 2013) and stress-induced neural 
plasticity (Keralapurath et al., 2014) is dependent on KOR activation. This has been demonstrated 
by pre-treatment with the KOR antagonist, nor-Binaltorphimine (nBNI), which blocks these stress-
induced behaviours (Allen et al., 2013, Keralapurath et al., 2014).  
Stress is also known to enhance a number of drug-induced behaviours, such as conditioned place 
preference (CPP) and locomotor sensitisation (Allen et al., 2013, Jackson et al., 2013, McLaughlin 
et al., 2003). Pre-treatment with nBNI attenuates the stress-induced potentiation of cocaine or 
nicotine-induced CPP and cocaine-induced sensitisation (Allen et al., 2013, Jackson et al., 2013, 
McLaughlin et al., 2003). Importantly, in an unstressed animal, nBNI pre-treatment does not affect 
drug-induced behaviour (Allen et al., 2013, Jackson et al., 2013, McLaughlin et al., 2003). This 
indicates the effect of KOR antagonism is selective to the effects of stress, leaving drug-induced 
behaviour unchanged. KORs are therefore hypothesised to contribute to the potentiating effects 
stress has on drug-induced behaviour (Knoll and Carlezon, 2010) and thereby represent a 
contributing mechanism for the pro-addictive effects of stress (Bruchas et al., 2010).  
In previous experiments I have shown that pharmacological inhibition of GRs led to an 
augmentation of MK-801 sensitisation (Chapter 4). A number of possibilities between the 
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interaction of RU486 and MK-801 were discussed previously (Chapter 4). An alternative 
hypothesis is that stress-induced factors associated with the sensitisation paradigm, have an 
attenuating effect on MK-801 sensitisation. Therefore, when stress-mediated signalling pathways 
are inhibited, this then allows for the augmentation of MK-801 sensitisation. The preliminary 
proteomics data (Chapter 3) identified an up-regulation of Gαz in the NAc of MK-801 sensitised 
animals. The KORs are densely expressed in the NAc (Svingos et al., 1999) and located on both 
MSNs and presynaptic excitatory synapses (Ma et al., 2003, Meshul and McGinty, 2000). The 
KORs are G-protein coupled receptors, reportedly bound to the following subtypes; Gαz, Gβγ, Gαi, 
Gαo, Gα16, and Gαs (Law et al., 2000). Therefore, it is plausible that through increased Gαz 
expression in the NAc, KOR signalling is enhanced in MK-801 sensitised animals. I hypothesise 
that if stress is an attenuating factor in the development of MK-801 sensitisation, then pre-treatment 
at the induction phase with the KOR antagonist nBNI would lead to a facilitation of MK-801-
induced sensitisation, as observed with RU486.  
Due to their modulatory role on presynaptic glutamate release, the mGlu2/3 receptors have been 
shown to play a role in drug-induced behavioural sensitisation. As described earlier (Chapter 1), 
evoked presynaptic glutamate release is attenuated, in part, by stimulation of the presynaptic Group 
II mGlu receptors (mGlu2/3) (Xi et al., 2002a). In amphetamine sensitised animals, the enhanced 
locomotor response, and enhanced NAc glutamate release, induced by amphetamine challenge is 
attenuated by the mGlu2/3 receptor agonist LY379268 (Kim et al., 2005). A number of studies 
demonstrated that when co-administered prior to challenge, mGlu2/3 receptor agonists block the 
expression of behavioural sensitisation to stress, amphetamine or PCP (Bruijnzeel et al., 2001, 
Clark et al., 2002, Kim and Vezina, 2002). However, co-administration of mGlu2/3 receptor agonists 
during the induction phase has no effect on behavioural sensitisation (Bruijnzeel et al., 2001, Clark 
et al., 2002, Kim and Vezina, 2002). Therefore, the role of the mGlu2/3 receptors is thought to be 
specific to the expression phase of behavioural sensitisation. 
By controlling presynaptic glutamate release, mGlu2/3 receptors also modulate the behavioural and 
neurochemical response to NMDAR antagonists. For example, the mGlu2/3 receptor agonist 
LY354740 was found to block PCP-induced locomotor activity (Moghaddam and Adams, 1998). 
This inhibition of behaviour was associated with an attenuation of PCP-induced glutamate release 
in the PFC and NAc, with no effects on dopamine release in these regions (Moghaddam and 
Adams, 1998). Similar results were reported with the mGlu2/3 receptor agonist LY379268, which 
attenuated MK-801-induced hyperlocomotor activity (Uslaner et al., 2009). Though the study by 
Uslaner et al (2009) did not measure glutamate release, the authors did reveal that LY379268 had 
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no effect on MK-801-induced dopamine release in the NAc. This suggests that the acute 
hyperlocomotor response to the NMDAR antagonists, PCP and MK-801, is dependent on glutamate 
but not dopamine release in the NAc. It is not currently known whether the expression of MK-801-
induced behavioural sensitisation can be attenuated by mGlu2/3 receptor stimulation. I have 
previously shown that MK-801-induced sensitisation is associated with a decrease in NAc 
excitatory synaptic strength and alterations in glutamate transport proteins (Chapter 3). This 
suggests glutamate signalling is altered and may contribute to the expression of MK-801-induced 
sensitisation. I hypothesise that, in MK-801 sensitised animals, administration of LY354740 prior 
to challenge will block the expression of sensitisation.  
 
5.2 MATERIALS AND METHODS 
5.2.1 Animals 
Adult male Sprague Dawley rats (ARC, Western Australia) were housed at the AIBN animal 
facility. They were given a minimum one-week acclimatization period to their homeroom at the 
AIBN animal facility after import.  The rats were housed in a temperature-controlled room (Room 
Temp. 24°C, 40-60% Humidity) on a constant 12h light/dark cycle (light phase 0600h-1800h). Rats 
were provided with standard rat chow (Specialty Feeds, Glen Forrest, Western Australia, Australia) 
and water ad libitum. Rats were pair-housed in opaque Makrolon wire topped cages 
(38x23.5x16cm), lined with Sani chip bedding. The animal facility technicians performed daily 
health checks and cleaned cages weekly. All procedures were performed with the approval from 
The University of Queensland Animal Ethics Committee, and followed the Australian code for the 
care and use of animals for scientific purposes (NHMRC, 8th Ed, 2013). 
 
5.2.2 Behavioural Testing  
Behavioural testing was conducted in a room separate to the homeroom at the AIBN animal facility. 
The behavioural room was also temperature controlled to the same conditions as the homeroom 
(room temperature 24° C, 40-60% humidity). Rats were transported in their home cages on a trolley 
from the homeroom to the behavioural room at least half an hour prior to behavioural testing 
commenced to allow them to habituate to the new environment. Behavioural testing was conducted 
after at least 2h into the light phase (0800h-1800h). 
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5.2.3 Apparatus  
The locomotor activity was assessed in twelve black Perspex chambers, 45cm x 45cm wide and 
60cm deep. The chambers were illuminated by a central strip of LEDs (17 lux). The locomotor 
activity was recorded via a centrally placed video camera (IP8152 Vivotek, Taiwan). The total 
locomotor distance travelled was calculated using the Ethovision automated video tracking software 
(Noldus Information Technology, Wageningen, Netherlands) using differencing background 
subtraction to identify the rat. All test cages were cleaned with 70% ethanol between animals.  
 
5.2.4 Preparation of drugs and administration procedure  
(+) MK-801 maleate was supplied by Sigma (Sigma, MO, USA) and made into solution with a 
concentration of 0.25mg/ml in 0.9% saline then stored under dark conditions at -20°C until use. The 
KOR antagonist nor-Binaltorphimine (nBNI) was purchased from Abcam and made directly into a 
10mg/ml concentration in 0.9% saline. LY354740 (Abcam) was dissolved in 1eq. NaOH and was 
made up to a 20mg/ml concentrated stock. LY354740 was brought up to a pH of ~7 before being 
diluted to a 1mg/ml concentration in 0.9% saline. All solutions were administered via 
intraperitoneal (i.p.) injection using a 1mL insulin syringe with a 29-gauge needle (Terumo, Japan). 
Injections were administered at a volume of 1ml/kg. To administer the injections rats were gently 
restrained with a towel and the process took no more than 2 min. 
 
5.2.5 Experiment 5.1: Effect of nBNI pre-treatment on MK-801 sensitisation 
On the first day of induction, rats were pre-treated with nBNI (10mg/kg, i.p.) or saline vehicle 
(Figure 5.1a). This single dose administration paradigm was used since the KOR antagonistic 
effects of nBNI have been shown to last for at least three weeks (Endoh et al., 1992, Jones and 
Holtzman, 1992, Patkar et al., 2013). After 30min rats were then injected with saline or MK-801 
(0.25mg/kg) (n=12/group). This 30min time point was chosen based on previous publication 
indicating that nBNI begins to exert its KOR antagonistic effects after 30min (Endoh et al., 1992). 
On the following days of the induction phase (Days 2-7) rats continued being administered saline or 
MK-801 (0.25mg/kg). After 5 days of withdrawal all rats were challenged with MK-801 
(0.25mg/kg). Locomotor activity was recorded for 30min before and 210min post-injection. 
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5.2.6 Experiment 5.2: Effect of LY354740 pre-treatment on the expression of MK-
801 sensitisation  
The induction phase consisted of once daily injections of saline or MK-801 over 7 consecutive 
days. After 5 days’ withdrawal rats were challenged with either saline or MK-801. To test the effect 
of LY354740 on the expression of MK-801-induced sensitisation, rats (n=12/group) were injected 
with saline or LY354740 (1mg/kg) 20min prior to the MK-801 challenge (Figure 5.2a). The 1mg/kg 
dose of LY354740 was selected based on the seminal work of Moghaddam and Adams (1998) 
demonstrating this dose was sufficient to block acute PCP-induced locomotor activity and PCP 
induced glutamate release in the PFC and NAc.  
 
5.2.7 Statistics  
Statistical analysis was performed using the SPSS statistics program (version 20, Armonk, NY: 
IBM Corp.). Data were analysed using the repeated measures or one-way ANOVA. Statistical 
significance was set at p<0.05.   
 
5.3 RESULTS  
5.3.1 Experiment 5.1: Effect of nBNI pre-treatment on MK-801 sensitisation  
On Day 1 of the induction phase, when nBNI was administered, locomotor activity was divided into 
and analysed as 10min time bins (Figure 5.1b). There was a significant interaction between Time 
and MK-801 treatment (F(23, 460) = 3.08 p<0.001). However no significant interaction between nBNI 
pre-treatment with MK-801 treatment was observed at any time points. This indicates that nBNI did 
not modulate the acute locomotor response to MK-801 (or saline). During the induction phase 
(Figure 5.1c), a repeated measures ANOVA revealed a main effect of MK-801 treatment on the 
total distance travelled (F(1, 20) = 32.3 p<0.001). There was no significant effect of nBNI Pre-
treatment and no significant Pre-treatment x MK-801 treatment interaction on locomotor activity 
during the induction phase. There was no significant effect of Day on locomotor activity, indicating 
that MK-801 sensitisation did not occur during the induction phase. This is consistent with 
experiments in previous chapters (Section 3.3.1 and Section 4.3.1). Repeated measures ANOVA 
indicated no main effects of MK-801 treatment, nBNI Pre-treatment or Pre-treatment x MK-801 
treatment interaction. Behavioural sensitisation to MK-801 was confirmed by a main effect of MK-
801 Treatment on the locomotor response to MK-801 challenge (F(1, 44) = 4.49 p=0.04)(Figure 
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5.1d). There was no main effect of nBNI pre-treatment and no significant Pre-treatment x Drug 
treatment interaction. Therefore pre-treatment with nBNI had no effect on the expression of MK-
801-induced sensitisation.  
5.3.2 Experiment 5.2: Effect of LY354740 pre-treatment on the expression of MK-
801 sensitisation  
In this experiment, behavioural sensitisation to MK-801 was again confirmed by a main effect of 
MK-801 Drug treatment on the locomotor response to MK-801 challenge (F 1, 44 = 4.7, 
p=0.035)(Figure 5.2b). There was no main effect of LY354740 Pre-treatment on the locomotor 
response to MK-801 and no significant interaction between LY354740 Pre-treatment and MK-801 
Drug treatment. Therefore, the expression of sensitisation to MK-801 was not attenuated by pre-
treatment with LY354740 (Figure 5.2b). In saline treated rats, the acute response to MK-801 was 
not attenuated by pre-treatment with LY354740 (Figure 5.2b).  
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Figure 5.1 Effect of nBNI pre-treatment on MK-801 sensitisation  
(a) Experiment 5.1 timeline. Rats received an injection of nBNI (10mg/kg) or vehicle 30min prior to saline or MK-801 
injection (n=12/group). This occurred only on Day 1 of the induction phase. On Days 2-7 rats were only injected with 
MK-801 or Saline. (b) On the first day of induction, injection of nBNI (first arrow) had no effect on the acute locomotor 
response to MK-801 injection (second arrow) and (c) subsequently had no effect on the induction or (d) on the 
expression of sensitisation to MK-801. Data are presented as the mean ± SEM. *p<0.05  
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Figure 5.2 Effect of LY354740 on MK-801 sensitisation  
(a) Rats were treated with saline or MK-801 during the induction phase. At the expression phase rats were injected with 
vehicle or LY354740 (n=12/group) 20min prior to MK-801 challenge. (b) The locomotor response to MK-801 
challenge was not affected by pre-treatment with LY354740 in either saline or MK-801 pre-treated rats. Data are 
presented as the mean ± SEM. *p<0.05 
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5.4 DISCUSSION  
The aim of this study was to pharmacologically probe two hypotheses on the role of selected 
signalling pathways in the induction and expression of MK-801-induced sensitisation. Firstly, I 
examined whether, when administered on the first day of induction, the long-lasting KOR 
antagonist nBNI would facilitate the induction and subsequent expression of MK-801-induced 
sensitisation. Contrary to my hypothesis, I found that nBNI had no modulatory effect on the 
behavioural sensitisation to MK-801. Secondly, I investigated the role of the mGlu2/3 receptors in 
the expression phase of MK-801 sensitisation. I hypothesised that using a pharmacological agent 
that stimulates mGlu2/3 receptor, and has previously been reported to attenuate evoked presynaptic 
glutamate release in the NAc, would block the sensitised locomotor response to MK-801 challenge. 
In this experiment, I found that co-administration of the mGlu2/3 receptor agonist LY354740, prior 
to MK-801 challenge, had no effect on the expression of MK-801 sensitisation.  
In Experiment 5.1, I sought to determine how other stress-signalling pathways could be contributing 
to MK-801 sensitisation. The KOR antagonist nBNI was administered only on the first day of 
induction because it has been shown to have antagonist activity in the rodent brain lasting up to 3 
weeks after administration (Endoh et al., 1992, Jones and Holtzman, 1992, Patkar et al., 2013). On 
the first day of induction nBNI had no effect on the acute locomotor response MK-801, either in the 
total distance travelled or when analysed in 10min time bins. GNTI [5'-guanidinyl-17-
(cyclopropylmethyl)-6,7- dehydro-4,5α-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan] is a KOR 
antagonist that is structurally related to nBNI (Jones et al., 1998). It has previously been shown that 
GNTI can reduce acute MK-801-induced hyperlocomotor activity (Qi et al., 2006). This effect 
occurs in a GNTI-dose and MK-801-dose dependent manner, as well as time-dependent manner (Qi 
et al., 2006). In Experiment 5.1, nBNI was administered to rats 30min prior to MK-801 or saline 
injection, which is the same time frame utilized by Qi et al., (2006). Although GNTI and nBNI are 
structurally similar, differences in the pharmacokinetic profile could account for the discrepancy 
between the results from this study, and those reported by Qi et al (2006). The KOR antagonist 
effects of nBNI emerge after 30min and increase until reaching a plateau at about 2h (Endoh et al., 
1992). In Experiment 5.1, acute MK-801-induced hyperlocomotor activity was monitored for 3h 
post-injection. Therefore, this would be sufficient time to observe an effect of nBNI administration 
on acute MK-801 locomotor activity. Conclusively, in this experiment nBNI did not modulate acute 
hyperlocomotor activity. Furthermore, nBNI did not facilitate the induction or expression of MK-
801 sensitisation.  
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Pharmacological manipulation of the KORs has previously been shown to modulate drug-induced 
behavioural sensitisation. For example, co-administration of KOR agonists inhibits the development 
of behavioural sensitisation to drugs of abuse including morphine, cocaine and amphetamine 
(Heidbreder et al., 1993, Spanagel, 1995, Vanderschuren et al., 2000). Conversely, pre-treatment 
with nBNI was found to facilitate morphine-induced behavioural sensitisation (Spanagel, 1995). 
Pre-treatment with nBNI was also found to augment the sensitised dopamine release in the NAc of 
morphine-sensitised rats (Spanagel and Shippenberg, 1993). Therefore, nBNI is thought to enhance 
morphine sensitisation via enhancement of dopamine release (Spanagel and Shippenberg, 1993). In 
the NAc, KORs have an inhibitory effect on dopamine release (Di Chiara and Imperato, 1988, 
Spanagel et al., 1992). Through disinhibition of the KORs, nBNI allows for enhanced stimulation of 
dopamine release in the NAc (Doyon et al., 2006, You et al., 1999). The results of Experiment 5.1 
indicate that a KOR antagonist has no effect on MK-801 sensitisation. Firstly this suggests that, in 
contrast to the initial hypothesis, the kappa opioid pathways are not likely a mediating factor in the 
role stress has on the induction of MK-801 sensitisation. Secondly, these results indicate a 
divergence in the role of KORs in MK-801 sensitisation compared to the role of KORs in morphine 
sensitisation (Spanagel, 1995, Spanagel and Shippenberg, 1993). It is thought that nBNI acts to 
augment morphine sensitisation by enhancing dopamine release. Therefore, it is plausible that nBNI 
could be enhancing MK-801-induced dopamine release during the induction phase, though without 
augmenting MK-801 sensitisation. Overall, there is a lack of modulation of MK-801 sensitisation 
by a KOR antagonist. A limitation of this study is that a single dose of nBNI was used. To confirm 
the lack of nBNI effects in this study, follow-up examination on a range of nBNI doses is 
recommended. Furthermore, given KOR agonists have been shown to block drug-induced 
behavioural sensitisation, it would be of interest for future studies to target the positive modulation 
of KORs.  
In Experiment 5.2, I sought to address the hypothesis that in MK-801 sensitised animals, 
administration of LY354740 prior to challenge would block the expression of sensitisation. 
Stimulation of the mGlu2/3 receptors by LY354740 however did not block the sensitised locomotor 
response to MK-801 challenge. This finding is in contrast to previous reports on the inhibitory 
effect of mGlu2/3 receptor agonists on the expression of sensitisation to PCP (Clark et al., 2002). 
This result is perhaps surprising, as overlapping glutamatergic mechanisms would be anticipated 
between sensitisation to the NMDAR antagonists PCP and MK-801. A number of experimental 
differences could account for the conflicting findings between the findings of this study and those 
of Clark et al., (2002). Firstly, MK-801 and PCP have differential sensitivity and affinity for the 
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NMDAR, and PCP also acts as a σ-receptor agonist (Wong et al., 1986). Secondly, the study by 
Clark et al., (2002) utilized the mGlu2/3 receptor agonist LY379268. This agonist has higher potency 
than LY354740 in regards to forskolin-stimulated cAMP production that is induced by the G-
proteins coupled to mGlu2/3 receptors (Monn et al., 1999). There is also a notable difference in the 
type of sensitisation paradigm implemented, wherein the sensitisation to PCP was observed only 
after 1 day of withdrawal from repeated PCP administration and was no longer observed after 8 
days’ withdrawal (Clark et al., 2002). Therefore the role of mGlu2/3 receptors may be more pertinent 
during early withdrawal phases of NMDAR antagonist sensitisation, compared to longer 
withdrawal periods such as that implemented in the current experiment (i.e. 5 days). Perhaps most 
critically though, Clark et al (2002) applied a range of LY379268 doses (1, 3 and 10mg/kg) on the 
expression of PCP-induced sensitisation. Inhibition of PCP sensitisation was observed only with the 
higher doses (3 and 10mg/kg) of LY379268 that had previously been reported to decrease basal 
locomotor activity (Cartmell et al., 1999). Therefore a potential confound in Experiment 5.2 is the 
dose of LY354740 implemented.  
In the current study, pre-treatment with LY354740 had no effect on the acute locomotor response to 
MK-801 (in rats that had received saline injections during the induction phase). The aim of 
Experiment 5.2 was to identify whether the sensitised response to MK-801 could be attenuated by 
LY354740. Therefore it was important not to induce any ‘floor’ effects on acute MK-801 locomotor 
activity such that the effect on the sensitised response would be indiscernible. It was previously 
demonstrated that a low dose of the mGlu2/3 receptor agonist LY379268 at 1mg/kg had no effect on 
MK-801 (0.2mg/kg) induced hyperlocomotion, but at doses of 3 & 10mg/kg LY379268 attenuated 
MK-801 induced locomotor activity (Uslaner et al., 2009). This low dose of LY379268 (1mg/kg) 
was previously shown to block the sensitised locomotor response to amphetamine challenge (Kim 
and Vezina, 2002), and was also sufficient to block the sensitised NAc glutamate release response 
to amphetamine challenge (Kim et al., 2005). Therefore in Experiment 5.2, the low dose of 
LY354740 (1mg/kg) would be expected to be sufficient to attenuate a sensitised NAc glutamate 
release response and the sensitised behavioural response to MK-801 challenge. From the results of 
this study, it appears that stimulation of the mGlu2/3 receptors does not attenuate the sensitised 
locomotor response to MK-801. Therefore a tentative conclusion would be that enhanced 
presynaptic glutamate release does not contribute to the expression of MK-801-induced 
sensitisation. Evidently further investigation is required into the role of mGlu2/3 receptors in the 
expression of MK-801 sensitisation. Finally, in vivo measurements of NAc glutamate release during 
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the expression phase of MK-801 sensitisation, in combination with administration of LY354740, is 
recommended for future studies to validate the findings from this study.  
This study describes a preliminary exploration into the role of the KORs during induction and the 
role of the mGlu2/3 receptors in the expression of MK-801-induced behavioural sensitisation. It was 
hypothesised that stress-related mechanisms associated with the sensitisation paradigm were having 
an ‘inhibitory’ effect on MK-801 sensitisation. Therefore, through disinhibition of the stress-
mediated KOR signalling pathways, nBNI was predicted to facilitate the development of MK-801 
sensitisation. Clearly, pharmacological inhibition of KORs by nBNI did not augment the induction 
of MK-801-induced sensitisation. Since no facilitation with nBNI was observed, I conclude that 
stress-related mechanisms are either 1) not having an inhibitory effect on MK-801 sensitisation or 
2) not acting via the dynorphin/KOR system. I have also demonstrated that pre-treatment with an 
mGlu2/3 receptor agonist, which reportedly attenuates PCP evoked presynaptic glutamate release 
(Moghaddam and Adams, 1998), does not block the sensitised locomotor response to MK-801 
challenge. Though further investigation is required, particularly into the effects on glutamate 
release, this finding suggests that MK-801-induced sensitisation is not associated with enhanced 
glutamate release. Overall, these pharmacological studies continue to imply a disparity in the 
mechanisms mediating sensitisation to MK-801 compared to other drugs of abuse.  
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Understanding the neural mechanisms underpinning behavioural sensitisation may elucidate some 
of the factors that lead to neuropsychiatric disorders such as addiction and schizophrenia (Robinson 
and Berridge, 2008, Ujike, 2002). In pre-clinical research, there is abundant literature on the neural 
mechanisms of behavioural sensitisation to the dopaminergic psychostimulants amphetamine and 
cocaine. In contrast, the neural mechanisms of sensitisation to glutamatergic psychomimetic agents, 
such as MK-801, remain largely elusive. Activation of the NMDAR is a converging mechanism for 
the development of sensitisation to many different classes of addictive substances (Wolf, 1998). 
Therefore sensitisation to MK-801, which acts to antagonise rather than activate the NMDAR, 
would be expected to have distinctive, and perhaps opposing, neural mechanisms that contribute to 
its sensitisation. The objective of this thesis was to investigate whether neural mechanisms that have 
previously been associated with sensitisation to other psychostimulants, also contribute to MK-801 
behavioural sensitisation. Specifically, the aims were to develop an MK-801 sensitisation paradigm 
and establish how external factors modulated the behavioural response (Chapter 2). I sought to gain 
insights into how glutamatergic transmission may be affected in MK-801 sensitisation by 
examining excitatory synaptic strength, protein expression in the NAc (Chapter 3) and by 
pharmacologically manipulating glutamate receptors (Chapter 5). I also aimed to determine 
whether certain previously implicated glucocorticoid-related mechanisms contributed to the 
development of MK-801 sensitisation by pharmacologically inhibiting the GRs with the antagonist 
RU486 (Chapter 4). This study was accompanied by assessing the interaction between MK-801 and 
RU486 administration on plasma corticosterone levels (Chapter 4). Furthermore, an alternative 
stress related pathway, via the KORs was investigated by pharmacological antagonism with nBNI 
(Chapter 5).  
I have established a method of MK-801 behavioural sensitisation using a repeated and intermittent 
administration regime. Using this paradigm, I showed that the dose of MK-801, the length of 
withdrawal from repeated administration and background rodent strain all affect MK-801-induced 
sensitisation. I have shown that environmental context does not modulate MK-801 sensitisation and 
that MK-801 sensitisation does not induce contextual conditioning, which is a common outcome in 
sensitisation to dopaminergic psychostimulants. I demonstrated that excitatory synaptic strength in 
the NAc was decreased following MK-801 sensitisation, suggesting decreased glutamatergic 
signalling. Preliminary proteomics further identified a possible role for calcium signalling and 
synaptic plasticity in the expression of MK-801-induced sensitisation. Results of the radioligand 
and HPLC assays suggest that dopamine in the NAc is not affected by MK-801 sensitisation. The 
pharmacological experiments provide evidence that stress via GR activation or the dynorphin/KOR 
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system does not contribute to the expression of MK-801 sensitisation. Together the findings in this 
thesis provide new insights into neural mechanisms of MK-801 sensitisation. The results suggest 
synaptic plasticity mechanisms contribute to the expression of MK-801 sensitisation. Furthermore, 
the contribution of stress-related factors in MK-801 sensitisation deviated from those that have 
previously been considered important for psychostimulant sensitisation. How these mechanisms 
may relate to the pathophysiology of neural disorders such as schizophrenia and drug addiction is 
discussed below. First I will consider the specific factors pertaining to NMDAR-mediated 
sensitisation in the context of sensitisation to psychostimulants of other classes.  
 
6.1 MECHANISMS OF MK-801 SENSITISATION  
6.1.1 MK-801 sensitisation and glutamatergic signalling  
It is well accepted that glutamatergic transmission is central to the expression of drug-induced 
behavioural sensitisation. As illustrated earlier (Chapter 1), very little is known of the role of 
glutamatergic transmission in MK-801 sensitisation. Here, I report that excitatory synaptic strength 
in the NAc is decreased following MK-801 sensitisation (Chapter 3). Excitatory synaptic strength, 
when measured prior to a drug challenge, is increased in the NAc of animals sensitised to cocaine, 
amphetamine, morphine and ethanol (Abrahao et al., 2013, Jedynak et al., 2016, Kourrich et al., 
2007, Wu et al., 2012).  In the current experiment, the AMPAR/NMDAR ratio was measured one 
day after the MK-801 challenge. In cocaine sensitisation, depotentiation of the AMPAR/NMDAR is 
also reported one day after drug challenge (Jedynak et al., 2016, Kourrich et al., 2007, Thomas et 
al., 2001). In the current study, the decrease in AMPAR/NMDAR ratio that was observed in MK-
801 sensitisation is in the same direction as seen in cocaine sensitisation, however the decrease is 
far greater than that ever observed in cocaine sensitisation (Prof Mark Thomas; personal 
communication). This suggests that MK-801 has the potential to induce robust decreases in 
excitatory synaptic strength. Furthermore, one of the critical questions to address from here is 
whether the observed decrease in excitatory synaptic strength is mediating the expression of MK-
801 sensitisation, or is a homeostatic compensation (Section 6.3 Future Directions).  
The bi-directionality of synaptic plasticity both prior to and in response to drug challenge is thought 
to be critical for the sensitised locomotor response (Jedynak et al., 2016). Reversing cocaine-evoked 
potentiation of excitatory synapses, using in vivo optogenetic depotentiation, attenuates the ability 
of cocaine challenge to induce a sensitised locomotor response (Pascoli et al., 2012). The 
depotentiation of excitatory transmission that occurs in response to a cocaine challenge is observed 
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within 30min of challenge (Jedynak et al., 2016). Decreases in synaptic strength purportedly share 
mechanisms with long-term depression (LTD) (Thomas et al., 2000). Consequently, blocking the 
ability of a drug (amphetamine) challenge to induce LTD attenuates the expression of behavioural 
sensitisation (Brebner et al., 2005). This suggests that the capacity to rapidly switch from a 
potentiated to de-potentiated state, through LTD mechanisms, contributes to a sensitised 
behavioural response (Kauer and Malenka, 2007). 
Though speculative, based on the cocaine literature, I hypothesise that the decrease in excitatory 
synaptic strength observed one day after MK-801 challenge, may be occurring earlier than the 
single time point measured (Chapter 3). If the change in excitatory synaptic strength occurs 
immediately in response to MK-801 challenge, this could potentially mediate the sensitised 
hyperlocomotor response. LTD can be induced via clathrin-dependent endocytosis (CME) of the 
post-synaptic AMPAR (Brebner et al., 2005).  In support of an LTD-like mechanism occurring in 
MK-801 sensitisation, increased expression of proteins relating to clathrin-dependent endocytosis, 
including dynamin was observed (Chapter 3). An important question to address in this MK-801 
sensitisation model is whether the changes in excitatory synaptic strength are bidirectional i.e. 
increased prior to MK-801 challenge and subsequently followed by a robust decrease induced by 
the MK-801 challenge.  
The differences in the significant decrease in AMPAR/NMDAR ratio induced by MK-801 
sensitisation, compared to that observed with cocaine sensitisation, may be attributed to the 
antagonistic action of MK-801 at the NMDAR. LTD can occur via at least three different 
mechanisms including NMDAR-dependent LTD, mGlu-dependent LTD (which occurs via CME) 
and endocannabinoid-mediated LTD (Kauer and Malenka, 2007). NMDAR-dependent LTD 
requires activation of the NMDARs, therefore MK-801 exposure would not be expected to induce 
this form of LTD. Studies using ex vivo slice electrophysiology techniques combined with in bath 
pharmacological manipulation would aid in further understanding the pathways through which MK-
801 induces changes in excitatory synaptic strength.  
The pharmacological manipulation of the mGlu2/3 receptors suggests that MK-801 sensitisation does 
not share similar glutamatergic mechanisms observed with sensitisation to other psychostimulants 
(Chapter 5). Stimulation of these receptors has previously been shown to block the sensitised 
locomotor response to amphetamine challenge (Kim et al., 2005, Kim and Vezina, 2002). I 
demonstrated that when the presynaptic Group II mGlu receptor agonist LY354740 was 
administered prior to MK-801 challenge, this had no effect on the expression of sensitisation 
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(Chapter 5). If the expression of MK-801 sensitisation were dependent on evoked increases in 
glutamate release, pre-treatment with LY354740 would be predicted to attenuate behavioural 
sensitisation. This suggests that the expression of MK-801 sensitisation may not evoke presynaptic 
glutamate release, or may not be dependent on increased presynaptic release. In vivo examination of 
glutamate release however is required to address this hypothesis (Section 6.3 Future directions).  
The preliminary proteomics data (Chapter 3) is also indicative of decreased glutamate signalling 
mechanisms, contrary to those reported for sensitisation to other drugs of abuse. The excitatory 
amino acid transporter 2 (EAAT2) protein tightly regulates extracellular glutamate and is 
responsible for removal of ~90% glutamate from the synapse (Rothstein et al., 2005, Danbolt, 
2001). Therefore subtle changes in this protein would be expected to have a severe impact on 
extracellular glutamate. After MK-801 challenge, MK-801 sensitised rats were found to have a 
~1.68 fold change increase in the protein levels of EAAT2. This increase in EAAT2 also provides 
an alternative hypothesis as to the lack of effect LY354740 had on the expression of MK-801 
sensitisation. If the extracellular glutamate were already being removed from the synapse to a 
greater degree than normal, then this would mask any effect of modulating presynaptic glutamate 
release with the administration of LY354740. It is thus plausible that in MK-801 sensitisation, 
glutamate signalling is predominately regulated by alterations in reuptake mechanisms in contrast to 
pre-synaptic release mechanisms.  
In cocaine sensitisation, the opposite effect is observed wherein animals were found to have small 
(though not statistically significant) decreases in the protein expression of EAAT2 in the striatum, 
post cocaine challenge (Kovalevich et al., 2012, Parikh et al., 2014). These decreases in EAAT2 
expression were linked to functional increases in glutamatergic transmission (Kovalevich et al., 
2012, Parikh et al., 2014). Ceftriaxone, a β-lactam antibiotic, was found to normalise the decreased 
levels of EAAT2 and the increased glutamatergic transmission observed in cocaine-sensitised 
animals (Parikh et al., 2014). Congruent with its effects on glutamatergic transmission, ceftriaxone 
is also capable of inhibiting cocaine-induced behavioural sensitisation (Sondheimer and Knackstedt, 
2011). Therefore increased glutamatergic transmission, mediated in part by decreased EAAT2 
levels, is required for the expression of cocaine-induced behavioural sensitisation. Therefore, I 
would suggest that decreased glutamatergic transmission, mediated in part by increased expression 
of EAAT2, could contribute to the expression of MK-801 sensitisation. This hypothesis could be 
tested by administration of a pharmacological agent such as the mTOR inhibitor rapamycin, which 
has previously been shown to decrease expression of EAAT2 (Wu et al., 2010). Together, this 
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suggests further divergence from similar mechanistic pathways in sensitisation to dopaminergic 
psychostimulants.  
 
6.1.2 MK-801 sensitisation and stress signalling  
The investigation of corticosterone signalling with RU486 revealed that GR antagonism induced a 
progressive enhancement of MK-801 induced hyperlocomotor activity (Chapter 4). RU486 also 
enhanced the ability of MK-801 to increase plasma corticosterone levels and this effect remained 
stable during the induction phase (Chapter 4). Thus the effect of RU486 on MK-801 locomotor 
activity and corticosterone release did not fit the same temporal pattern during induction. Therefore 
corticosterone is not hypothesised as the sole contributing factor to the effect of RU486 on MK-801 
sensitisation. Non-genomic effects such as increasing glutamatergic transmission are a proposed 
mechanism through which RU486 could act to enhance MK-801 sensitisation (for discussion see 
Chapter 4). Methamphetamine-induced cross-sensitisation to MK-801 challenge is dependent on 
increased glutamate release occurring in the NAc during the induction phase (Ito et al., 2006a, Ito et 
al., 2006b). It is therefore proposed that the induction of MK-801 sensitisation requires enhanced 
glutamatergic transmission. In contrast, as stated above, I propose that the expression of MK-801 
sensitisation is associated with decreased glutamatergic transmission.   
The present study using pharmacological manipulation of the GR with RU486 (Chapter 4) depicted 
further divergence in the mechanistic pathways underling the behavioural sensitisation to MK-801 
and behavioural sensitisation to psychostimulants (for review see Chapter 1). At the 
endocrinological level however, the enhancing effect of RU486 on MK-801 induced corticosterone 
levels was consistent with the effects of RU486 on ethanol induced corticosterone levels measured 
during the induction of sensitisation (Roberts et al., 1995). Despite the similarities on 
corticosterone-induced effects, this was not reflected in the behavioural response. Ethanol-induced 
behavioural sensitisation was inhibited by the co-administration of RU486 (Roberts et al., 1995). 
Although ethanol also has some NMDAR antagonist properties (Lovinger et al., 1989b), the manner 
in which stress signalling contributes to ethanol sensitisation is analogous to the dopaminergic 
psychostimulants rather than to MK-801.  
Based on the previous report by Wedzony and Czyrak (1994), it was initially hypothesised that GR 
antagonism would block the development of MK-801-induced sensitisation. The study by Wedzony 
and Czyrak (1994) demonstrated that the co-administration of RU486 with a single administration 
of MK-801 blocked the development of a sensitised response when rats were challenged with MK-
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801 48h later. The authors reported no effect of RU486 on the acute hyperlocomotor effects to MK-
801 on the first day of testing (Wedzony and Czyrak, 1994). This was also evident on the first day 
of induction in the current study (Chapter 4). The differential effect of RU486 on sensitisation to 
acute MK-801 (Wedzony and Czyrak, 1994) versus repeated MK-801 (Chapter 4) could be 
attributed to a number of factors including the development of non-genomic and genomic changes 
to glutamatergic transmission as described earlier. A better understanding on the role of glutamate 
as a mediator between RU486 and MK-801 could be gained by further experiments examining in 
vivo glutamate release and EPSC properties during the co-administration of these drugs.  
The differences between the effects of RU486 on MK-801 sensitisation between the two studies 
could also be attributed to the use of different rodent strains. The acute MK-801 sensitisation study 
by Wedzony and Czyrak (1994) utilised male outbred albino Wistar rats, whereas this study utilised 
male outbred albino Sprague Dawley rats. Although these are both outbred albino rat strains, I have 
already shown that they have a markedly different propensity to MK-801 sensitisation (Chapter 2). 
The role of corticosteroids in drug-induced behavioural sensitisation has previously been shown to 
be genotype-dependent (de Jong et al., 2007). It is therefore also plausible that whilst 
corticosteroids contribute to MK-801 sensitisation in Wistar rats, other signalling pathways play a 
more prominent role in sensitisation to MK-801 in the Sprague Dawley rat strain. This hypothesis is 
supported by previous reports demonstrating that Wistar and Sprague Dawley rats display 
differential behavioural, neurochemical and physiological responses to stress (Bekris et al., 2005).  
In rats, exposure to a novel environment has dichotomous effects acting as both a stressor and 
reward. Environmental novelty has been shown to induce an increase in NAc synaptic strength, 
similar to what is observed after a conventional stress exposure (Rothwell et al., 2011). Drug-
induced behavioural sensitisation is enhanced when drug administration is paired to a novel context 
(Badiani and Robinson, 2004). It is postulated that the enhancing effect of environmental context on 
drug-induced behavioural sensitisation is due in part to a learning and memory process dependent 
on activation of NMDARs (Battisti et al., 2000, Battisti et al., 1999). Therefore it is not surprising 
that drugs that antagonize NMDARs such as PCP and ethanol (Lovinger et al., 1989b), are also not 
modulated by environmental context (Clark et al., 2002, Xu and Domino, 1994, Didone et al., 
2008). Our study is the first to provide evidence that sensitisation to MK-801 is not modulated by 
environmental context. Rats administered MK-801 in the home cage developed behavioural 
sensitisation to the same degree as rats that received MK-801 administrations in the test cage 
(Chapter 2). A potential explanation is that the degree of sensitisation to MK-801 is at a maximum 
that cannot be further augmented by environmental context. However, the finding that RU486 
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augments MK-801 sensitisation (Chapter 5) does not support this hypothesis. Therefore I conclude 
that the lack of modulation by environmental context is due to the antagonistic action of MK-801 at 
the NMDAR thereby inhibiting learning and memory processes.  
 
6.1.3 MK-801 sensitisation and dopaminergic signalling  
MK-801 sensitisation was not associated with basal alterations to dopaminergic signalling in the 
NAc (Chapter 4). Tissue levels of dopamine and the metabolites DOPAC and HVA in the NAc 
were not different between rats sensitised to MK-801 and rats that had received acute MK-801. This 
is consistent with in vivo microdialysis findings showing that MK-801-stimulated dopamine levels, 
but not basal dopamine levels, are increased in MK-801 sensitised animals (Wolf et al., 1993). MK-
801 sensitisation has previously been associated with increased sensitivity of the dopamine D1R in 
the NAc (Wolf et al., 1993). No difference in dopamine D1R-binding density was identified in the 
NAc of MK-801 sensitised rats (Chapter 3). MK-801-induced sensitisation was not enhanced by 
pre-treatment with the KOR antagonist nBNI (Chapter 5). The ability of nBNI to augment 
morphine-induced sensitisation is attributed to its ability to enhance morphine-induced 
mesoaccumbens dopamine release (Spanagel et al., 1993). If nBNI were acting to enhance MK-
801-induced dopamine transmission during the induction phase, then it does not appear to have a 
facilitatory effect on MK-801 sensitisation (Chapter 5).  
The increased tissue levels of dopamine observed after repeated RU486, and the enhanced 
locomotor response to MK-801 challenge in RU486 treated rats, suggests enhancing dopaminergic 
transmission can have a facilitatory or ‘cross-sensitisation’ like effect on MK-801 sensitisation 
(Chapter 4). In our study, co-administration of the GR antagonist RU486 did not block MK-801 
sensitisation (Chapter 4). The GR antagonist has been shown to block sensitisation to many other 
drugs of abuse, and this is in part attributed to its ability to attenuate drug-induced increases in 
dopamine release (Marinelli et al., 1998). The inability of RU486 to inhibit the induction of MK-
801 sensitisation may mean dopamine release within the NAc is not essential for MK-801 
sensitisation. In support of this proposal the KOR antagonist nBNI, which can act to enhance drug-
induced dopamine release (Doyon et al., 2006), also had no effect on the induction of MK-801 
sensitisation. The experiments of this thesis were not designed to directly examine the role of 
dopamine because previous literature indicated that dopamine signalling is modulated but not 
central to the expression of MK-801-induced behavioural sensitisation (Wolf et al., 1993). The 
secondary findings on dopamine signalling reported in this thesis do not contradict the previous 
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literature. Furthermore, the data presented here does not indicate any novel potential causative role 
for dopamine in MK-801 sensitisation.  
 
6.1.4 MK-801 sensitisation summary 
Together with previous literature on MK-801-induced sensitisation, I propose that most neural 
pathways involved in MK-801 sensitisation are divergent from those involved in sensitisation to 
other drugs of abuse. MK-801 has the capacity to induce dopaminergic changes such as increasing 
VTA TH expression and decreasing D2R density in the VTA (Huang et al., 2012). These types of 
dopaminergic alterations are postulated to allow for enhanced dopamine synthesis and release 
through disinhibition of short negative feedback loops, respectively (Kalivas and Duffy, 1993a). 
However previous pharmacological studies with dopamine antagonists (Wolf et al., 1993), as well 
as the previously discussed effects with RU486 and nBNI (section 6.1.3) indicate dopaminergic 
signalling does not mediate MK-801 sensitisation.  
As mentioned earlier, the proposed model of MK-801 sensitisation involves increased 
glutamatergic signalling during the induction phase and decreased glutamatergic signalling at the 
expression phase. The decrease in AMPAR/NMDAR ratio is indicative of increased NMDAR 
function or number in the NAc. This is congruent with previous reports of repeated MK-801 
administration increasing NMDAR number in limbic regions such as the hippocampus (Xi et al., 
2009) and PFC (Rujescu et al., 2006). This switch in AMPAR/NMDAR function alters calcium-
signalling pathways (Chapter 3), with downstream effects on many other signalling pathways. Not 
all of our findings are consistent with the hypothesis of decreased glutamatergic transmission. One 
of the top canonical pathways identified in MK-801 was mitochondrial dysfunction (Chapter 3). In 
mitochondria, glutamate is produced from the phosphate-activated glutaminase and aspartate 
aminotransferase action on glutamine (Fonnum, 1984). Since increased protein levels of aspartate 
aminotransferase were identified in the NAc (Chapter 3) this suggests there is increased capacity to 
produce glutamate, potentially arising as a compensation in response to decreased glutamatergic 
transmission. One of the most pertinent future directions (section 6.3) is to determine whether the 
neuroadaptations are compensation mechanisms occurring in response to the repeated MK-801 
exposure or are contributing to the behavioural sensitisation.  
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6.2 DRUG ADDICTION AND SCHIZOPHRENIA   
Behavioural sensitisation is one hypothesised mechanism in the pathophysiology of a multitude of 
neuropsychiatric disorders. This includes disorders such as schizophrenia (Lieberman et al., 1997), 
bipolar disorder (Post et al., 2001), obsessive-compulsive disorders (Szechtman et al., 2001), 
depressive disorders (Patten, 2008) and drug addiction (Robinson and Berridge, 1993). Drug 
addiction is attributed to an incentive sensitisation i.e. an increase in the incentive motivational 
effects of drugs and drug-associated stimuli (Robinson and Berridge, 1993). In schizophrenia, 
patients show a behavioural and endogenous sensitisation to the effects of amphetamine (Laruelle, 
2000). Thus schizophrenia is postulated to represent an endogenous dopamine sensitisation 
(Lieberman et al., 1997). Schizophrenic patients also show sensitivity to the effects of the NMDAR 
antagonist ketamine (Lahti et al., 1995, Lahti et al., 2001, Malhotra et al., 1997). The co-morbidity 
of substance abuse and dependence in schizophrenia is also thought to be due to shared dysfunction 
of the NMDARs (Coyle, 2006).  
In rodents, MK-801 has been shown to have abuse potential by facilitation of brain stimulation 
reward (Clements and Greenshaw, 2005, Tzschentke and Schmidt, 1999), self-administration 
(Carlezon and Wise, 1996), and intracranial self-stimulation (Hillhouse et al., 2014). The abuse 
potential of MK-801 is also demonstrated in its ability to induce CPP (Layer et al., 1993, Panos et 
al., 1999, Steinpreis et al., 1995). Sensitisation to MK-801 did not induce a conditioned response to 
the MK-801 paired context (Chapter 2). This suggests that MK-801 sensitisation may not increase 
the addictive liability of an individual. The conditioned response is only one measure though. 
Further testing into whether animals sensitised to MK-801 have an increased propensity towards 
other addictive-like behaviours is required.  
The changes in excitatory synaptic plasticity, as measured by changes in synaptic strength or other 
factors discussed earlier, that are associated with drug-induced behavioural sensitisation are 
relevant to addiction (Kauer and Malenka, 2007). Pharmacological, molecular or optogenetic 
manipulations have shown that reversing the changes in synaptic plasticity associated with 
behavioural sensitisation, blocks not only the locomotor sensitisation but also other addiction 
related behaviours including drug seeking and reinstatement (Britt et al., 2012, Sutton et al., 2003, 
Todtenkopf et al., 2006, Van den Oever et al., 2008). The fact that animals sensitised to MK-801 
(but not those acutely exposed) have such alterations in synaptic plasticity mechanisms in the NAc 
suggests this may be a useful model for addiction. Changes in excitatory synaptic transmission and 
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plasticity are attributed to core features of schizophrenia pathophysiology (Grace, 2000, Yin et al., 
2012). Animal models of schizophrenia using MK-801 have previously shown alterations in 
synaptic plasticity in the hippocampus (Buck et al., 2006, Manahan-Vaughan et al., 2008, Wohrl et 
al., 2007) and PFC (Blot et al., 2013, Blot et al., 2015). Thus the decrease in NAc synaptic strength 
shown in this thesis provides further support that the NAc brain region, the interface for limbic and 
motor signalling, could be involved in schizophrenia pathophysiology.  
Stress is involved in the vulnerability to develop many psychiatric disorders including 
schizophrenia (Walker et al., 2008) and drug addiction (Sinha, 2008). Drug-induced behavioural 
sensitisation has provided a useful animal model for investigating the critical time windows for the 
effects of stress. Physiological stress has been shown to cross-sensitise with drugs of abuse. Stress 
also induces changes in excitatory synaptic strength similar to those evoked by drugs of abuse. 
Since it was found that MK-801 also induces changes in excitatory synaptic strength (Chapter 3), 
this may suggest that a cross-sensitisation to physiological stress is possible. The results of this 
study however, suggest that the interaction between stress hormones and NMDAR hypofunction, as 
induced by MK-801, is not so straightforward. The same GR antagonist used in this study (Chapter 
4), RU486 has also been used in clinical trials for treatment of a range of neuropsychiatric disorders 
(DeBattista and Belanoff, 2006, Gallagher and Young, 2006) including schizophrenia (Gallagher et 
al., 2005, Howland, 2013) and addiction (Donoghue et al., 2016). The results of this study suggest 
that RU486 would not likely be useful in the treatment of individuals who abuse NMDAR 
antagonists such as PCP and ketamine. In addition, this raises the critical question of how NMDAR 
dysfunction in schizophrenia would be affected, possibly potentiated, by clinical treatment with 
RU486.  
Overall, I do not propose that the MK-801 sensitisation model established in this thesis is an animal 
model of schizophrenia per se. Further investigation into its construct, predictive and face validity, 
as an animal model of schizophrenia would be required. Rather, I propose that MK-801 
sensitisation is a useful tool for understanding NMDAR dysfunction in animal models of 
schizophrenia. Enhanced sensitivity to MK-801 is a hallmark feature tested and observed in a 
multitude of neurodevelopmental animal models of schizophrenia. Therefore by understanding the 
neuroadaptations required for enhanced ‘exogenous’ sensitisation to MK-801, this research may 
shape the direction of research seeking to understand the ‘endogenous’ sensitisation to MK-801 
prominent in animal models of schizophrenia. Understanding sensitisation is pertinent to our 
understanding of the pathophysiology of schizophrenia. As such, the drive in understanding 
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sensitisation to dopaminergic agents such as amphetamine needs to be equally matched in 
understanding the sensitisation to glutamatergic agents such as MK-801. 
 
6.3 METHODOLOGICAL CONSIDERATIONS  
In terms of the electrophysiological work, due to limitations of the available methodologies, the 
specificity of the MSN cell-type (i.e. D1 or D2 MSN) was not discernable. This was due to the fact 
that this would require performing the experiment in a bacterial artificial chromosome (BAC) 
drd1a-tdTomato and drd2-GFP reporter transgenic mouse line, which was not within the scope of 
the thesis. An alternative method for identifying the cell-type would be to fill the cell with biocytin 
and subsequently analyse by immunohistochemistry. However the cesium internal that was 
available to us did not contain biocytin and thus this additional experimentation could not be 
conducted in the present experiment. The limitations of electrical stimulation should also be taken 
into consideration. When using electrical stimulation on excitatory afferents, there is no means of 
determining the primary brain region from which these afferents arise. To achieve input-specificity 
would require application of ex-vivo optogenetics, a technique far beyond the scope of this thesis.  
Though earlier proteomic literature typically required validation by Western blot analysis this did 
not seem appropriate in this study. Western blots are less sensitive than mass spectrometry in 
identifying small relative fold changes (Aebersold et al., 2013). In the case of this study, where the 
majority of the fold changes are small (<2, see Appendix I), then Western blot analysis would be 
unlikely to determine with confidence protein changes between these treatment groups. A limitation 
of this study would be that biological validation with mass spectrometry has not been performed in 
a second cohort of animals.  
In our Sprague Dawley rats, females have been shown to have a heightened sensitivity to acute 
MK-801 induced hyperlocomotor activity compared to males (Kesby et al., 2012). Furthermore, 
female hormones and the subsequent fluctuations that occur over the estrus cycle are well known to 
affect the propensity to develop drug-induced behavioural sensitisation (Cailhol and Mormede, 
1999, Sircar and Kim, 1999, Souza et al., 2014, Vanhaaren and Meyer, 1991). Therefore in this 
thesis, only male rats were used in order to enhance the simplicity and clarity of teasing apart neural 
mechanisms without the confounding effects of hormone fluctuations. However, to fully understand 
MK-801 induced behavioural sensitisation requires that female rats be implemented in subsequent 
investigations, with cautious consideration of the estrus cycle. The use of female rats would be of 
particular interest in investigating the interaction between MK-801 sensitisation and RU486. This is 
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due to the fact that RU486 acts not only as a glucocorticoid receptor antagonist, but also as an 
antagonist for the receptor of the predominately female hormone, progesterone (Baulieu, 1989). 
 
6.4 FUTURE DIRECTIONS  
The current study suggests MK-801-induced behavioural sensitisation could serve as a useful model 
for investigating the glutamatergic mechanisms underlying the pathophysiology of schizophrenia. 
An additional potential direction of research for MK-801 sensitisation would be to assess its 
potential as a model for drug addiction. Animals sensitised to MK-801 display alterations in 
excitatory synaptic function that may leave them more susceptible to addiction-like behaviours. 
Thus the next step would be the extrapolation of the present results to other models of drug 
addiction, such as self-administration paradigms. However, it is also important to take into 
consideration the lack of cross-sensitisation between MK-801 and other drugs of abuse.  
Furthermore, the results of this study identified a number of molecular and functional adaptations 
relevant to schizophrenia in animals sensitised to MK-801 compared to acutely exposed individuals. 
Sensitisation to drug effects is considered as a model for the worsening of symptoms in 
schizophrenia (Jentsch et al., 1998; Jentsch and Roth, 1999; Lieberman et al., 1997). It would be of 
value to identify whether this MK-801 sensitisation paradigm induces schizophrenia-like 
behaviours relating to the positive and negative symptoms as well as cognitive deficits. In this 
study, ‘long-term’ expression of sensitisation to MK-801 was not observed. This presents a 
potential limitation for the application of this MK-801 sensitisation paradigm to study long-term 
drug-induced effects. With a larger cohort of animals, it may have been possible to discern whether 
only certain individuals develop long-lasting sensitisation to MK-801. Individual differences in the 
propensity to develop long-term sensitisation has been described for many drugs of abuse including 
cocaine (Boudreau and Wolf, 2005, Churchill et al., 1999, Pierce et al., 1996a), ethanol (Abrahao et 
al., 2012), apomorphine (Voikar et al., 1999) and amphetamine (Hooks et al., 1992, Hooks et al., 
1991).  
In the present study, a considerable level of inter-individual variability in the acute response to MK-
801 was noted, as well as in the propensity to develop behavioural sensitisation following repeated 
exposure. Research from our lab has previously shown that in a large cohort, animals show a 
bimodal distribution into ‘sensitisers’ and ‘non-sensitisers’ based on their behavioural response (Cui 
et al., 2015).  This method of phenotyping can be useful for defining molecular adaptations that are 
specifically related to the onset of a behavioural adaptation compared to an unrelated drug-induced 
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effect. As I have now identified a large number of proteins of interest, these could be investigated in 
a larger cohort that allows for phenotyping into ‘sensitisers’ and ‘non-sensitisers’. Furthermore, 
genetic background is thought to be a key component in individual variability and susceptibility to 
sensitisation. The preliminary study with the Wistar rat strain showed this to be case. Thus even two 
outbred albino rat strains provide sufficient background variability to alter susceptibility to MK-801 
sensitisation.  
The preliminary proteomics findings identified proteins in pathways such as calcium signalling and 
clathrin-dependent endocytosis that have previously been attributed to synaptic plasticity and 
behavioural sensitisation. Proteins within these pathways, especially CaMKII, PKC and dynamin 1 
should be considered as primary targets for future studies. Intra-cerebral microinjection of 
pharmacological antagonists or ‘interference’ peptides would allow us to determine whether these 
proteins and subsequent signalling pathways are contributing to synaptic plasticity mechanisms 
involved in MK-801-induced sensitisation. To determine whether the changes in excitatory synaptic 
strength are contributing to the expression of MK-801 sensitisation, techniques previously utilised 
in psychostimulant sensitisation research could be employed, such as optogenetic reversal (Pascoli 
et al., 2012) or administration of the GluA23Y peptide that acts to inhibit AMPAR endocytosis and 
synaptic plasticity (Brebner et al., 2005, Choi et al., 2014a).  
The results strongly suggest that excitatory function in a region that projects to the NAc is altered. 
Application of optogenetics to the ex vivo slice electrophysiology technique employed in this study 
would allow identification of which specific input from either the PFC, ventral hippocampus or 
basolateral amygdala was contributing to this alteration. In the NAc, there are two key subtypes of 
MSNs that are distinguished based on their expression of D1R or D2R and their respective output 
pathways. Research has shown that drug-induced adaptations in synaptic strength have cell-type 
specificity critical to the mechanisms of drug related behaviours. Thus it would be informative to 
investigate MSN cell-type specific changes in synaptic strength that are induced by MK-801 
sensitisation. Currently this can be achieved by using bacterial artificial chromosome (BAC) drd1a-
tdTomato and drd2-GFP reporter transgenic mice (Shuen et al., 2008). This would require the 
development of a protocol that induces sensitisation to MK-801 mice.  A thorough investigation of 
the neural circuitry would help us to understand whether MK-801 sensitisation evokes alterations in 
the same reward pathway as other drugs of abuse.  
From these molecular adaptations, it will be crucial to begin teasing apart the neural circuitry 
contributing to MK-801 induced behavioural sensitisation. In addition to the key regions associated 
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with sensitisation such as the VTA, NAc and PFC, it would be important to understand how 
repeated MK-801 enhances the output of the motor circuitry. The neurotransmitters and circuitry 
involved in the hyperlocomotor response to an acute administration of MK-801 is largely unclear. 
As highlighted earlier, MK-801 hyperlocomotor activity can be induced in animals deplete of 
dopamine, further complicating the nature of its action (Carlsson and Carlsson, 1989). The motor 
circuit itself involves an incredibly complex set of afferents and efferents between multiple brains 
regions (Pierce and Kalivas, 1997). The NAc serves as an interface in the motor circuit for thalamic 
and cortical information. The ventral pallidum receives GABAergic input from the NAc MSNs and 
is thereby under inhibitory control from the NAc (Pierce and Kalivas, 1997). The ventral pallidum 
is connected to the thalamus, which subsequently sends excitatory afferents to the PFC, which 
connects to the motor cortex. In the presence of the NMDAR antagonist MK-801, the feedback 
inhibition from the NAc to the ventral pallidum is disrupted (Carter, 1995). This disinhibition leads 
to increased activity in the pallidum and subsequent pathways. In Chapter 3, I have shown there is a 
shift in the functional ratio of AMPAR to NMDARs on MSNs in the NAc following repeated, but 
not acute, MK-801. I would therefore speculate that, in MK-801 sensitised animals, the altered 
balance of the excitatory control of the GABAergic MSNs allows for greater disinhibition of the 
ventral pallidum in response to an MK-801 challenge. This would then be hypothesized to result in 
increased activation of the motor cortex via the corticothalamic input, providing a potential 
mechanism through which repeated MK-801 administration increases motor activity.  
The mechanism by which RU486 modulates the sensitisation to MK-801 forms an important focus 
for future research. Furthermore, the results of this study have not elucidated a role for HPA axis 
alterations in MK-801 sensitisation. Given the critical modulation of stress in neuropsychiatric 
diseases this could prove informative. The effects on circulating plasma corticosterone levels 
strongly suggest other factors are involved. Other hormones released by the HPA axis including 
corticotropin-releasing hormone and adrenocorticotropic hormone would be the first points of 
investigation. Perhaps the RU486 drug administration via intraperitoneal injection was too invasive 
a method to investigate the role of GRs and had confounding effects on corticosterone levels. Other 
possible routes of administration for RU486 could be taken into consideration such as the oral 
gavage or even through oats (Dalm et al., 2008). These reportedly less invasive techniques may 
reduce potential confounding effects of an injection-stress induced corticosterone release. 
Alternatively, the application of small-interference (si) RNA-mediated transient knockdown of the 
GR could be applied to targeted brain regions. The focus would be on the hippocampus, as this 
region is abundant with both NMDARs and GRs. Furthermore, it is well established that the 
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hippocampus has a negative regulatory feedback role on the activity of the HPA axis (Herman et 
al., 2005, Jacobson and Sapolsky, 1991). Thus, the hippocampus would be predicted to play a 
central role in modulating the interaction between MK-801 and stress-mediated signalling 
pathways.  
The signalling pathways that have been the predominate focus of this thesis were glutamate, stress 
and dopamine. Based on the current findings, I suggest that dopaminergic and stress-related factors 
are not critical to MK-801-induced behavioural sensitisation. However, I propose that glutamate 
signalling is pertinent to the induction and expression of MK-801 sensitisation. I hypothesise that 
the induction of MK-801 sensitisation is associated with enhanced glutamate release and the 
expression of MK-801 sensitisation is associated with decreased glutamate release. The application 
of chronically implanted glutamate micro-biosensors would be best suited to assess potential 
switches in glutamatergic signalling across the induction, withdrawal and expression phases of MK-
801 sensitisation.  
The role of GABAergic signalling has not been addressed here, as it is still a lesser-understood facet 
of psychostimulant sensitisation. Sodium valproate, an anticonvulsant agent that acts to enhance 
GABA function (Baldino and Geller, 1981), is known to block sensitisation to the dopaminergic 
agents methylphenidate (Yang et al., 2000), amphetamine (Enman and Unterwald, 2012) and 
methamphetamine (Coccurello et al., 2007), as well as sensitisation to morphine (Li et al., 2004a). 
Furthermore, sodium valproate blocks not only methamphetamine-induced cross-sensitisation to 
MK-801 challenge (Ito et al., 2006b), but also blocks MK-801-induced behavioural sensitisation 
(Yang et al., 2002). Therefore based on previous literature it appears GABAergic signalling may be 
a convergence point for similar mechanisms between MK-801 sensitisation and sensitisation to 
other drugs of abuse. Sodium valproate however also acts as a HDAC inhibitor (Gottlicher et al., 
2001). Therefore its effects on behavioural sensitisation could also be attributed to mechanisms 
alternative to GABA function, such as blocking chromatin remodelling (Botia et al., 2012, 
Legastelois et al., 2013). Given the pharmacological limitations of sodium valproate, alternative 
approaches to examining the role of GABA signalling in MK-801 sensitisation would be 
recommended including the use of selective GABA receptor modulators.  
 
6.5 CONCLUSION 
The present findings, combined with previous studies, elucidate more of the neural mechanisms 
contributing to MK-801-induced behavioural sensitisation. The examination of external factors 
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revealed MK-801 sensitisation was heavily influenced by drug dose, withdrawal phase and rodent 
strain. This method of examination also revealed for the first time that environmental context does 
not modulate sensitisation to MK-801. This first finding in this thesis demonstrates the difference in 
the mechanisms contributing to MK-801 sensitisation compared to the literature on sensitisation to 
other drugs of abuse. This effect of environmental context was similar to reports with PCP and 
ethanol, suggesting overlap in mechanisms contributing to sensitisation to drugs with an 
antagonistic action at the NMDAR.  
The work presented in this thesis demonstrates a role for excitatory transmission and plasticity in 
MK-801 sensitisation, with the current results indicative of excitatory depression. Moreover, 
several biological pathways in the NAc, including calcium signalling and mitochondrial 
dysfunction, were identified specifically in MK-801 sensitised animals and not in animals acutely 
exposed to MK-801. The molecular and functional changes identified in the NAc suggest MK-801 
evokes mechanisms of synaptic plasticity that contribute to the behavioural sensitisation. Whether 
these alterations in synaptic plasticity are convergent or divergent with drug-induced sensitisation 
literature remains to be examined. 
Lastly, the results of this thesis suggest underlying stress-mediated signalling via the GRs or KORs 
does not contribute to the development of MK-801 sensitisation. One of the most intriguing 
findings was that repeated RU486 administration had a long-term enhancement on NAc dopamine 
levels and the sensitivity to MK-801 hyperlocomotor effects. This finding also has potential clinical 
significance because RU486 is trialled in humans for the treatment of neuropsychiatric disorders.  
The present findings, together with further behavioural investigation, could be important for 
studying the glutamatergic pathophysiology of schizophrenia, drug addiction, and the co-morbidity 
that occurs between these two disorders. The MK-801 sensitisation phenotype presents a potential 
model for extending basic research on drug addiction and schizophrenia models where NMDAR 
signalling is altered. Furthermore the research from this thesis presents novel clues into neural 
pathways that induce behavioural sensitisation in a manner independent of NMDAR activation.  
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Appendix I  
Table 1: Proteins significantly altered between Naïve control and MK-801 acute rats 
List of significantly different proteins (p <0.05) in order from lowest p-value to highest. 
 
 
 
 
 
 
 
Accession 
No. Gene Name Protein Name p-value Fold Change
P54939 TLN1 talin 1 0.0003 2.095
Q5RJR2 TWF1 twinfilin actin-binding protein 1 0.0052 1.820
Q9ET43 CLDN12 claudin 12 0.0097 2.139
P47727 CBR1 carbonyl reductase 1 0.0120 -1.604
Q9DCW4 ETFB
electron-transfer-flavoprotein, 
beta polypeptide 0.0142 2.331
Q9QYF9 NDRG3 NDRG family member 3 0.0146 1.125
Q5KR47 TPM3 tropomyosin 3 0.0169 -2.625
Q9JKE3 SCAMP5
secretory carrier membrane 
protein 5 0.0180 12.094
Q8BSS9 PPFIA2
protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein 
(liprin), alpha 2 0.0192 1.309
Q62318 TRIM28 tripartite motif containing 28 0.0230 1.365
P26373 RPL13 ribosomal protein L13 0.0243 -1.927
P25788 PSMA3
proteasome (prosome, 
macropain) subunit, alpha 
type, 3 0.0251 1.238
Q15555 MAPRE2
microtubule-associated 
protein, RP/EB family, member 
2 0.0312 1.527
Q8VEH3 ARL8A ADP-ribosylation factor-like 8A 0.0424 -1.348
Q96E17 RAB3C
RAB3C, member RAS 
oncogene family 0.0457 -1.195
Q2KJ46 PSMD3
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 3 0.0469 1.735
P56812 PDCD5 programmed cell death 5 0.0484 1.246
Q9DAW9 CNN3 calponin 3, acidic 0.0489 1.288
Q9WVB1 RAB6A
RAB6A, member RAS 
oncogene family 0.0507 -3.492
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Table 2: Proteins significantly altered between Naïve control and MK-801 sensitised rats 
List of significantly different proteins (p <0.05) in order from lowest p-value to highest. 
 
 
 
Accession 
No. Gene Name Protein Name p-value Fold Change
P28656 NAP1L1
nucleosome assembly protein 
1-like 1 0.000 1.307
Q9NQX3 GPHN gephyrin 0.001 1.258
Q9DCW4 ETFB
electron-transfer-flavoprotein, 
beta polypeptide 0.001 4.123
Q811X6 CRYL1 crystallin, lambda 1 0.002 1.694
P50247 AHCY adenosylhomocysteinase 0.003 1.477
Q9DAW9 CNN3 calponin 3, acidic 0.003 1.322
P62874 GNB1
guanine nucleotide binding 
protein (G protein), beta 
polypeptide 1 0.003 1.350
Q9ET43 CLDN12 claudin 12 0.004 1.899
Q92561 PHYHIP
phytanoyl-CoA 2-hydroxylase 
interacting protein 0.005 1.401
Q99NA5 IDH3A
isocitrate dehydrogenase 3 
(NAD+) alpha 0.006 1.261
Q6NYB7 RAB1A
RAB1A, member RAS 
oncogene family 0.006 1.511
P42025 ACTR1B
ARP1 actin-related protein 1 
homolog B, centractin beta 
(yeast) 0.006 1.383
P49803 RGS7
regulator of G-protein signaling 
7 0.006 2.189
Q91YE6 IPO9 importin 9 0.006 1.296
Q64568 ATP2B3
ATPase, Ca++ transporting, 
plasma membrane 3 0.007 1.371
P63319 PRKCG protein kinase C, gamma 0.007 1.403
Q5I6B8 PIP5K1C
phosphatidylinositol-4-
phosphate 5-kinase, type I, 
gamma 0.007 1.265
P47736 RAP1GAP
RAP1 GTPase activating 
protein 0.007 1.295
Q8BRT1 CLASP2
cytoplasmic linker associated 
protein 2 0.007 1.404
Q9UI12 ATP6V1H
ATPase, H+ transporting, 
lysosomal 50/57kDa, V1 
subunit H 0.008 1.263
Q9QYF3 MYO5A
myosin VA (heavy chain 12, 
myoxin) 0.008 1.314
Q9H0Q0 FAM49A
family with sequence similarity 
49, member A 0.009 1.532
Q9Y2A7 NCKAP1 NCK-associated protein 1 0.009 1.435
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Q2KJ46 PSMD3
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 3 0.009 1.863
Q62812 MYH9
myosin, heavy chain 9, non-
muscle 0.009 1.632
Q63754 SNCB synuclein, beta 0.010 1.430
Q9UQM7 CAMK2A
calcium/calmodulin-dependent 
protein kinase II alpha 0.011 1.540
Q9WV34 MPP2
membrane protein, 
palmitoylated 2 (MAGUK p55 
subfamily member 2) 0.011 1.393
P68404 PRKCB protein kinase C, beta 0.011 1.323
P56812 PDCD5 programmed cell death 5 0.012 1.290
Q62261 SPTBN1
spectrin, beta, non-erythrocytic 
1 0.012 1.278
Q28009 Fus fused in sarcoma 0.012 1.861
Q7L5N1 COPS6 COP9 signalosome subunit 6 0.013 1.607
Q8BLQ9 CADM2 cell adhesion molecule 2 0.014 1.311
Q62950 CRMP1
collapsin response mediator 
protein 1 0.015 1.217
Q9XSU0 RPL13A ribosomal protein L13a 0.015 1.472
Q922R8 PDIA6
protein disulfide isomerase 
family A, member 6 0.015 1.505
Q56A07 SCN2B
sodium channel, voltage gated, 
type II beta subunit 0.015 1.153
Q9JLT0 MYH10
myosin, heavy chain 10, non-
muscle 0.015 1.285
P50398 GDI1 GDP dissociation inhibitor 1 0.016 1.087
Q99832 CCT7
chaperonin containing TCP1, 
subunit 7 (eta) 0.016 1.328
Q9CWZ7 NAPG
N-ethylmaleimide-sensitive 
factor attachment protein, 
gamma 0.016 1.221
P48500 Tpi1 triosephosphate isomerase 1 0.016 1.453
P46109 CRKL
v-crk avian sarcoma virus 
CT10 oncogene homolog-like 0.016 1.228
P13596 NCAM1
neural cell adhesion molecule 
1 0.017 1.214
P85845 FSCN1 fascin actin-bundling protein 1 0.017 1.683
P00507 GOT2
glutamic-oxaloacetic 
transaminase 2, mitochondrial 0.017 1.138
P31939 ATIC
5-aminoimidazole-4-
carboxamide ribonucleotide 
formyltransferase/IMP 
cyclohydrolase 0.017 -18.479
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Q7TP47 Syncrip
synaptotagmin binding, 
cytoplasmic RNA interacting 
protein 0.017 1.628
P27546 MAP4
microtubule-associated protein 
4 0.018 1.570
Q62420 SH3GL2 SH3-domain GRB2-like 2 0.018 1.409
Q9Z2L0 VDAC1
voltage-dependent anion 
channel 1 0.018 1.223
Q15555 MAPRE2
microtubule-associated 
protein, RP/EB family, member 
2 0.018 1.761
Q9WV92 EPB41L3
erythrocyte membrane protein 
band 4.1-like 3 0.019 1.365
P97546 NPTN neuroplastin 0.019 1.387
Q66HF1 NDUFS1
NADH dehydrogenase 
(ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q 
reductase) 0.019 1.362
P38650 DYNC1H1
dynein, cytoplasmic 1, heavy 
chain 1 0.019 1.402
Q8BSS9 PPFIA2
protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein 
(liprin), alpha 2 0.020 1.502
Q6NS52 DGKB
diacylglycerol kinase, beta 
90kDa 0.020 1.538
Q5KR47 TPM3 tropomyosin 3 0.021 1.715
Q68FS2 COPS4 COP9 signalosome subunit 4 0.021 1.414
Q62910 SYNJ1 synaptojanin 1 0.022 1.644
Q8BYI9 TNR tenascin R 0.022 1.392
Q63198 CNTN1 contactin 1 0.022 1.277
P21571 ATP5J
ATP synthase, H+ transporting, 
mitochondrial Fo complex, 
subunit F6 0.022 1.170
Q9R0K7 ATP2B2
ATPase, Ca++ transporting, 
plasma membrane 2 0.022 1.519
Q8K3J1 NDUFS8
NADH dehydrogenase 
(ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q 
reductase) 0.022 1.298
Q9Z1X4 ILF3
interleukin enhancer binding 
factor 3, 90kDa 0.023 1.454
Q62318 TRIM28 tripartite motif containing 28 0.024 1.286
Q8N3V7 SYNPO synaptopodin 0.024 1.506
O95394 PGM3 phosphoglucomutase 3 0.025 1.281
Q8BPN8 DMXL2 Dmx-like 2 0.025 1.342
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P15999 ATP5A1
ATP synthase, H+ transporting, 
mitochondrial F1 complex, 
alpha subunit 1, cardiac 
muscle 0.025 1.261
Q9D855 UQCRB
ubiquinol-cytochrome c 
reductase binding protein 0.026 2.181
Q9QWN8 SPTBN2
spectrin, beta, non-erythrocytic 
2 0.027 1.325
P13637 ATP1A3
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide 0.027 1.152
P40329 RARS arginyl-tRNA synthetase 0.028 6.225
P35565 CANX calnexin 0.029 1.392
Q9UNW9 NOVA2
neuro-oncological ventral 
antigen 2 0.029 1.755
Q8C8R3 Ank2 ankyrin 2, brain 0.029 1.403
Q8BFR5 TUFM
Tu translation elongation 
factor, mitochondrial 0.029 1.307
Q64433 HSPE1 heat shock 10kDa protein 1 0.030 1.254
P00125 CYC1 cytochrome c-1 0.030 1.202
P15146 MAP2
microtubule-associated protein 
2 0.030 1.399
Q9Z2U0 PSMA7
proteasome (prosome, 
macropain) subunit, alpha 
type, 7 0.030 1.400
Q4V8B0 OXR1 oxidation resistance 1 0.031 1.200
F1PBJ0 RAPGEF2
Rap guanine nucleotide 
exchange factor (GEF) 2 0.031 1.916
Q8BLK3 LSAMP
limbic system-associated 
membrane protein 0.031 1.862
Q6AYH5 DCTN2 dynactin 2 (p50) 0.031 1.563
Q8R478 WBP2 WW domain binding protein 2 0.031 1.845
P11505 ATP2B1
ATPase, Ca++ transporting, 
plasma membrane 1 0.031 1.286
Q05175 Basp1
brain abundant, membrane 
attached signal protein 1 0.032 1.589
Q9QXY2 SRCIN1
SRC kinase signaling inhibitor 
1 0.032 1.351
O35987 NSFL1C NSFL1 (p97) cofactor (p47) 0.032 1.226
Q9JHL4 DBNL drebrin-like 0.034 1.666
Q5ZIQ3 LOC100359916
heterogeneous nuclear 
ribonucleoprotein K-like 0.034 1.205
P50516 ATP6V1A
ATPase, H+ transporting, 
lysosomal 70kDa, V1 subunit A 0.035 1.370
P07323 ENO2 enolase 2 (gamma, neuronal) 0.036 1.506
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Q00577 PURA
purine-rich element binding 
protein A 0.037 1.190
Q62952 DPYSL3 dihydropyrimidinase-like 3 0.037 1.302
Q4LDG9 DNAL1 dynein, axonemal, light chain 1 0.037 2.161
Q16740 CLPP
caseinolytic mitochondrial 
matrix peptidase proteolytic 
subunit 0.038 -1.403
P29419 Atp5k
ATP synthase, H+ transporting, 
mitochondrial F1F0 complex, 
subunit E 0.039 1.099
Q8NE86 MCU mitochondrial calcium uniporter 0.039 2.352
P19627 GNAZ
guanine nucleotide binding 
protein (G protein), alpha z 
polypeptide 0.039 1.787
P43006 SLC1A2
solute carrier family 1 (glial 
high affinity glutamate 
transporter), member 2 0.039 1.681
Q5E958 RPS8 ribosomal protein S8 0.039 1.345
Q64542 ATP2B4
ATPase, Ca++ transporting, 
plasma membrane 4 0.040 1.650
P28480 TCP1 t-complex 1 0.040 1.468
Q8BNY6 NCS1 neuronal calcium sensor 1 0.040 1.876
Q07076 ANXA7 annexin A7 0.040 1.449
P24587 AKAP5
A kinase (PRKA) anchor 
protein 5 0.041 1.227
O35964 SH3GL1 SH3-domain GRB2-like 1 0.041 1.961
D3ZW55 ITPA
inosine triphosphatase 
(nucleoside triphosphate 
pyrophosphatase) 0.041 1.394
P21575 DNM1 dynamin 1 0.041 1.330
Q6AY84 SCRN1 secernin 1 0.041 1.316
Q9CRY7 GDPD1
glycerophosphodiester 
phosphodiesterase domain 
containing 1 0.042 1.494
Q05546 TNR tenascin R 0.042 1.779
Q99MN9 PCCB
propionyl CoA carboxylase, 
beta polypeptide 0.043 1.575
Q9ULU8 CADPS
Ca++-dependent secretion 
activator 0.044 1.339
Q5XIF6 TUBA4A tubulin, alpha 4a 0.044 1.247
Q9D1G1 RAB1B
RAB1B, member RAS 
oncogene family 0.046 1.379
P51150 RAB7A
RAB7A, member RAS 
oncogene family 0.046 1.225
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Q5ZKV9 CCDC132
coiled-coil domain containing 
132 0.047 1.955
Q5E9T6 LGI1
leucine-rich, glioma inactivated 
1 0.048 1.439
P0DME0 SETSIP SET-like protein 0.048 1.266
P68511 YWHAH
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, eta 0.048 1.497
Q9CQI3 GMFB glia maturation factor, beta 0.048 1.321
P04764 ENO1 enolase 1, (alpha) 0.048 1.413
Q9C0D0 PHACTR1
phosphatase and actin 
regulator 1 0.049 1.608
Q9QYF9 NDRG3 NDRG family member 3 0.050 1.230
P63045 VAMP2
vesicle-associated membrane 
protein 2 (synaptobrevin 2) 0.050 1.252
Q99JY9 ACTR3
ARP3 actin-related protein 3 
homolog (yeast) 0.050 1.269
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Appendix II  
Table 1: Complete list of significant canonical pathways identified by Ingenuity Pathway Analysis in MK-801 
sensitised rats 
Significant (p<0.05) canonical pathways are listed in order of significance. The ratio value (orange square) is the 
number of proteins in that pathway altered by MK-801 sensitisation over the total number of proteins in that pathway.  
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